0001829126-23-002497.txt : 20230331 0001829126-23-002497.hdr.sgml : 20230331 20230331160557 ACCESSION NUMBER: 0001829126-23-002497 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rebus Holdings, Inc. CENTRAL INDEX KEY: 0001421204 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55331 FILM NUMBER: 23787556 BUSINESS ADDRESS: STREET 1: 2629 TOWNSGATE RD, SUITE 215 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 BUSINESS PHONE: (210) 479-8112 MAIL ADDRESS: STREET 1: 2629 TOWNSGATE RD, SUITE 215 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 FORMER COMPANY: FORMER CONFORMED NAME: Inspyr Therapeutics, Inc. DATE OF NAME CHANGE: 20160802 FORMER COMPANY: FORMER CONFORMED NAME: GENSPERA INC DATE OF NAME CHANGE: 20071213 10-K 1 rebusholdings_10k.htm 10-K
0001421204 false FY 2022 0001421204 2022-01-01 2022-12-31 0001421204 2022-06-30 0001421204 2023-03-30 0001421204 2022-12-31 0001421204 2021-12-31 0001421204 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesEPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesFPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesFPreferredStockMember 2021-12-31 0001421204 2021-01-01 2021-12-31 0001421204 us-gaap:PreferredStockMember 2020-12-31 0001421204 us-gaap:CommonStockMember 2020-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001421204 us-gaap:RetainedEarningsMember 2020-12-31 0001421204 2020-12-31 0001421204 us-gaap:PreferredStockMember 2021-12-31 0001421204 us-gaap:CommonStockMember 2021-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001421204 us-gaap:RetainedEarningsMember 2021-12-31 0001421204 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001421204 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001421204 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001421204 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001421204 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001421204 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001421204 us-gaap:PreferredStockMember 2022-12-31 0001421204 us-gaap:CommonStockMember 2022-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001421204 us-gaap:RetainedEarningsMember 2022-12-31 0001421204 us-gaap:IntellectualPropertyMember 2022-01-01 2022-12-31 0001421204 2020-03-31 0001421204 us-gaap:CashMember 2020-10-31 0001421204 us-gaap:CashMember 2021-01-31 0001421204 us-gaap:CashMember 2021-06-30 0001421204 RBSH:SeriesFPreferredStocksMember 2022-12-31 0001421204 2021-01-31 0001421204 2021-06-30 0001421204 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001421204 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001421204 us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0001421204 us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001421204 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001421204 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001421204 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001421204 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001421204 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001421204 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001421204 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001421204 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001421204 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001421204 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001421204 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2022-12-31 0001421204 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2022-12-31 0001421204 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-12-31 0001421204 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-12-31 0001421204 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-12-31 0001421204 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-12-31 0001421204 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001421204 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001421204 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2022-12-31 0001421204 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2022-12-31 0001421204 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-12-31 0001421204 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-12-31 0001421204 us-gaap:SeriesFPreferredStockMember 2020-10-06 0001421204 us-gaap:SeriesFPreferredStockMember RBSH:RidgewayTherapeuticsIncMember 2020-10-01 2020-10-06 0001421204 RBSH:SeriesE0ConvertiblePreferredStockMember 2020-05-01 2020-05-02 0001421204 RBSH:SeriesE0ConvertiblePreferredStockMember 2020-05-02 0001421204 us-gaap:SeriesDPreferredStockMember 2018-12-31 0001421204 us-gaap:SeriesDPreferredStockMember 2018-12-01 2018-12-31 0001421204 us-gaap:SeriesCPreferredStockMember 2017-04-30 0001421204 us-gaap:SeriesCPreferredStockMember 2017-04-01 2017-04-30 0001421204 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001421204 us-gaap:SeriesAPreferredStockMember 2015-12-31 0001421204 2021-08-29 2021-09-02 0001421204 2021-01-01 2021-03-31 0001421204 us-gaap:StockOptionMember 2020-12-31 0001421204 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001421204 us-gaap:StockOptionMember 2021-12-31 0001421204 us-gaap:WarrantMember 2020-12-31 0001421204 us-gaap:WarrantMember 2021-12-31 0001421204 us-gaap:WarrantMember 2022-12-31 0001421204 us-gaap:WarrantMember RBSH:ConsultantMember 2022-12-31 0001421204 us-gaap:WarrantMember RBSH:ConsultantMember 2022-01-01 2022-12-31 0001421204 RBSH:June2021DebentureMember 2021-06-01 2021-06-18 0001421204 RBSH:June2021DebentureMember 2021-06-18 0001421204 RBSH:June2021DebentureMember 2022-01-01 2022-12-31 0001421204 RBSH:June2021DebentureMember 2021-01-01 2021-12-31 0001421204 RBSH:June2021DebentureMember 2022-12-31 0001421204 RBSH:January2021DebentureMember 2021-01-01 2021-01-12 0001421204 RBSH:January2021DebentureMember 2021-01-12 0001421204 RBSH:January2021DebentureMember 2022-01-01 2022-12-31 0001421204 RBSH:October2020DebenturesMember 2020-10-01 2020-10-23 0001421204 RBSH:October2020DebenturesMember 2020-10-23 0001421204 RBSH:October2020DebenturesMember 2022-01-01 2022-12-31 0001421204 RBSH:March2020DebenturesMember 2020-03-01 2020-03-06 0001421204 RBSH:November2019DebenturesMember 2022-01-01 2022-12-31 0001421204 RBSH:November2019DebenturesMember 2022-12-31 0001421204 RBSH:October2019DebenturesMember 2022-01-01 2022-12-31 0001421204 RBSH:July2019DebentureMember 2019-07-01 2019-07-16 0001421204 RBSH:July2019DebentureMember srt:MinimumMember 2022-01-01 2022-12-31 0001421204 RBSH:July2019DebentureMember srt:MaximumMember 2022-01-01 2022-12-31 0001421204 RBSH:July2019DebentureMember 2022-01-01 2022-12-31 0001421204 RBSH:December2018DebenturesMember 2018-12-01 2018-12-13 0001421204 RBSH:July2018DebenturesMember 2018-07-01 2018-07-03 0001421204 RBSH:July2018DebenturesMember 2018-07-03 0001421204 RBSH:September2017DebenturesMember 2017-09-12 0001421204 RBSH:September2017DebenturesMember 2017-09-01 2017-09-12 0001421204 RBSH:September2017DebenturesMember RBSH:SeriesAConvertiblePreferredStockMember 2017-09-12 0001421204 RBSH:September2017DebenturesMember RBSH:SeriesBConvertiblePreferredStockMember 2017-09-12 0001421204 RBSH:September2017DebenturesMember 2017-09-05 2017-09-12 0001421204 RBSH:September2017DebenturesMember 2022-01-01 2022-12-31 0001421204 RBSH:September2017DebenturesMember 2022-12-31 0001421204 RBSH:SilvestreLawGroupPCMember 2021-09-30 0001421204 RBSH:SilvestreLawGroupPCMember 2022-01-01 2022-12-31 0001421204 RBSH:SilvestreLawGroupPCMember 2015-08-01 2015-08-15 0001421204 RBSH:SilvestreLawGroupPCMember 2021-08-16 2021-12-31 0001421204 RBSH:SilvestreLawGroupPCMember 2022-12-31 0001421204 RBSH:SilvestreLawGroupPCMember 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________.

 

Commission File Number 000-55331

 

REBUS HOLDINGS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   20-0438951
State or other jurisdiction of
incorporation or organization		   (I.R.S. Employer
Identification No.)

 

2629 Townsgate Road Suite 215
Westlake Village, CA		   91361
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (818) 597-7552

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Class   Trading Symbol   Name of Each Exchange on Which Registered
N/A   N/A   N/A

 

Securities registered pursuant to Section 12(g) of the Act:

 

Common Stock, $0.0001 par value

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes   ☒ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes   ☒ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes   ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes   ☐ No

 

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging Growth Company ☐    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes   ☒ No

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed using the price at which the common equity was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was $766,023 based on a closing price of $0.0245 per share on such date. As of June 30, 2022, there were 32,132,907 shares of the registrant’s common stock outstanding.

 

As of March 30, 2023, the issuer had 32,132,907 common shares, $0.0001 par value, issued and outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None

 

 

 

 

 

 

REBUS HOLDINGS, INC.

FORM 10-K

FOR THE YEAR ENDED DECEMBER 31, 2022

 

INDEX

 

      Page
PART I
Item 1. Business   2
Item 1A. Risk Factors   10
Item 1B. Unresolved Staff Comments   23
Item 2. Properties   23
Item 3. Legal Proceedings   23
Item 4. Mine Safety Disclosure   23
       
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities   24
Item 6. Selected Financial Data   26
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations   27
Item 7A. Quantitative and Qualitative Disclosures About Market Risk   32
Item 8. Financial Statements and Supplementary Data   32
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure   32
Item 9A. Controls and Procedures   32
Item 9B. Other Information   33
       
PART III
Item 10. Directors, Executive Officers and Corporate Governance   34
Item 11. Executive Compensation   40
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters   42
Item 13. Certain Relationships and Related Transactions, and Director Independence   45
Item 14. Principal Accounting Fees and Services   46
       
PART IV
Item 15. Exhibits, Financial Statement Schedules   47

 

i

 

 

PART I

 

We urge you to read this entire Annual Report on Form 10-K, including the “Risk Factors” section and the financial statements and related notes included herein. As used in this Annual Report, unless context otherwise requires, the words “we,” “us”, “our,” “the Company,” “Rebus Holdings, Inc.” and “Registrant” refer to Rebus Holdings, Inc. (formerly known as Inspyr Therapeutics, Inc.) Also, any reference to “common shares,” or “common stock,” refers to our $0.0001 par value common stock. Also, any reference to “preferred stock” or “preferred shares” refers to our $0.0001 par value Series A preferred stock, our $0.0001 par value series B preferred stock, our $0.0001 par value Series C preferred stock, our $.0.0001 par value Series D preferred stock, our $0.0001 par value Series E Preferred Stock, and our $0.0001 par value Series F Preferred Stock. All references to common stock, share and per share amounts have been retroactively restated to reflect the 1:75 reverse stock split that became effective on October 12, 2021, as if it had taken place as of the beginning of the earliest period presented.

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Annual Report includes “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to our business development plans, clinical trials, regulatory reviews, timing, strategies, expectations, anticipated expense levels, business prospects and positioning with respect to the market for our proposed products, business outlook, technology spending and various other matters (including contingent liabilities and obligations and changes in accounting policies, standards and interpretations), express our current intentions, beliefs, expectations, strategies or predictions, as well as historical information. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, to be materially different from anticipated results, performance or achievements expressed or implied by such forward-looking statements. When used in this report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “plan,” “intend,” “may,” “will,” “expect,” “believe,” “could,” “anticipate,” “estimate,” or “continue” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Our future operating results are dependent upon many factors which are outside our control. You should not place undue reliance on forward-looking statements. Forward-looking statements may not be realized due to a variety of factors, including, without limitation, our ability to:

 

  ● continue to increase our corporate operations;

 

  ● attract, build and retain a senior management team;

 

  ● manage our business given continuing operating losses and negative cash flows;

 

  ● obtain sufficient capital or a strategic business arrangement to fund our operations and expansion plans;

 

  ● build the infrastructure necessary to support the growth of our business;

 

  ● manage competitive factors and developments beyond our control;

 

  ● manage scientific and medical developments which may be beyond our control;

 

  ● manage the governmental regulation of our business including state, federal and international laws;

 

  ● maintain and protect our intellectual property;

 

  ● obtain patents based on our current and/or future patent applications;

 

  ● obtain and maintain other rights to technology required or desirable to conduct or expand our business;

 

1

 

 

  ● achieve any potential strategic benefits of licensing transactions, collaborations, acquisitions, or in-licensing of new technologies, if any;

 

  ● successfully integrate the assets previously licensed to Ridgeway Therapeutics, Inc. pursuant to the termination of such license in October 2020; and

 

  ● manage any other factors discussed in the “Risk Factors” section, and elsewhere in this Annual Report.

 

All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. We undertake no obligation to update or revise these forward-looking statements, whether to reflect events or circumstances after the date initially filed or published, to reflect the occurrence of unanticipated events or otherwise, except to the extent required by federal securities laws. The risks discussed in this report should be considered in evaluating our business and future prospects.

 

ITEM 1. BUSINESS

 

Overview

 

Rebus Holdings, Inc. (fka Inspyr Therapeutics, Inc.) is a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer. Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allows for better tumor infiltration. The adenosine A2 Receptor is one of many T-cell surface immune checkpoint proteins. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific adenosine targets found in each type of cancer.

 

Adenosine Receptor Modulators

 

The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability including indications within immuno-oncology. Very high concentrations of adenosine are produced in the tumor microenvironment which prevents the host’s own immune cells from attacking the tumor. Adenosine receptor antagonists as single-agents and in combination with other existing immuno-oncology agents may overcome this immunosuppression and boost the host immune response leading to enhanced anti-tumor activity as well as inhibition of metastasis. Preclinical data has shown the direct effects with our drug candidates on certain types of cancer cells.

 

We have completed the manufacture of our novel platform delivery system of nano- or microparticle formulations that will be used in toxicology studies anticipated to begin in the second half of 2023, that will support the submission of an IND in 2024.

 

While we believe that the data from our nonclinical studies appear encouraging, the outcome of our ongoing or future studies may ultimately be unsuccessful.

 

We have manufactured sufficient amounts of nano- or microparticle formulations, to take us through the IND and initial clinical studies.

 

Rebus Holdings/ Ridgeway Licensing Agreement

 

Pursuant to our recent termination of license with Ridgeway Therapeutics, Inc., we reacquired the rights to certain intellectual property, discussed above, and are currently focusing on a pipeline of small molecule adenosine receptor modulators. In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2A, A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.

 

2

 

 

Our ability to execute the business plan is contingent upon our ability to raise the necessary funds. During January 2021, we sold $500,000 of debt securities for cash, and in June 2021, we sold $600,000 of debt securities for $500,000 in cash and $100,000 in cancellation of outstanding obligations. We are currently using such funds to maintain our SEC reporting requirements, pay outstanding invoices to our independent registered accounting firm, legal fees, and to retain consultants and other personnel in preparation for an Investigational New Drug Application (“IND”) filing related to our unique delivery platform and portfolio of adenosine A2R antagonists for the treatment of certain solid tumors. Should we fail to further raise sufficient funds to execute our business plan, our priority would be to maintain our intellectual property portfolio and seek business development opportunities with potential development partners and/or acquirors.

 

Pre-Revenue

 

We are a pre-revenue, early-stage company that has not achieved profitability, and has no product revenues. Additionally, we have no approved products for sale.

 

Going Concern

 

Our auditors’ report on our December 31, 2022 consolidated financial statements expressed an opinion that our capital resources as of the date of their Audit Report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. As of December 31, 2022 we had sufficient cash on hand to operate until March, 2023. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

 

Recent Developments

 

  ● Effective October 12, 2021, we (i) completed a 1-for-75 Reverse Stock Split and (ii) a holding company reorganization whereby we changed our name to Rebus Holdings, Inc.
     
  ● On August 16, 2021, we appointed Raul Silvestre, Esq. as (i) our interim chief executive officer and principal accounting officer and (ii) a member of the Board of Directors.
     
  ● On June 18, 2021, we completed the private placement of $600,000 of non-interest bearing senior convertible debentures consisting of (i) $500,000 purchased in cash and (ii) $100,000 purchased pursuant to the cancellation of outstanding obligations.
     
  ● On January 12, 2021, we completed the private placement of $500,000 of non-interest bearing senior convertible debentures

 

Product Development of Adenosine Receptor Modulators

 

As a result of the License Termination, the Company has refocused its business plan on the research and development of its lead asset, RT-AR001, an adenosine A2 receptor antagonist, which is differentiated by its intratumoral delivery of nano- or microparticle formulations that allows for better tumor infiltration.

 

Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation. The adenosine A2 receptor is one of many T-cell surface immune checkpoint proteins. High levels of adenosine in the tumor microenvironment are produced and, therefore, adenosine signaling, mediated through the A2A and A2B receptors, suppresses the host immune response to the tumor cells.

 

3

 

 

As such, our portfolio of adenosine receptor antagonists has broad applicability as potential immuno-oncology (IO) therapeutic agents in multiple solid tumor types both as a potential single agent and in combination with other IO agents, in addition to traditional cytotoxic chemotherapy. We are actively seeking licensing opportunities and/or partners to further develop our unique platform delivery system of A2A, A2B and dual A2A/A2B receptor antagonists. Our current product development plan for adenosine receptor antagonists contemplates the following major initiatives, subject to the Company receiving sufficient funds:

 

  ● Continue development of anti-cancer agents with partner company, Ridgeway Therapeutics, Inc.

 

  ● Further characterization of our platform delivery system and existing agents in preclinical studies, and towards an investigational new drug (IND) application.

 

  ● Support ongoing licensing / partnership activities.

 

Pre-IND and IND

 

The Company is currently pursuing an IND filing related to our unique delivery platform and portfolio of adenosine A2R antagonists for the treatment of certain solid tumors, and is preparing its pre-IND application, for its lead asset, RT-AR001, an adenosine A2A receptor antagonist.

 

Between September 2021 and February 2022, our CMO manufactured to GMP standards; both our adenosine A2A receptor antagonist as well as the nano- or microparticle formulation for intratumoral delivery known as RT-AR001. We have sufficient material to take us through the IND and initial clinical studies.

 

We have completed in-vitro testing of our adenosine A2A receptor antagonist and will begin toxicology testing with RT-AR001 in the second half of 2023. The Company plans to provide a further update on RT-AR001’s clinical development in the fourth quarter of 2023.

 

Our Technology

 

We have what we believe to be a robust intellectual property portfolio covering proprietary A2A agonists (LNC-001, see below), A2B antagonists (LNC-002, see below), and dual A2A/A2B antagonists (LNC-003, see below). We also have a substantial catalogue of synthesized compounds, specifically A2A agonists and A2B antagonists that require further characterization and testing for potential clinical candidates. We believe that our proprietary dual A2A/A2B antagonists have great potential and should be further explored.

 

Patents and Proprietary Rights

 

Our success will likely depend upon our ability to preserve our proprietary technologies and operate without infringing the proprietary rights of other parties. However, we may rely on certain proprietary technologies and know-how that are not patentable or that we determine to keep as trade secrets. We protect our proprietary information, in part, using confidentiality agreements with our employees, consultants, significant scientific collaborators, and sponsored researchers that generally provide that all inventions conceived by the individual in the course of rendering services to us shall be our exclusive property.

 

The intellectual property underlying our technology is covered by certain patents and patent applications previously owned by Lewis and Clark Pharmaceuticals, Inc. (“LNC”) and now fully owned by the Company. All of the LNC intellectual property has been assigned to the Company. We solely own all of our patents and patent applications for adenosine receptor modulators, which include three patent estates, one for A2A agonists (LNC-001), the second for A2B antagonists (LNC-002), and the third for dual A2A/A2B antagonists (LNC-003). Ownership of these patent estates came from our purchase (in exchange for 7,122,172 shares of our common stock) of Lewis and Clark Pharmaceuticals, Inc. (LNC) on July 31, 2017. The purchase of LNC also included all know-how, pre-clinical data, and development data that relate to and form the basis of our technology. Under the purchase agreement, we are sole owners of the technology and patent estates and are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to LNC.

 

4

 

 

FILE #   COUNTRY   STATUS   APPLICATION #   DATE FILED   PATENT #   GRANT DATE
LNC-001-US   United States of America   Issued   13/956,111   Jul 31, 2013   9067963   Jun 30, 2015
LNC-001-US-CNT1   United States of America   Issued   14/752,861   Jun 27, 2015   9822141   Nov 21, 2017
LNC-002-AU   Australia   Issued   2016246068   Apr 8, 2016   2016246068   10-Dec-20
LNC-002-BE   Belgium   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-BR   Brazil   Pending   BR 11 2017 021386-9   Apr 8, 2016        
LNC-002-CH   Switzerland   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-CN   China   Issued   201680026835.1   Apr 8, 2016   ZL 20160026835   Jan 8, 2021
LNC-002-CZ   Czech Republic   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-DE   Germany   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-DK   Denmark   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-EA   Eurasian Patent Office   Issued   201792156   Apr 8, 2016   36954   Jan 19, 2021
LNC-002-EP   European Patent Office   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-ES   Spain   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-FR   France   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-GB   United Kingdom   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-IE   Ireland   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-IL   Israel   Issued   254902   Apr 8, 2016   254902   Sep 1, 2021
LNC-002-IN   India   Issued   201727039305   Apr 8, 2016   375108   Aug 23, 2021
LNC-002-IT   Italy   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-JP   Japan   Issued   2018-504080   Apr 8, 2016   6738405   Jul 21, 2020
LNC-002-KR   Republic of Korea   Pending   10-2017-7031978   Apr 8, 2016        
LNC-002-MX   Mexico   Issued   MX/a2017/012783   Apr 8, 2016   380672   Mar 17, 2021
LNC-002-NL   Netherlands   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-NZ   New Zealand   Pending   736705   Apr 8, 2016        
LNC-002-PL   Poland   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-PT   Portugal   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-SE   Sweden   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-SG   Singapore   Issued   11201707753X   Apr 8, 2016   11201707753X   Dec 31, 2021
LNC-002-TR   Turkey   Issued   16777436.3   Apr 8, 2016   3280417   Jul 29, 2020
LNC-002-US   United States of America   Issued   15/094,903   Apr 8, 2016   9593118   Mar 14, 2017
LNC-002-ZA   South Africa   Issued   2017/07248   Apr 8, 2016   201707248   Oct 31, 2018
LNC-003-EP   European Patent Office   Pending   EP21774246.9   Sep 30, 2022        
LNC-003-US   United States of America   Pending   17/907,096   Sep 30, 2022        

 

When appropriate, we will continue to seek patent protection for inventions in our core technologies and in ancillary technologies that support our core technologies or which we otherwise believe will provide us with a competitive advantage. We will accomplish this by filing and maintaining patent applications for discoveries we make, either alone or in collaboration with scientific collaborators and strategic partners. Typically, we plan to file patent applications in the United States. In addition, we plan to obtain licenses or options to acquire licenses to patent filings from other individuals and organizations that we anticipate could be useful in advancing our research, development, and commercialization initiatives and our strategic business interest.

 

5

 

 

Development Strategy

 

We anticipate that under the planning and direction of key personnel, to outsource all our nonclinical development and manufacturing, and the majority of our clinical development activities to contract research organizations (CROs) and contract manufacturing organizations (CMOs). Our contract CROs and CMOs are required to comply with federal, state and United States Food and Drug Administration or FDA regulations including Good Manufacturing Practices (cGMP), Good Clinical Practices (GCP), and Good Lab Practices (GLP).

 

We intend to conduct toxicology testing of our A2A antagonist RT-AR001 the select a candidate for clinical trials in an oncology indication. This oncology work is expected to be run in conjunction with and oversight from Ridgeway Therapeutics, Inc. for the selection of an anti-cancer agent.

 

Commercialization Strategy

 

We intend to (i) license or sell the underlying technology of our therapeutics to third parties during or after our clinical trials, (ii) seek a corporate partner for further development, or (iii) continue developing our drug candidates ourselves. It is expected that such third parties would then continue to develop, market, sell, and distribute any resulting products. As part of our overall strategic plan, we are exploring our options and actively seeking to engage in a collaborative, strategic and/or licensing arrangement with another pharmaceutical company. If we enter into any such transaction, we may be required to give up certain rights to our technology and control over its future development.

 

Intellectual Property

 

We regard the protection of patents and other intellectual property rights that we own or license as critical to our business and competitive position. To protect our intellectual property, we rely on patent, trade secret, and copyright law, as well as confidentiality, nondisclosure, assignment of invention and other contractual arrangements with our officers, directors, employees, consultants, investigators, clinical trial sites, contractors, collaborators and other third parties to whom we disclose confidential information. Our policy is to pursue patent applications on inventions and discoveries that we believe are commercially important to the development and growth of our business. We solely own or have exclusive licenses to our patents and patent applications.

 

Our pipeline currently includes a substantial catalogue of synthesized compounds, specifically A2A agonists and A2B antagonists that require further characterization and testing for potential clinical candidates. Our proprietary dual A2A/A2B antagonists have great potential and need to be further explored.

 

Our intellectual property estate, shown above, has twenty-eight (28) issued patents in twenty-five (25) different jurisdictions and five (5) currently pending applications.

 

When appropriate and funding permitting, we plan to continue to seek patent protection for inventions in our core technologies and in ancillary technologies that support our core technologies or which we otherwise believe would provide us with a competitive advantage. We expect to be able to accomplish this by filing and maintaining patent applications for discoveries we make, either alone or in collaboration with scientific collaborators and strategic partners. Typically, we plan to file patent applications in the United States as well as foreign countries, where applicable. In addition, we may obtain licenses or options to acquire licenses to patent filings from other individuals and organizations that we anticipate could be useful in advancing our research, development and commercialization initiatives and our strategic business interest.

 

6

 

 

Manufacturing and Supply

 

We do not plan to develop company-owned or company-operated manufacturing facilities. We historically have and we plan to in the future, outsource all drug manufacturing to contract manufacturers that are required to operate in compliance with cGMP. We may also seek to refine the current manufacturing process in order to achieve improvements in efficiency, costs, purity and the like as well as address different drug formulations to achieve improvements in stability and/or drug delivery.

 

Between September 2021 and February 2022, our CMO manufactured to GMP standards, both our adenosine A2A receptor antagonist as well as the nano- or microparticle formulation for intratumoral delivery known as RT-AR001. We have sufficient material to take us through the IND and initial clinical studies.

 

Governmental Regulations

 

FDA Approval Process

 

Prior to commencement of clinical studies involving humans, preclinical testing of new pharmaceutical products is generally conducted on animals in the laboratory to evaluate the potential efficacy and safety of the product candidate. The results of these studies are submitted to the FDA as part of an IND application, which must become effective before clinical testing in humans can begin. Typically, human clinical evaluation involves a time-consuming and costly three-phase process. In Phase I, clinical trials are conducted with a small number of people to assess safety, tolerability and to evaluate the pattern of drug distribution within the body. In Phase II, clinical trials are conducted with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety. (In some cases, an initial trial is conducted in diseased patients to assess both preliminary efficacy and preliminary safety, in which case it is referred to as a Phase I/II trial.) In Phase III, large-scale, multi-center, comparative trials are conducted with patients afflicted with a target disease in order to provide enough data to demonstrate the efficacy and safety required by the FDA. The FDA closely monitors the progress of each of the three phases of clinical testing and may, at its discretion, re-evaluate, alter, suspend, or terminate the testing based upon the data which have been accumulated to that point and its assessment of the risk/benefit ratio to the patient. All adverse events must be reported to the FDA. Monitoring of all aspects of the study to minimize risks is a continuing process.

 

The results of the preclinical and clinical testing on non-biologic drugs and certain diagnostic drugs are submitted to the FDA in the form of a New Drug Application (NDA) for approval prior to commencement of commercial sales. In responding to an NDA submission, the FDA may grant marketing approval, may request additional information, may deny the application if it determines that the application does not provide an adequate basis for approval, and may also refuse to review an application that has been submitted if it determines that the application does not provide an adequate basis for filing and review. There can be no assurance that approvals would be granted on a timely basis, if at all, for any of our proposed products.

 

Orphan Drugs

 

Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally defined as a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same orphan indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.

 

7

 

 

Asia, European and Other Regulatory Approval

 

Whether or not FDA approval has been obtained, approval of a product by comparable regulatory authorities in Europe and other countries is necessary prior to commencement of marketing the product in such countries. The regulatory authorities in each country may impose their own requirements and may refuse to grant an approval, or may require additional data before granting it, even though the relevant product has been approved by the FDA or another authority. As with the FDA, the regulatory authorities in the European Union (EU), countries located in Asia, and other developed regions have lengthy approval processes for pharmaceutical products. The process for gaining approval in particular countries and regions varies, but generally follows a similar sequence to that described for FDA approval. In Europe, the European Committee for Proprietary Medicinal Products provides a mechanism for EU-member states to exchange information on all aspects of product licensing. The EU has established a European agency for the evaluation of medical products, with both a centralized community procedure and a decentralized procedure, the latter being based on the principle of licensing within one member country followed by mutual recognition by the other member countries. In China, the CFDA functions as the counterpart to the FDA in the United States and is responsible for overseeing drug approvals in China and its territories.

 

Reimbursement and Health Care Cost Control

 

Reimbursement for the costs of treatments and products such as ours from government health administration authorities, private health insurers and others, both in the United States and abroad, is a key element in the success of new health care products. Significant uncertainty often exists as to the reimbursement status of newly approved health care products. The revenue and profitability of some health care-related companies have been affected by the continuing efforts of governmental and third-party payors to contain or reduce the cost of health care through various means. Payors are increasingly attempting to limit both coverage and the levels of reimbursement for new therapeutic products approved for marketing by the FDA, and are refusing, in some cases, to provide any coverage for uses of approved products for disease indications for which the FDA has not granted marketing approval. In certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control.

 

In the United States, there have been a number of federal and state proposals to implement government control over health care costs. The U.S. Patient Protection and Affordance Care Act and the Health Care and Education Reconciliation Act were signed into law in March 2010. A number of provisions of those laws require further rulemaking action by governmental agencies to implement. The laws change access to health care products and services and create new fees for the pharmaceutical and medical device industries. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. The laws also include new authorization to the FDA to approve companies to market biosimilar products within the United States, although to date FDA rulemaking under this legislation has been limited. We cannot predict the timing or impact of any such future rulemaking on our business.

 

Other Regulations

 

We are also subject to various U.S. federal, state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our business. Additionally, we are subject to regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002, and Securities and Exchange Commission regulations. We cannot accurately predict the extent of government regulation which might result from future legislation or administrative action.

 

Employees

 

As of March 15, 2023, we employed only Mr. Silvestre, on a part time basis, as our interim chief executive officer who is our only employee. In addition, we contract with a limited number of consultants to assist in activities related to our operations.

 

8

 

 

Corporate History

 

We were incorporated in the State of Delaware in November 2003. In August of 2016, we changed our name from GenSpera, Inc. to Inspyr Therapeutics, Inc. In October 2021, we completed a holding company reorganization structure, changing our name to Rebus Holdings, Inc. Our principal office is located in Westlake Village, California. Since our inception, we have invested a substantial portion of our efforts and financial resources in the development of mipsagargin (G-202). In July of 2017, we acquired Lewis and Clark Pharmaceuticals and licensed certain assets to Ridgeway Therapeutics for further development. Upon the termination of such license in October 2020, we resumed operations focusing our efforts on our Adenosine Receptor Modulators. On October 12, 2021, we completed a 1:75 reverse stock split of our common stock. We have generated no revenues from the sale of our product candidates and have experienced substantial net operating losses.

 

Where to Find More Information

 

We make our public filings with the SEC, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all exhibits and amendments to these reports. These materials are available on the SEC’s web site, www.sec.gov.

 

You may also read and copy any materials you file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE., Washington, DC 20549, on official business days during the hours of 10 a.m. to 3 p.m. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1–800–SEC–0330. Additionally, the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The Internet site is located at www.sec.gov. Alternatively, you may obtain copies of these filings, including exhibits, by writing or telephoning us at:

 

REBUS HOLDINGS, INC.

2629 Townsgate Road #215

Westlake Village, CA 91361

Attn: Chief Executive Officer

Tel: (818) 597-7552

 

PROPERTIES

 

Our executive offices are located at 2629 Townsgate Road, Suite 215, Westlake Village, CA 91361. At present our employee and consultants work virtually from around the country. We currently pay no money for these facilities. There is no affiliation between us or any of our principals or agents and our landlords or any of their principals or agents.

 

9

 

 

ITEM 1A. RISK FACTORS

 

We have described below a number of uncertainties and risks which, in addition to uncertainties and risks presented elsewhere in this Annual Report, may adversely affect our business, operating results and financial condition. The uncertainties and risks enumerated below as well as those presented elsewhere in this Annual Report should be considered carefully in evaluating us, our business and the value of our securities. The following important factors, among others, could cause our actual business, financial condition and future results to differ materially from those contained in forward-looking statements made in this Annual Report or presented elsewhere by management from time to time. In these circumstances, the market price of our common stock could decline, and you could lose your entire investment.

 

Risks Related to our Financial Position, Need to Raise Additional Capital, and Series F Preferred Stock

 

We were forced to curtail our operations due to a lack of operating capital and we will not be able to continue as a going concern if we do not obtain additional financing.

 

Since our inception, we have funded our operations through the sale of our securities. Our cash balances at December 31, 2022 and 2021 were approximately $5,000 and $711,000, respectively. Despite raising $1,000,000 in gross proceeds through the sale of convertible debentures consisting of (i) $500,000 in January 2021 and (ii) $500,000 (for cash) in June 2021, our ability to continue as a going concern is still wholly dependent upon obtaining sufficient capital to fund our operations. We have no committed sources of additional capital and our access to capital funding is always uncertain. Accordingly, despite our ability to secure capital in the past, we cannot assure you that we will be able to secure additional capital through financing transactions, including issuance of debt, or through other means such as the licensing of our technology or grants. In the event that we are not able to secure additional funding, we may be forced to curtail operations, delay or stop ongoing clinical trials, cease operations altogether or file for bankruptcy.

 

Our auditors have expressed substantial doubt about our ability to continue as a going concern.

 

Our auditors’ report on our December 31, 2022 consolidated financial statements expressed an opinion that our capital resources as of the date of their audit report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Our current cash level raises substantial doubt about our ability to continue as a going concern past the first quarter of 2023. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

 

If we do not raise sufficient capital, we may lose rights to certain intellectual property which is the basis of our lead product candidates.

 

In October 2020, pursuant to the cancellation of a license agreement, we reacquired the rights to US Patent 9,593,118, which covers both A2B and dual A2A/A2B antagonists. The intellectual property contained in US Patent 9,593,118 is the basis of our lead product candidates. As a condition to the cancelation of the license, we are required to raise an aggregate of $5 million prior to October of 2023. As of the date of this Annual Report, we have raised approximately $1,500,000 in capital beginning from October 5, 2020 (the date of the termination of license agreement). If we are unable to raise such capital, the license cancelation will be revoked, and the license will be reinstated in exchange for the return of the common shares and Series F Preferred Stock. In such event, we will lose all rights to the technology which forms the basis of our lead product candidate which will have a material adverse effect on our business and prospects.

 

Our shareholders will experience substantial dilution upon the conversion of our Series F Preferred Stock.

 

On October 5, 2020, we reacquired the rights to certain intellectual property that is the basis of our lead proposed product. In exchange for the cancelation of the prior license, which resulted in our reacquisition of such technology, we issued 8,000 shares of Series F Preferred Stock. The 8,000 shares of Series F Preferred Stock are convertible into an aggregate amount that will equal 80% of our issued and outstanding Common Stock immediately post conversion. Upon conversion, our shareholders will experience substantial dilution.

 

10

 

 

Risks Relating to Our Stage of Development and Business

 

If we are unable to successfully attract and retain a new management team and secure additional members and employees, our business could be harmed.

 

On June 16, 2021, Michael Cain, our interim chief executive officer and principal accounting officer resigned as an officer and as a member of the Board of Directors. On August 16, 2021, we appointed Raul Silvestre as interim chief executive officer and principal accounting officer. We will need to augment senior management as well as engage additional personnel to execute our business plan and grow our business. Our success depends largely on the development and execution of our business strategy by our management team. The recent transitions in our executive team may be disruptive to our business, and if we are unable to manage an orderly transition, our business may be adversely affected. Additionally, since our management team consists of only one individual, Mr. Silvestre, the loss of Mr. Silvestre would likely harm our ability to implement our business strategy and respond to the rapidly changing market conditions in which we operate. There may be a limited number of persons with the requisite skills to serve in these positions, and we cannot assure you that we would be able to identify or employ such qualified personnel on acceptable terms, if at all. Additionally, we cannot assure you that management will succeed in working together as a team. In the event that we are unsuccessful, our business and prospects could be harmed.

 

We are an early-stage company, have no product revenues, are not profitable and may never be profitable.

 

From inception through December 31, 2022, we have raised approximately $39.1 million through the sale of our securities and exercise of outstanding warrants. During this same period, we have recorded an accumulated deficit of approximately $65.3 million. Our net loss for the fiscal year ended December 31, 2022 was $1,020,000. We recognized $2,698,000 of income for the year ended December 31, 2021 (resulting from net noncash income of $3,720,000 related to our convertible notes payable and related derivatives). Our increase in net loss is primarily the result of a reduction in gain from the change in fair value of our derivative instruments and a reduction in gains from conversion of debt, partially offset by reductions in interest expense and operating expenses. None of our products in development have received approval from the United States Food and Drug Administration or FDA, or other regulatory authorities; we have no sales and have never generated revenues nor do we expect to for the foreseeable future. We have currently curtailed our pre-clinical and clinical trials related to mipsagargin and are currently focusing our efforts on the development of our adenosine receptor modulators. We expect to incur significant operating losses for the foreseeable future as we continue the research, pre-clinical and clinical development of our product candidates as well as the possible in-licensing of additional clinical and pre-clinical assets. Accordingly, we will need additional capital to fund our continuing operations and any expansion plans. Since we do not generate any revenue, the most likely sources of such additional capital include the sale of our securities, a strategic licensing collaboration transaction or joint venture involving the rights to one or more of our product candidates, or from grants. To the extent that we raise additional capital by issuing equity securities, our stockholders are likely to experience dilution with regard to their percentage ownership of the company, which may be significant. If we raise additional funds through collaborations or licensing arrangements, we may be required to relinquish some or all the rights to our technologies, product candidates, or grant licenses on terms that are not favorable to us. If we raise additional capital by incurring debt, we could incur significant interest expense and become subject to covenants that could affect the manner in which we conduct our business, including securing such debt obligations with our assets.

 

Our product candidates are at various stages of early development and significant financial resources are required to develop commercially viable products and obtain regulatory approval to market and sell such products. We will need to devote significantly more research and development efforts, financial resources and personnel to develop commercially viable products and obtain regulatory approvals. We may encounter hurdles and unexpected issues as we proceed in the development of our other product candidates. While initial data from our research appear promising, the outcome of the pre-clinical and development work is uncertain and future trials may ultimately be unsuccessful. If we fail to develop and successfully commercialize our product candidates, our business may be materially harmed and could fail.

 

We have a limited operating history as a company and may not be able to effectively operate our business.

 

Our limited staff and operating history mean that there is a high degree of uncertainty regarding our ability to:

 

  ● develop and commercialize our technologies and proposed products;

 

  ● obtain regulatory approval to commence the marketing of our products;

 

11

 

 

  ● identify, hire and retain the needed personnel to implement our business plan;

 

  ● manage growth;

 

  ● achieve market acceptance or insurance reimbursement for any of our proposed products, if successfully developed; or

 

  ● respond to competition.

 

No assurances can be given as to exactly when, if at all, we will be able to fully develop, and take the necessary steps to derive any revenues from our proposed product candidates.

 

We rely on technologies that we may not be able to commercially develop, which will prevent us from generating revenues, operating profitably or providing investors any return on their investment.

 

We have refocused our development on our adenosine receptor modulator technologies and our ability to generate revenue and operate profitably will depend on us being able to develop these technologies for human applications. We cannot guarantee that the results obtained in clinical evaluation of our therapies will be sufficient to warrant approval by the FDA for clinical use. Even if our therapies are approved for use by the FDA, there is no guarantee that they will exhibit an enhanced efficacy relative to competing products such that they will be adopted by the medical community. Without significant adoption by the medical community our product candidates will have limited commercial potential which will likely result in the loss of your entire investment.

 

Inability to complete pre-clinical and clinical testing and trials will impair the viability of the Company.

 

We are in the development stage and have not yet applied for approval by the FDA to conduct clinical trials. Even if we successfully file an IND application and receive clearance from the FDA to commence trials, the outcome of pre-clinical, clinical and product testing of our product candidates is uncertain, and if we are unable to satisfactorily complete such testing, or if such testing yields unsatisfactory results, we will be unable to commercially produce our proposed products. Before obtaining regulatory approvals for the commercial sale of any potential human products, our product candidates will be subjected to extensive pre-clinical and clinical testing to demonstrate their safety and efficacy in humans. No assurances can be given that the clinical trials of our product candidates, or those of licensees or collaborators, will demonstrate the safety and efficacy of such product candidates at all, or to the extent necessary to obtain appropriate regulatory approvals, or that the testing of such product candidates will be completed in a timely manner, if at all, or without significant increases in costs, program delays or both, all of which could harm our ability to generate revenues. In addition, our product candidates may not prove to be more effective for treating disease than current therapies. Accordingly, we may have to delay or abandon efforts to research, develop or obtain regulatory approval to market our product candidates. Many companies involved in biotechnology research and development have suffered significant setbacks in advanced clinical trials, even after promising results in earlier trials. The failure to adequately demonstrate the safety and efficacy of a therapeutic product under development could delay or prevent regulatory approval of the product and could harm our ability to generate revenues, operate profitably or produce any return on an investment in our company.

 

Raising capital may be difficult as a result of our history of losses and limited operating history in our current stage of development.

 

When making investment decisions, investors typically look at a company’s management, earnings and historical performance in evaluating the risks and operations of the business and the business’s future prospects. Our history of losses, new senior management team and relatively limited operating history in our current stage of development makes such evaluation, as well as any estimation of our future performance, substantially more difficult. As a result, investors may be unwilling to invest in us or on terms or conditions which are acceptable. If we are unable to secure additional financing, we may need to materially scale back our business plan and/or operations or cease operations altogether.

 

12

 

 

A pandemic, epidemic or outbreak of an infectious disease in the markets in which we operate or that otherwise impacts our facilities or advisors could adversely impact our business.

 

If a pandemic, epidemic, or outbreak of an infectious disease including the recent outbreak of respiratory illness caused by a novel coronavirus (COVID-19) or other public health crisis were to affect our facilities or those of our suppliers, our business could be adversely affected. A pandemic typically results in social distancing, travel bans and quarantine, and this may limit access to our facilities, management, support staff and professional advisors. These factors, in turn, may not only materially impact our operations and financial condition, but our overall ability to react timely to mitigate the impact of this event. Also, it may hamper our efforts to comply with our filing obligations with the Securities and Exchange Commission.

 

Business or economic disruptions or global health concerns could seriously harm our development efforts and increase our costs and expenses.

 

Broad-based business or economic disruptions could adversely affect our ongoing or planned research and development activities. For example, in November 2019 an outbreak of a novel strain of coronavirus originated in Wuhan, China, and has since spread around the world, including to the United States. To date, this outbreak has already resulted in extended shutdowns of many businesses around the world, including in the United States. Global health concerns, such as coronavirus, could also result in social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate. We cannot presently predict the scope, severity and longevity of any potential business shutdowns or disruptions, but if we or any of the third parties with whom we engage or plan to engage, including the suppliers, clinical trial sites, regulators and other third parties with whom we conduct business or plan to conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. It is also possible that global health concerns such as this one could disproportionately impact the hospitals and clinical sites in which we conduct or plan to conduct any of our clinical trials, which could have a material adverse effect on our business and our results of operation and financial condition.

 

Risks Related to Commercialization

 

The market for our proposed products is rapidly changing and competitive.

 

The pharmaceutical and biotechnology industries are subject to rapid and substantial technological change and innovation. Developments by others may render our proposed products non-competitive or obsolete, or we may be unable to keep pace with technological developments and other market factors. Competition from pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is intense and is expected to increase.

 

As a pre-revenue company, our resources are limited, and we may experience challenges inherent in the early development of novel therapeutics. Competitors have developed or are in the process of developing technologies that are, or in the future may be, the basis for competition. Some of these technologies may have an entirely different approach or means of accomplishing similar therapeutic efforts compared to our proposed products. Our competitors may develop therapies that are safer, more effective and less costly than our proposed products and therefore, present a serious competitive threat to us.

 

The acceptance of therapies that are alternatives to ours may limit market acceptance of our proposed products, even if commercialized. Many of our targeted diseases and conditions can also be treated by other medications and treatments. These treatments may be widely accepted in medical communities and have a longer history of use. The established use of other competing therapies may limit the potential for our proposed products, even if commercialized.

 

13

 

 

Our proposed products may not be accepted by the healthcare community.

 

Our proposed products, if approved for marketing, may not achieve market acceptance by the healthcare community since hospitals, physicians, patients, or the medical community in general may decide not to utilize them. We are attempting to develop products that are likely to be first approved for marketing as a treatment for late-stage cancer where there is no truly effective standard of care. If approved for use in late-stage cancer, our proposed products might then be evaluated in earlier stages where they could represent a substantial departure from established treatment methods and would most likely compete with a number of more conventional drugs and therapies which are manufactured and marketed by major pharmaceutical companies. It is too early in the development cycle of our proposed products for us to predict our major competitors. The degree of market acceptance of our products, if developed, will depend on a number of factors, including but not limited to:

 

  ● our ability to demonstrate the clinical efficacy and safety of our proposed products to the medical community;

 

  ● our ability to create products that are superior to alternative products;

 

  ● our ability to establish in the medical community the potential advantage of our treatments over alternative treatment methods; and

 

  ● the reimbursement policies of government and third-party payors.

 

If the healthcare community does not accept our products, our business could be materially harmed.

 

Our potential competitors in the biotechnology and pharmaceutical industries have significantly greater resources than we have.

 

We compete against numerous companies, many of which have substantially greater resources than we have. Several such competitors have research programs and/or efforts to treat the same diseases we target. Companies that may compete with us have substantially greater financial, research, manufacturing and marketing resources than we do. As a result, such competitors may find it easier to compete in our industry and bring competing products to market.

 

Risks Related to the Development and Manufacturing of Our Product Candidates

 

We intend to rely exclusively upon third-party FDA-regulated manufacturers and suppliers for our proposed products.

 

We currently have no internal manufacturing capability and intend to rely exclusively on FDA-approved licensees, strategic partners or third-party contract manufacturers or suppliers for the foreseeable future. Because manufacturing facilities are subject to regulatory oversight and inspection, the failure of any of our third-party FDA regulated manufactures or suppliers to comply with regulatory requirements could result in material manufacturing delays and product shortages, which could delay or otherwise negatively impact our clinical trials and product development plans. Should we be forced to manufacture our proposed products, we cannot give any assurance that we would be able to develop internal manufacturing capabilities or secure third-party suppliers for raw materials. In the event that we seek third party suppliers or alternative manufacturers, they may require us to purchase a minimum amount of materials or could require other unfavorable terms. Any such event could materially impact our business prospects and could delay the development of our proposed products. Moreover, we cannot give any assurance that the contract manufacturers or suppliers that we select will be able to supply our products in a timely or cost-effective manner or in accordance with applicable regulatory requirements or our own specifications.

 

We may not be able to establish or maintain the third-party relationships that are necessary to develop or potentially commercialize our product candidates.

 

As needed, we plan to rely heavily on third party collaborators, partners, licensees, clinical research organizations, clinical investigators, vendors or other third parties to support our research and development efforts and to conduct clinical trials for our product candidates. We cannot guarantee that we will be able to successfully negotiate agreements for, or maintain relationships with, these third parties on a commercially reasonable basis, if at all. Additionally, to commercialize our proposed products, we intend to rely on third party licensees or the outright sale of our proposed products to pharmaceutical partner(s). If we fail to establish or maintain such third-party relationships as anticipated, our business could be adversely affected.

 

14

 

 

We are dependent upon third parties to develop our product candidates, and such parties are, to some extent, outside of our control.

 

We depend and plan to depend upon independent contract research organizations, investigators, and collaborators, such as universities and medical institutions, to conduct our pre-clinical and clinical studies. These individuals and/or entities are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These third parties may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If these third parties fail to devote sufficient time and resources to our programs, or if their performance is substandard, the development of our drug candidates and corresponding FDA approval could be delayed or fail entirely.

 

Our therapeutic compounds may not be able to be manufactured profitably on a large enough scale to support commercialization.

 

To date, our therapeutic compounds have only been manufactured at a scale which is adequate to supply our research activities and early-stage clinical trials. There can be no assurance that the procedures currently used to manufacture our therapeutic compounds will work at a scale which is adequate for commercial needs. In the event our therapeutic compounds cannot be manufactured in sufficient quantities for commercialization, our future prospects could be significantly impacted, and our financial prospects would be materially harmed.

 

Risks Relating to our Intellectual Property

 

Our competitive position is dependent on our intellectual property and we may not be able to withstand challenges to our intellectual property rights.

 

We rely on our intellectual property, including our issued and applied for U.S. and foreign patents as the foundation of our business. If our intellectual property rights are challenged, no assurances can be given that our patents or licenses would survive claims alleging invalidity or infringement on other patents and/or licenses. In addition, disputes may arise regarding inventorship of our intellectual property. It is possible that our intellectual property may be infringing upon existing patents that we are not currently unaware of. As the number of participants in the marketplace grows, the possibility of patent infringement claims against us increases. It is difficult, if not impossible, to determine how such disputes would be resolved. Furthermore, because of the substantial amount of discovery required in connection with patent litigation, there is a risk that some of our confidential information could be required to be publicly disclosed. Any litigation claims against us may cause us to incur substantial costs and could place a significant strain upon our financial resources, divert the attention of management or restrict our core business or result in the public disclosure of confidential information.

 

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use of, our technology.

 

Some or all of our patent applications may not issue as patents, or the claims of any issued patents may not afford meaningful protection for our technologies or products. In addition, patents issued to us or our licensors, if any, may be challenged and subsequently narrowed, invalidated or circumvented. Patent litigation is widespread in the biotechnology industry and could harm our business. Litigation might be necessary to protect our patent position or to determine the scope and validity of third-party proprietary rights. If we choose to go to court to stop someone else from using the inventions claimed in our patents, that individual or company would have the right to ask the court to rule that such patents are invalid and/or should not be enforced against that third party. These lawsuits are expensive, and we may not have the required resources to pursue such litigation or to protect our patent rights. In addition, there is a risk that the court might decide that these patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of these patents is upheld, the court could refuse to stop the other party on the ground that such other party’s activities do not infringe on our rights contained in these patents.

 

Furthermore, a third party may claim that we are using inventions covered by their patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates. These lawsuits are costly and could materially increase our operating expenses and divert the attention of managerial and technical personnel. There is a risk that a court would decide that we are infringing the third party’s patents and would order us to stop the activities covered by the patents. In addition, there is a risk that a court would order us to pay the other party damages for having violated the other party’s patents. The biotechnology industry has produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.

 

15

 

 

Because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications and could further require us to obtain rights to issued patents covering such technologies.

 

If another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference or other proceeding in the U.S. Patent and Trademark Office, or the PTO, or a court to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our United States patent position with respect to such inventions.

 

Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the capital necessary to continue our operations.

 

Obtaining and maintaining our patent protection depends upon compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

 

The PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.

 

We may not be able to adequately protect our intellectual property.

 

We rely in part on trade secret protection in order to protect our proprietary trade secrets and unpatented know-how. However, trade secrets are difficult to protect, and we cannot be certain that others do not develop the same or similar technologies on their own. Additionally, research with regard to our technologies has been performed in countries outside of the United States, and we also anticipate conducting joint ventures, collaborations and future clinical trials outside the US. The laws in some of these countries may not provide protection for our trade secrets and intellectual property. We have taken steps, including entering into confidentiality agreements with our employees, consultants, service providers, and potential strategic partners to protect our trade secrets and unpatented know-how. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party’s relationship with us. We also typically obtain agreements from these parties which provide that inventions conceived by the party in the course of rendering services to us are our property. However, these agreements may not be honored, including in foreign countries in which we conduct research, and may not effectively assign intellectual property rights to us. Enforcing a claim that a party illegally obtained and is using our trade secrets or know-how is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets or know-how. The failure to obtain or maintain trade secret protection could adversely affect our competitive position.

 

We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets of their former employers.

 

As is common in the biotechnology and pharmaceutical industries, we may employ and hire individuals and/or entities who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these individuals, entities or that we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

 

16

 

 

Risks Relating to Marketing Approval and Government Regulations

 

Data obtained from clinical trials are susceptible to varying interpretations and may not be sufficient to support approval of our proposed products by the FDA.

 

The design of our potential clinical trials will be based on many assumptions about the expected effect of our product candidates and if those assumptions are incorrect, our potential clinical trials may not produce statistically significant results. Preliminary results may not be confirmed on full analysis of the detailed results of early clinical trials. Data already obtained, or in the future obtained, from pre-clinical studies and clinical trials do not necessarily predict the results that may be obtained from later trials. Moreover, pre-clinical and clinical data are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after promising results in earlier trials. The failure to adequately demonstrate the safety and effectiveness of a proposed formulation or product under development could delay or prevent regulatory clearance of the potential drug. Our products may not prove to be safe and effective in clinical trials and may not meet all regulatory requirements needed to receive regulatory approval. While data from our completed trials appear promising, the outcome of the current trials is uncertain, and these trials or future trials may ultimately be unsuccessful. Our clinical trials may among other things, not demonstrate sufficient levels of safety and efficacy necessary to obtain the requisite regulatory approvals for our drugs, and thus our proposed drugs may not be approved for marketing.

 

Our proposed products may not receive FDA or other regulatory approvals.

 

The FDA and comparable government agencies in foreign countries impose substantial regulations on the manufacture and marketing of pharmaceutical products through expensive, lengthy and detailed laboratory, pre-clinical and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Satisfaction of these regulations typically takes several years or more and varies substantially based upon the type, complexity and novelty of the proposed product. Our proposed products are subject to extensive regulation and/or acceptance by numerous governmental authorities in the United States, including the FDA, and authorities in other countries. Most of our proposed products will require governmental approval before they can be commercialized. Our failure to receive the regulatory approvals in the United States or foreign countries will materially impact our business.

 

Our proposed products may not have favorable results in clinical trials or receive regulatory approval.

 

Encouraging results from our studies to date should not be relied upon as evidence that our planned pre-clinical and clinical trials will ultimately be successful, or our products approved for marketing. Even though the results of our studies to date may seem promising in certain respects, we will be required to demonstrate through further pre-clinical and clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their commercial sale. There is typically an extremely high rate of attrition from the failure of product candidates as they proceed through clinical trials. If any product candidate fails to demonstrate sufficient safety and efficacy in any clinical trial, then we could experience potentially significant delays in, or be required to abandon, development of that product candidate. While initial data from our preliminary studies appear promising, the outcome of any clinical trials is uncertain and such trials or future trials may ultimately be unsuccessful.

 

If users of our proposed products are unable to obtain adequate reimbursement from third-party payors, market acceptance of our proposed products may be limited, and we may not achieve revenues or profits.

 

The continuing efforts of governments, insurance companies, health maintenance organizations and other payers of healthcare costs to contain or reduce costs of health care may affect our future revenues and profitability as well as the future revenues and profitability of our potential customers, suppliers and collaborative partners in addition to the availability of capital. In other words, our ability to commercialize our proposed products depends in large part on the extent to which appropriate reimbursement levels for the cost of our proposed formulations, products and related treatments are obtained by the health care providers of these products and treatments. At this time, we cannot predict the precise impact that recently adopted or future laws will have on these reimbursement levels.

 

17

 

 

We may be unable to comply with our reporting and other requirements under federal securities laws.

 

The Sarbanes-Oxley Act of 2002, as well as related new rules and regulations implemented by the United States Securities and Exchange Commission, or SEC, and the Public Company Accounting Oversight Board, require changes in the corporate governance practices and financial reporting standards for public companies. These laws, rules and regulations, including compliance with Section 404 of the Sarbanes-Oxley Act of 2002 relating to internal control over financial reporting, would be expected to materially increase the Company’s legal and financial compliance costs and make some activities more time-consuming and more burdensome. Presently we qualify as a non-accelerated filer. Accordingly, we are exempt from the requirements of Section 404(b) and our independent registered public accounting firm is not required to audit the design and operating effectiveness of our internal controls and management’s assessment of the design and the operating effectiveness of such internal controls. In the event that we become an accelerated filer, we will be required to expend substantial capital in connection with compliance.

 

We do not have effective internal controls over our financial reporting.

 

Because of our limited resources, management has concluded that our internal control over financial reporting may not be effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Effective internal controls over financial reporting and disclosure controls and procedures are necessary for us to provide reliable financial and other reports and effectively prevent fraud. If we cannot provide reliable financial or SEC reports or prevent fraud, investors may lose confidence in our SEC reports, our operating results and the trading price of our common stock could suffer materially, and we may become subject to litigation.

 

Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses and will divert time and attention away from revenue generating activities.

 

Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 and related SEC regulations, have created uncertainty for public companies and significantly increased the costs and risks associated with accessing the public markets and public reporting. Our management team invests significant time and financial resources to comply with both existing and evolving standards for public companies, which will lead to increased general and administrative expenses and a diversion of management time and attention from developing our business to compliance activities which could have an adverse effect on our business.

 

Risks Relating to our Securities

 

Our common stock price may be particularly volatile because of our stage of development and business.

 

The market prices for the securities of biotechnology and pharmaceutical companies in general, and early-stage drug development companies in particular, such as ours, have been highly volatile and may continue to be highly volatile in the future. The following may have a significant impact on the market price of our common stock:

 

  ● our ability to retain and augment our current management team and workforce, which currently consists of only one employee, our chief executive officer;

 

  ● the development status of our drug candidates, particularly the results of our clinical trials;

 

  ● market conditions or trends related to the biotechnology and pharmaceutical industries, or the market in general;

 

  ● announcements of technological innovations, new commercial products, or other material events by our competitors or us;

 

  ● disputes or other developments concerning our proprietary rights;

 

18

 

 

  ● changes in, or failure to meet, securities analysts’ or investors’ expectations of our financial and developmental performance;

 

  ● additions or departures of key personnel;

 

  ● loss of any strategic relationship;

 

  ● discussions of our business, products, financial performance, prospects, or stock price by the financial and scientific press and online investor communities such as chat rooms;

 

  ● industry developments, including, without limitation, changes in healthcare policies or practices or third-party reimbursement policies;

 

  ● public concern as to, and legislative action with respect to, testing or other research areas of biopharmaceutical and pharmaceutical companies, the pricing and availability of prescription drugs, or the safety of drugs;

 

  ● regulatory developments in the United States or foreign countries; and

 

  ● economic, political and other external factors.

 

Broad market fluctuations may cause the market price of our common stock to decline substantially. Additionally, fluctuations in the trading price or liquidity of our common stock may materially and adversely affect, among other things, the interest of investors to purchase our common stock on the open market and, generally, our ability to raise capital.

 

Our board of directors has broad discretion to issue additional securities, in the event that we have adequate authorized capital to issue such securities.

 

We are authorized under our certificate of incorporation to issue up to 1,000,000,000 shares of common stock and 30,000,000 “blank check” shares of preferred stock. Shares of our blank check preferred stock provide the board of directors with broad authority to determine voting, dividend, conversion, and other rights. As of March 15, 2023, we have issued and outstanding 32,132,907 shares of common stock. We have also authorized 1,853 shares of Series A 0% Convertible Preferred Stock, of which 133.8125 are outstanding, 1,000 shares of Series B 0% Convertible Preferred Stock, of which 71 are outstanding, 290.43148 shares of Series C 0% Convertible Preferred Stock, that are all outstanding, 5,000 shares of Series D 0% Convertible Preferred Stock, all of which are outstanding, 5,000 shares of Series E 0% Convertible Preferred Stock, all of which are outstanding, and 8,000 shares of Series F 0% Convertible Preferred Stock, all of which are outstanding. Accordingly, we are entitled to issue 967,867,093 shares of common stock, and 29,981,505 additional shares of “blank check” preferred stock. Notwithstanding, all of our Series F Convertible Preferred Stock is convertible into 80% of our issued and outstanding common stock immediately prior to issuance. Our board may generally issue those common and preferred shares, or convertible securities to purchase those shares, without further approval by our shareholders. Any additional preferred shares we may issue could have such rights, preferences, privileges, and restrictions as may be designated from time-to-time by our board, including preferential dividend rights, voting rights, conversion rights, redemption rights and liquidation provisions.

 

It is likely that we will issue a large number of additional securities to raise capital in order to further our business plans. It is also likely that we will issue a large number of additional securities to directors, officers, employees and consultants as compensatory grants in connection with their services, both in the form of stand-alone grants or under our various stock plans. Any issuances could be made at a price that reflects a discount to, or a premium from, the then-current market price of our common stock. These issuances would dilute the percentage ownership interest of our current shareholders, which would have the effect of reducing your influence on matters on which our stockholders vote, and might dilute the net tangible book value per share of our common stock.

 

19

 

 

Future sales of our common stock could cause our stock price to fall.

 

Transactions that result in a large amount of newly issued shares become readily tradable, or other events that cause current stockholders to sell shares, could place downward pressure on the trading price of our common stock. In addition, the lack of a robust trading market may require a stockholder who desires to sell a large number of shares of common stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market price of our stock. If our stockholders sell, or the market perceives that our stockholders intend to sell for various reasons, substantial amounts of our common stock in the public market, including shares issued upon the exercise of outstanding options or warrants, the market price of our common stock could fall. Sales of a substantial number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate. We may become involved in securities class action litigation that could divert management’s attention and harm our business.

 

As of March 15, 2023, we had 1,000,000,000 shares of common stock authorized and 32,132,907 shares outstanding, 1,853 shares of Series A 0% Convertible Preferred Stock authorized and 133.8125 Series A 0% Convertible Preferred Stock outstanding, 1,000 shares of Series B 0% Convertible Preferred Stock authorized and 71 Series B 0% Convertible Preferred Stock outstanding, 290.43148 shares of Series C 0% Convertible Preferred Stock authorized and outstanding, 5,000 shares of Series D 0% Convertible Preferred Stock authorized and outstanding, 5,000 shares of Series E 0% Convertible Preferred Stock authorized and outstanding, and 8,000 shares of Series F 0% Convertible Preferred Stock authorized and outstanding. We additionally have issued an aggregate of $5,591,048 of senior convertible debentures and convertible notes that are convertible into common stock at any time, of which $310,072 is outstanding. Substantially all of the common shares and common shares underlying the Series A 0% Convertible Preferred, Series B 0% Convertible Preferred, Series C 0% Convertible Preferred, Series D 0% Convertible Preferred, Series E 0% convertible Preferred, and Series F 0% Convertible Preferred are available for public sale, subject in some cases to volume and other limitations or delivery of a prospectus. As of March 15, 2023, we were obligated to reserve for issuance (i) 5 shares of our common stock issuable upon the conversion of 133.8125 shares of Series A 0% Convertible Preferred Stock including an additional number of common shares we are contractually obligated to reserve pursuant to our December 2015 offering; (ii) 6,543,778 shares of our common stock issuable upon the conversion of 71 shares of Series B 0% Convertible Preferred Stock including an additional number of common shares we are contractually obligated to reserve pursuant to our December 2016 offering; (iii) 678 shares of our common stock issuable upon the conversion of 290.43148 shares of Series C 0% Convertible Preferred Stock including an additional number of common shares we are contractually obligated to reserve pursuant to our March 2017 offering, (iv) 18 shares of common stock issuable upon the conversion of 5,000 shares of Series D 0% Convertible Preferred Stock, (v) 222 shares of common stock issuable upon the conversion of 5,000 shares of Series E 0% Convertible Preferred Stock, (vi) an indeterminate number of shares of common stock issuable upon the conversion of 8,000 shares of Series F 0% Convertible Preferred Stock (such amount will equal 80% of the common stock post conversion), (vii) 1 share of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $244,688 per share, and (viii) 36,358,766 shares of our common stock issuable upon conversion of our outstanding convertible notes/debentures. Subject to applicable vesting requirements and holding periods, upon conversion or exercise of the outstanding convertible notes and warrants, the underlying shares may be resold into the public market. We cannot predict if future issuances or sales of our common stock, or the availability of our common stock for sale, would harm the market price of our common stock or our ability to raise capital.

 

The market for our common stock has historically been illiquid and our investors may be unable to sell their shares.

 

Our common stock has historically traded with limited volume on the pink sheets of the OTC Markets Group Inc. Accordingly, although there has been an increased public market for our common stock, it still has historically been relatively illiquid compared to that of a seasoned issuer. Prior to making an investment in our securities, you should consider the historically limited market for our common stock. No assurances can be given that the trading volume of our common stock will increase or remain the same.

 

We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future.

 

We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the market price of our common stock appreciates.

 

20

 

 

Provisions of Delaware law and executive employment agreements may prevent or delay a change of control, which could depress the trading price of our common stock.

 

We are subject to the Delaware anti-takeover laws regulating corporate takeovers. These anti-takeover laws prevent Delaware corporations from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation’s outstanding voting stock, for three years following the date that the stockholder acquired 15% or more of the corporation’s assets unless:

 

  ● the Board of Directors approved the transaction in which the stockholder acquired 15% or more of the corporation’s assets;

 

  ● after the transaction in which the stockholder acquired 15% or more of the corporation’s assets, the stockholder owned at least 85% of the corporation’s outstanding voting stock, excluding shares owned by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or

 

  ● on or after this date, the merger or sale is approved by the Board of Directors and the holders of at least two-thirds of the outstanding voting stock that is not owned by the stockholder.

 

A Delaware corporation may opt out of the Delaware anti-takeover laws if its certificate of incorporation or bylaws so provides. We have not opted out of the provisions of the anti-takeover laws. As such, these laws could prohibit or delay mergers or other takeover or change of control transactions and may discourage attempts by other companies to acquire us.

 

In addition, employment agreements with certain executive officers provide for the payment of severance and accelerated vesting of options and restricted stock in the event of termination following a change of control. These provisions could have the effect of discouraging potential takeover attempts even if it would be beneficial to shareholders.

 

Our certificate of incorporation and bylaws contain provisions that could discourage a third-party from acquiring us.

 

Our certificate of incorporation and bylaws, as applicable, among other things (i) provide our board with the ability to alter the bylaws without stockholder approval and (ii) provide that vacancies on our board of directors may be filled by a majority of directors in office. These provisions, while designed to reduce vulnerability to an unsolicited acquisition proposal, and to discourage certain tactics used in proxy fights, may negatively impact a third-party’s decision to acquire us even if it would be beneficial to shareholders.

 

If securities or industry analysts do not publish research or reports or if they publish unfavorable research or reports, an active market for our common stock may not develop and the price of our common stock could decline.

 

We are a small company which is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume. Even if we come to the attention of such persons, they may be reluctant to follow or recommend an unproven company such as ours until such time as we became more seasoned and viable. Generally, the trading market for a company’s securities depends in part on the research and reports that securities or industry analysts publish. We currently have limited research coverage by securities and industry analysts. As a consequence, there may be periods of time when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer with significant research coverage. We cannot give you any assurance that a broader or more active public trading market for our common stock will develop or if developed, will be sustained, or that current trading levels could be sustained or not diminish. In addition, in the event any analysts downgrades our securities, the price of our shares would likely decline. If one or more of these analysts ceases to cover us or fails to publish regular reports on us, interest in the purchase of our securities could decrease, which could cause the price of our common stock and its trading volume, if any, to decline.

 

21

 

 

If securities or industry analysts do not publish research or reports or if they publish unfavorable research or reports, an active market for our common stock may not develop and the price of our common stock could decline.

 

We are a small company which is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume. Even if we come to the attention of such persons, they may be reluctant to follow or recommend an unproven company such as ours until such time as we became more seasoned and viable. Generally, the trading market for a company’s securities depends in part on the research and reports that securities or industry analysts publish. We currently have limited research coverage by securities and industry analysts. As a consequence, there may be periods of time when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer with significant research coverage. We cannot give you any assurance that a broader or more active public trading market for our common stock will develop or if developed, will be sustained, or that current trading levels could be sustained or not diminish. In addition, in the event any analysts downgrades our securities, the price of our shares would likely decline. If one or more of these analysts ceases to cover us or fails to publish regular reports on us, interest in the purchase of our securities could decrease, which could cause the price of our common stock and its trading volume, if any, to decline.

 

Our common stock is considered a “penny stock,” and is subject to additional sale and trading regulations that may make it more difficult to sell.

 

Our common stock is considered a “penny stock.” The principal result or effect of being designated a penny stock is that securities broker-dealers participating in sales of our common stock are subject to the penny stock regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange Act. For example, Rule 15g-2 requires broker-dealers dealing in penny stocks to provide potential investors with a document disclosing the risks of penny stocks and to obtain a manually signed and dated written receipt of the document at least two business days before effecting any transaction in a penny stock for the investor’s account. Moreover, Rule 15g-9 requires broker-dealers in penny stocks to approve the account of any investor for transactions in such stocks before selling any penny stock to that investor. This procedure requires the broker-dealer to (i) obtain from the investor information concerning his or her financial situation, investment experience and investment objectives; (ii) reasonably determine, based on that information, that transactions in penny stocks are suitable for the investor and that the investor has sufficient knowledge and experience as to be reasonably capable of evaluating the risks of penny stock transactions; (iii) provide the investor with a written statement setting forth the basis on which the broker-dealer made the determination in (ii) above; and (iv) receive a signed and dated copy of such statement from the investor, confirming that it accurately reflects the investor’s financial situation, investment experience and investment objectives. Compliance with these requirements may make it more difficult and time consuming for holders of our common stock to resell their shares to third parties or to otherwise dispose of them in the market or otherwise.

 

The number of brokerage firms depositing and transacting trades for penny stock companies is very limited.

 

Currently, our Common Stock is traded on the OTC Markets Pink Tier. Many traditional brokerage firms and on-line brokerages refuse to accept for deposit and trade any penny stocks generally. For those that do, the time, effort and costs associated with depositing common stock in companies such as ours which has recently had sub-penny bid and ask are onerous, time consuming and costly. This may present material concerns and obstacles to those persons beneficially owning our common stock in certificate or book entry form, and wish to deposit same into a brokerage account.

 

22

 

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2. PROPERTIES

 

Our executive offices are located at 2629 Townsgate Road, Suite 215, Westlake Village, CA 91361. At present our employee and consultants work virtually from around the country. We currently pay no money for these facilities. There is no affiliation between us or any of our principals or agents and our landlords or any of their principals or agents.

 

ITEM 3. LEGAL PROCEEDINGS

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable

 

23

 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Our common shares are quoted on the pink sheets of the OTC Markets under the symbol RBSH. Any over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

 

Holders

 

As of March 15, 2023, we had approximately 165 record holders of our common stock.

 

Dividend Policy

 

We have never declared or paid any cash dividends on our capital stock and we do not currently anticipate declaring or paying cash dividends on our capital stock in the foreseeable future. We currently intend to retain all of our future earnings, if any, to finance the operation and expansion of our business. Any future determination relating to our dividend policy will be made at the discretion of our board of directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions, future prospects, contractual restrictions and covenants, applicable law and other factors that our board of directors may deem relevant. If we do not pay dividends, a return on your investment will occur only if the market price of our common stock appreciates.

 

Equity Compensation Plan Information

 

See information contained in Part III, Item 12 of this Annual Report filed on Form 10-K.

 

Equity Compensation Plans Not Approved by Security Holders

 

See information contained in Part III, Item 12 of this Annual Report filed on Form 10-K.

 

Item 15. Recent Sales of Unregistered Securities.

 

The following information is given with regard to unregistered securities sold during the preceding three years including the dates and amounts of securities sold, the persons or class of persons to whom we sold the securities, the consideration received in connection with such sales and, if the securities were issued or sold other than for cash, the description of the transaction and the type and amount of consideration received. The descriptions contained below are a summary and qualified by the agreements, if applicable, included as Exhibits to this Annual Report. The following securities were issued in private offerings pursuant to the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended, or the Securities Act and the rules promulgated thereunder. All share amounts and prices reflect the 1-for-75 reverse stock split that was effective October 12, 2021 and include adjustment for any prior reverse stock splits that may have occurred subsequent the issuances described hereunder.

 

  ● Between January 1, 2020 and March 31, 2020, debenture holders converted an aggregate of $451,662 into approximately 58,379 shares of common stock at per share conversion prices ranging from $0.1575 to $35.25.

 

24

 

 

  ● On March 6, 2020, we issued an aggregate of $250,000 in senior convertible debentures (“March 2020 Debentures”) to certain accredited investors for cash. At issuance, the conversion price of the March 2020 Debentures was equal to the lesser of (i) $24.75 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. Pursuant to an amendment to the March 2020 Debentures and all other outstanding convertible debentures owned by certain shareholders, the conversion price was amended such that the conversion price is equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. As of the date of this Registration Statement, the March 2020 Debentures have been fully converted into common stock.

 

  ● On May 2, 2020, we sold 5,000 shares of Series E 0% Convertible Preferred Stock to an accredited investor at a price per share of $1.00 for aggregate gross proceeds of $5,000. The Series E Preferred Stock are convertible into shares of Common Stock at a conversion price of $22.50 per share.

 

  ● Between July 1, 2020 and August 12, 2020, debenture holders converted an aggregate of $80,906 into approximately 21,138 shares of common stock at per share conversion prices ranging from $2.3625 to $6.45.

 

  ● On October 5, 2020, we entered into an agreement with Ridgeway Therapeutics (“Ridgeway”) to terminate an outstanding license agreement previously entered into with Ridgeway (“Termination Agreement”). Pursuant to the Termination Agreement, as consideration, we issued Ridgeway (i) 866,667 shares of our Common Stock and (ii) 8,000 shares of Series F 0% Convertible Preferred Stock. The 8,000 shares of Series F Preferred Stock are convertible into an aggregate of eighty percent (80%) of the issued and outstanding Common Stock post-conversion on the conversion date. The Series F Preferred Stock votes on an as converted to Common Stock basis. Additionally, upon the termination, conversion, or otherwise extinguishment of certain or our outstanding convertible debentures, the Series F Preferred Stock will automatically convert into Common Stock.

 

  ● On October 23, 2020, we issued an aggregate of $600,000 in senior convertible debentures (“October 2020 Debentures”) to certain accredited investors for $500,000 cash and the cancellation of $100,000 in outstanding obligations. The October 2020 Debentures have the same terms as the March 2020 Debentures, as amended, and mature on October 23, 2021. As of the date hereof, they have been fully converted into common stock.

 

  ● Between August 17, 2020 and October 9, 2020, debenture holders converted an aggregate of $525,290 into approximately 1,045,504 shares of common stock at per share conversion prices ranging from $0.195 to $1.425.

 

  ● Between November 30, 2020 and December 31, 2020, debenture holders converted an aggregate of $252,210 into approximately 475,000 shares of common stock at per share conversion prices ranging from $0.3375 to $0.6675.

 

  ● Between January 1, 2021 and March 15, 2021, debenture holders converted an aggregate of $1,964,500 into 4,248,864 shares of common stock at per share conversion prices ranging from $0.3375 to $0.5475.

 

  ● On January 12, 2021 we issued an aggregate of $500,000 in senior convertible debentures (“January 2021 Debentures”) to certain accredited investors for cash. The January 2021 Debentures mature on January 12, 2022. The conversion price of the January 2021 Debentures is equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. As of the date of this report, all of January 2021 Debentures have been converted into common stock of the Company.

 

25

 

 

  ● Between March 16, 2021 and June 30, 2021, debenture holders converted an aggregate of $191,068 into 378,167 shares of common stock at per share conversion prices ranging from $0.3975 to $0.7275.

 

  ● On June 18, 2021, we issued an aggregate of $600,000 in senior convertible debentures (“June 2021 Debentures”) to certain accredited investors for $500,000 cash and $100,000 in cancellation of obligations. The June 2021 Debentures have the same terms as the January 2021 Debentures and mature on June 18, 2022. As of the date of this report, $500,000 of June 2021 Debentures have been converted into common stock of the Company.

 

  ● Between July 1, 2021 and August 2, 2021, debenture holders converted an aggregate of $58,000 into 133,333 shares of common stock at per share conversion prices ranging from $0.315 to $0.3375.
     
  ● Between August 3, 2021 and September 30, 2021, debenture holders converted an aggregate of $354,480 into 2,340,667 shares of common stock at per share conversion prices ranging from $0.12 to $0.37.

 

  ● Between October 1, 2021 and October 31, 2021, debenture holders converted an aggregate of $87,520 into 729,333 shares of common stock at a per share conversion price of $0.12.

 

  ● Between November 1, 2021 and December 31, 2021, debenture holders converted an aggregate of $38,028 into 1,460,000 shares of common stock at a per share conversion prices ranging from $0.0219 to $0.0323.

 

  ● During January 2022, debenture holders converted an aggregate of $461,972 into 20,363,686 shares of common stock at a per share conversion prices ranging from $0.0217 to $0.0247.

 

ITEM 6. SELECTED FINANCIAL DATA

 

We are not required to provide the information as to selected financial data as we are considered a smaller reporting company.

 

26

 

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements regarding our business development plans, pre-clinical and clinical studies, regulatory reviews, timing, strategies, expectations, anticipated expenses levels, business prospects and positioning with respect to market, demographic and pricing trends, business outlook, technology spending and various other matters (including contingent liabilities and obligations and changes in accounting policies, standards and interpretations) and express our current intentions, beliefs, expectations, strategies or predictions. These forward-looking statements are based on a number of assumptions and currently available information and are subject to a number of risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Special Note Regarding Forward-Looking Statements” and under “Risk Factors” and elsewhere in this annual report. The following discussion should be read in conjunction with our financial statements and related notes thereto included elsewhere in this annual report.

 

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is provided in addition to the accompanying financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. MD&A is organized as follows:

 

● Company Overview – Discussion of our business plan and strategy in order to provide context for the remainder of MD&A.

 

● Critical Accounting Policies – Accounting policies that we believe are important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.

 

● Results of Operations – Analysis of our financial results comparing the year ended December 31, 2022 to the year ended December 31, 2021.

 

● Liquidity and Capital Resources – Liquidity discussion of our financial condition and potential sources of liquidity.

 

Company Overview

 

Business

 

We are a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer. Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine A2B receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allows for better tumor infiltration. The adenosine A2 Receptor is one of many T-cell surface immune checkpoint proteins. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific adenosine targets found in each type of cancer.

 

Adenosine Receptor Modulators

 

The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability including indications within immuno-oncology. Very high concentrations of adenosine are produced in the tumor microenvironment which prevents the host’s own immune cells from attacking the tumor. Adenosine receptor antagonists as single-agents and in combination with other existing immuno-oncology agents may overcome this immunosuppression and boost the host immune response leading to enhanced anti-tumor activity as well as inhibition of metastasis. Preclinical data has shown the direct effects with our drug candidates on certain types of cancer cells.

 

27

 

 

Rebus Holdings/ Ridgeway Licensing Agreement

 

Pursuant to our recent termination of license with Ridgeway Therapeutics, Inc., we reacquired the rights to certain intellectual property, discussed above, and are currently focusing on a pipeline of small molecule adenosine receptor modulators. In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2A, A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.

 

Pre-Revenue

 

We are a pre-revenue, early-stage company that has not achieved profitability, and has no product revenues. Additionally, we have no approved products for sale.

 

Recent Developments

 

  ● Effective October 12, 2021, we (i) completed a 1-for-75 Reverse Stock Split and (ii) a holding company reorganization whereby we changed our name to Rebus Holdings, Inc.
     
  ● On August 16, 2021, we appointed Raul Silvestre, Esq. as (i) our interim chief executive officer and principal accounting officer and (ii) a member of the Board of Directors.
     
  ● On June 18, 2021, we completed the private placement of $600,000 of non-interest bearing senior convertible debentures in exchange for $500,000 in cash and the cancellation of $100,000 in obligations.
     
  ● On January 12, 2021, we completed the private placement of $500,000 of non-interest bearing senior convertible debentures.

 

Financial

 

To date, we have devoted substantially all of our efforts and financial resources to the development of our proposed drug candidates. We have not received FDA approval to market, distribute or sell any products. We have recently begun working on developing IND approved studies for our adenosine receptor technology platform.

 

Since our inception in 2003, we have generated no revenue from product sales and have funded our operations principally through the private and public sales of our equity securities. We have never been profitable and as of December 31, 2022, we had an accumulated deficit of approximately $65.3 million. We expect to continue to incur significant operating losses for the foreseeable future as we continue the development of our product candidates and advance them through clinical trials.

 

Our cash balances at December 31, 2022 were approximately $5,000 representing 100% of total assets. In January 2021, we completed a private placement of $500,000 in cash of our debt securities and in June 2021 we completed an additional private placement of $500,000 in cash of our debt securities. Based on our current expected level of operating expenditures and current cash balance as of the date of this report, we expect to be able to fund our operations into the first quarter of 2023. This period could be shortened if there are any significant increases in spending that were not anticipated or other unforeseen events.

 

We anticipate raising additional cash through the private or public sales of equity or debt securities to continue to fund our operations and the development of our product candidates. There is no assurance that any such collaborative arrangement will be entered into or that financing will be available to us when needed in order to allow us to continue our operations, or if available, on terms acceptable to us. If we do not raise sufficient funds in a timely manner, we may be forced to curtail operations, delay or stop our ongoing pre-clinical studies and potential clinical trials, cease operations altogether, or file for bankruptcy. We currently do not have commitments for future funding from any source.

 

28

 

 

Going Concern

 

Our auditors’ report on our December 31, 2022 consolidated financial statements expressed an opinion that our capital resources as of the date of their Audit Report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Upon the cancellation of the Ridgeway license, we resumed preclinical development. Our current cash level raises substantial doubt about our ability to continue as a going concern. If we do not obtain additional funds, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

 

Critical Accounting Policies and Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make significant judgments and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management bases these significant judgments and estimates on historical experience and other assumptions it believes to be reasonable based upon information presently available.

 

Recent Accounting Pronouncements

 

There have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the twelve months ended December 31, 2022 that are of significance or potential significance to the Company.

 

Results of Operations

 

Year Ended December 31, 2022 Compared to the Year Ended December 31, 2021

 

Our results of operations have varied significantly from year to year and quarter to quarter and may vary significantly in the future. We did not have revenue during the years ending December 31, 2022 and 2021. We do not anticipate generating any revenues during 2023. Net loss for 2022 was approximately $1.0 million and net income for 2021 was approximately $2.7 million, resulting from the operational activities described below.

 

Operating Expenses

 

Operating expense totaled $0.7 million and $1.0 million during 2022 and 2021, respectively. The decrease in operating expenses is the result of the following factors.

 

    Year Ended     Change in 2022  
    December 31,     Versus 2021  
    2022     2021     $     %  
    (amount in thousands)              
Operating Expenses                                
Research and development   $ 239     $ 494     $ (255 )     (52 )%
General and administrative     425       528       (103 )     (20 )%
Total operating expense   $ 664     $ 1,022     $ (358 )     (35 )%

 

29

 

 

Research and Development

 

Research and development expenses totaled $0.2 million and $0.5 million for the years ended 2022 and 2021, respectively. The decrease of approximately $0.3 million, or 52%, for the year ended December 31, 2022 compared to the same period in 2021, was primarily due to decreased development expense.

 

Our current research and development expenses currently consist primarily of consulting fees and development expense related to development of the adenosine A2R antagonists and preparation for an IND filing.

 

General and Administrative

 

General and administrative expenses totaled $0.4 million and $0.5 million during 2022 and 2021, respectively. The decrease of approximately $0.1 million, or 20%, in 2022 compared to 2021 was primarily due to decreased professional fees, director compensation and corporate communications.

 

Our general and administrative expenses currently consist primarily of expenditures related to legal, accounting and tax, other professional services, and general operating expenses.

 

Other Income (Expense)

 

Other income (expense) totaled approximately $0.3 million of expense and $3.7 million of income for 2022 and 2021, respectively.

 

    Year Ended     Change in 2022  
    December 31,     Versus 2021  
    2022     2021     $     %  
    (amount in thousands)              
Gain (loss) on change in fair value of derivative liability   $ (263 )   $ 3,687     $ (3,950 )     (107 )%
Gain on conversion of debt     (24 )     1,116       (1,140 )     (102 )%
Interest (expense), net     (69 )     (1,083 )     1,014       94 %
Total other income (expense)   $ (356 )   $ 3,720     $ (4,076 )     (110 )%

 

Gain (loss) on change in fair value of derivative liability

 

As a result of a change in the fair value of our derivative liability, we realized loss of $0.3 million and gain of $3.7 million during the years ended December 31, 2022 and 2021, respectively. The change in the fair value of our derivative liability was the result of our convertible debentures and notes issued in September 2017, July 2018, December 2018, July 2019, October 2019, November 2019, March 2020, October 2020, January 2021 and June 2021, where we issued convertible notes with variable conversion rates, and to the issuance of our Series F preferred stock in October 2020, which is convertible into a variable number of shares of common stock. Refer to Note 7 in our Consolidated Financial Statements for further discussion on our derivative liability.

 

Gain on conversion of debt

 

There was a loss on conversion of debt of approximately $0.02 million during the year ended December 31, 2022, with a gain of approximately $1.1 million during the year ended December 31, 2021. Gain on conversion of debt results from the difference between the fair value of common stock issued upon conversion and the carrying amount of the debt converted.

 

Interest income (expense)

 

We had $0.1 million net interest expense in 2022, compared to $1.1 million of expense in 2021. The decrease of $1.0 million was attributable to a decrease in the cost associated with derivative instruments issued with a value in excess of proceeds received.

 

30

 

 

Liquidity and Capital Resources

 

We have incurred losses since our inception in 2003 as a result of significant expenditures for operations and research and development and the lack of any approved products to generate revenue. We have an accumulated deficit of approximately $65.3 million as of December 31, 2022 and anticipate that we will continue to incur additional losses for the foreseeable future. Through December 31, 2022, we have funded our operations through the private sale of our equity securities, convertible debt and exercise of options and warrants, resulting in gross proceeds of $39.1 million. Cash at December 31, 2022 was approximately $5,000.

 

Our auditors’ report on our December 31, 2022 financial statements expressed an opinion that our capital resources as of the date of their Audit Report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Based on our current level of expected operating expenditures, we expect to be able to fund our operations into the first quarter of 2023. This assumes that we spend minimally on general operations and only continue conducting our ongoing clinical trials, and that we do not encounter any unexpected events or other circumstances that could shorten this time period. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

 

We are actively seeking sources of financing to fund our continued operations and research and development programs. To raise additional capital, we may sell equity or debt securities, or enter into collaborative, strategic and/or licensing transactions. There can be no assurance that we will be able to complete any financing transaction in a timely manner or on acceptable terms or otherwise. If we are not able to raise additional cash, we may be forced to further delay, curtail, or cease development of our product candidates, or cease operations altogether.

 

    Year Ended  
    December 31,  
    2022     2021  
    (amounts in thousands)  
Cash at beginning of year   $ 711     $ 404  
Net cash used in operating activities     (706 )     (693 )
Net cash provided by investing activities     -       -  
Net cash provided by financing activities     -       1,000  
Cash at end of year   $ 5     $ 711  

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities was $0.7 million and $0.7 million during 2022 and 2021, respectively. A decrease in net loss (after adjusting for noncash items) of approximately $0.4 million was offset by an increase in changes in accounts payable and accrued expense of approximately $0.4 million.

 

Net Cash Used in Investing Activities

 

Cash provided by investing activities was $0 for each of the years 2022 and 2021.

 

Net Cash Provided by Financing Activities

 

There was no cash provided by financing activities for the year ended December 31, 2022. During 2021, we received net proceeds of $1,000,000 from the sales of our securities and convertible debentures. We are actively seeking sources of financing to fund our continued operations and research and development programs.

 

31

 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

 

We are not required to provide the information as to selected financial data as we are considered a smaller reporting company.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The information required by this Item is included in our Financial Statements and Supplementary Data listed in Item 15 of Part IV of this Annual Report.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, which consists only of our Principal Executive Officer and Principal Accounting Officer (who is also our Principal Executive Officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2022. Based on that evaluation, management concluded that our disclosure controls and procedures as of December 31, 2022 were ineffective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

 

Inherent Limitations Over Internal Controls

 

The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles (“GAAP”). The Company’s internal control over financial reporting includes those policies and procedures that:

 

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets;

 

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that the Company’s receipts and expenditures are being made only in accordance with authorizations of the Company’s management and directors; and

 

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

 

Management, which consists only of our Principal Executive Officer and Principal Accounting Officer (who is also our Principal Executive Officer), does not expect that the Company’s internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

32

 

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on the criteria set forth in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013). Based on the Company’s assessment, management has concluded, that due to limited resources and limited number of employees, its internal control over financial reporting was ineffective as of December 31, 2022 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. To mitigate the current limited resources and employees, we rely heavily on direct management oversight of transactions, along with the use of legal and accounting professionals. As we grow, we expect to increase the number of employees, which would enable us to implement adequate segregation of duties within the internal control framework.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting during the fourth quarter of 2022, which were identified in connection with management’s evaluation required by paragraph (d) of rules 13a-15 and 15d-15 under the Exchange Act that has materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

This annual report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to the rules of the SEC that permit smaller reporting companies to provide only the management’s report in this annual report.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

33

 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Directors, Executive Officers and Significant Employees

 

The names of our directors and executive officers and their ages, positions, and biographies as of March 15, 2023, are set forth below. Our executive officers are appointed by, and serve at the discretion of the Board. There are no family relationships among any of our directors or executive officers. All directors hold office until the next annual meeting of shareholders or until their respective successors are elected, except in the case of death, resignation, or removal. On August 16, 2021, we appointed Raul Silvestre, Esq. as our interim chief executive officer, principal accounting officer, president, and a member of our Board of Directors.

 

Name   Position   Age   Position Since
Executive Directors            
Raul Silvestre   Chief Executive Officer, Chief Financial Officer, President and Director   52   8/2021
Independent Directors            
Scott V. Ogilvie   Director   68   3/2008
Claire Thom, Pharm.D.   Director   68   10/2016

 

Raul Silvestre, Esq., has been general outside counsel to Rebus Holdings since 2008 and the managing partner of the Silvestre Law Group, P.C. since 1999. While serving as counsel to the company, Mr. Silvestre has been responsible for managing and overseeing all legal aspects of the company including capital raising transaction and corporate governance and has been instrumental in the reacquisition of the technology which is the basis of our lead proposed product. Mr. Silvestre’s legal career has focus on corporate and securities law where he has assisted both private and public companies in capital raising, merger and acquisition transactions as well as general corporate matters, recapitalizations and restructurings. Mr. Silvestre has also been an active investor, manager, and principal in, public and private entities with an emphasis in the biotechnology and pharmaceutical industries. Mr. Silvestre received a B.S. with an emphasis in Finance from the University of Southern California and his Juris Doctorate from Pepperdine School of Law. In evaluating Mr. Silvestre’s specific experience, qualifications, attributes, and skills in connection with his appointment to our Board, we took into account his prior service to the company, corporate legal experience, knowledge of capital markets, and experience in publicly traded biotechnology and drug development companies.

 

Scott V. Ogilvie has served as a director on our board since February 2008. Mr. Ogilvie is currently the President of AFIN International, Inc., a private equity/business advisory firm, which he founded in 2006. He is also Exec. Chairman of Oxigen Beverages, Inc., a BC, Canadian privately held company. Prior to December 31, 2009, he was CEO of Gulf Enterprises International, Ltd, a company that brings strategic partners, expertise and investment capital to the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group, Inc., an investment manager, a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill, Farrer & Burrill, and has extensive public and private corporate management and board experience in finance, real estate, and technology companies. Mr. Ogilvie also previously served on the board of directors of Preferred Voice Inc. (OTCQB: PRFV), Innovative Card Technologies, Inc. (OTCBB: INVC), National Healthcare Exchange, Inc. (OTCBB: NHXS), and Research Solutions, Inc. (OTCQB: RSSS). In evaluating Mr. Ogilvie’s specific experience, qualifications, attributes and skills in connection with his appointment to our board, we took into account his prior work in both public and private organizations regarding corporate finance, securities and compliance and international business development.

 

34

 

 

Claire Thom, PharmD has served as a director on our board since October 2016. Dr. Thom has two decades of experience in the pharmaceutical industry, with responsibilities including drug development, new product planning, and marketing. Most recently, from July 2013 until June 2016, Dr. Thom was the Senior Vice President Global Therapeutic Head for Oncology at Astellas Pharma (TOKYO: ALPMY). At Astellas, she developed and supervised the implementation of the company’s oncology strategy. In addition, she was appointed to serve on the Board of Directors for Agensys, a fully-owned subsidiary of Astellas. Prior to her roles at Astellas, Dr. Thom served as Senior Vice President of Portfolio Management, Drug Development Management and Strategic Business Operations at Millennium Pharmaceuticals, the Takeda Oncology Company, (TOKYO: TKPYY) from August 2008 until January 2013. Prior to her assignment at Millennium, she held several positions of increasing responsibility at Takeda to become the company’s Oncology Franchise Leader. Earlier, she worked at G.D. Searle and began her career as a clinical pharmacist. Ms. Thom was awarded a Doctor of Pharmacy and a Bachelor of Pharmacy, both with honors, from the University of Illinois. In evaluating Dr. Thom’s specific experience, qualifications, attributes and skills in connection with her appointment to our board, we took into account her knowledge of scientific matters affecting our business and her understanding of our industry.

 

Family Relationships

 

There are no family relationships between any director, executive officer, or person nominated or chosen by the registrant to become a director or executive officer.

 

35

 

 

CORPORATE GOVERNANCE

 

Independent Directors

 

For purposes of determining independence, the Company has adopted the definition of independence as contained in NASDAQ Market Place Rule 5605(a)(2). Pursuant to the definition, the Company has determined that Dr. Thom and Mr. Ogilvie qualify as independent.

 

Committees

 

The board of directors has established three standing committees: (1) an Audit Committee, (2) a Nominating and Corporate Governance Committee, and (3) a Leadership Development and Compensation Committee. Each of the committees operates under a written charter adopted by the board of directors. A copy of each respective committee’s charter can be viewed as Exhibits 99.01, 99.02 and 99.03 to this Annual Report.

 

The table below identifies the Board’s standing committees and committee membership as of March 15, 2023:

 

Director   Independent   Audit
Committee		   Nominating
and
Corporate
Governance
Committee		   Leadership
Development
and
Compensation
Committee		  
Scott Ogilvie   Yes   Chair   Chair   -  
                   
Claire Thom, PharmD   Yes   Member   -   Chair  

 

Each member of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee is considered independent under the NASDAQ Market Place Rules.

 

Audit Committee

 

The main function of our Audit Committee, which was established in accordance with Section 3(a)(58)(A) of the Exchange Act, is to oversee our accounting and financial reporting processes, internal systems of control, independent auditor relationships and the audits of our financial statements. This committee’s responsibilities include:

 

  ● Selecting and hiring our independent auditors.

 

  ● Evaluating the qualifications, independence and performance of our independent auditors.

 

  ● Approving the audit and non-audit services to be performed by our independent auditors.

 

  ● Reviewing the design, implementation, adequacy and effectiveness of our internal controls and our critical accounting policies.

 

  ● Overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to financial statements or accounting matters.

 

  ● Reviewing with management any earnings announcements and other public announcements regarding our results of operations.

 

  ● Reviewing regulatory filings with management and our auditors.

 

  ● Preparing any report the SEC requires for inclusion in our annual proxy statement.

 

  ● The Audit Committee will review and approve all related party transactions.

 

Our Audit Committee is currently comprised of Scott V. Ogilvie and Claire Thom, each of whom is a non-employee member of our board of directors. Our board of directors has determined that each of the directors serving on our Audit Committee is independent within the meaning of the rules of the SEC and rule 5605(a)(2) of the Marketplace Rules of NASDAQ. Additionally, our board has determined that Scott V. Ogilvie is an audit committee financial expert as defined under the rules of the SEC. A copy of the charter is contained in Exhibit 99.01 to this Annual Report.

 

36

 

 

Nominating and Corporate Governance Committee

 

Our Nominating and Corporate Governance Committee’s purpose is to assist our board of directors in identifying individuals qualified to become members of our board of directors consistent with criteria set by our board of directors and to develop our corporate governance principles. This committee’s responsibilities include:

 

  ● Evaluating the composition, size, organization and governance of our board of directors and its committees, determining future requirements, and making recommendations regarding future planning, the appointment of directors to our committees and selection of chairs of these committees.

 

  ● Reviewing and recommending to our board of directors, director independence determinations made with respect to continuing and prospective directors.

 

  ● Establishing a policy for considering stockholder nominees for election to our board of directors.

 

  ● Recommending ways to enhance communications and relations with our stockholders.

 

  ● Evaluating and recommending candidates for election to our board of directors.

 

  ● Overseeing our board of directors’ performance and self-evaluation process and developing continuing education programs for our directors.

 

  ● Evaluating and recommending to the board of directors, termination of service of individual members of the board of directors as appropriate, in accordance with governance principles, for cause or for other proper reasons.

 

  ● Making regular written reports to the board of directors.

 

  ● Reviewing and re-examining the committee’s charter and making recommendations to the board of directors regarding any proposed changes.

 

  ● Reviewing annually the committee’s own performance against responsibilities outlined in its charter and as otherwise established by the board of directors.

 

Our Nominating and Corporate Governance Committee is currently comprised of Scott V. Ogilvie, a non-employee member of our board of directors. Our board of directors has determined that Mr. Ogilvie is independent as defined in rule 5605(a)(2) of the Marketplace Rules of NASDAQ. The charter of the Nominating and Corporate Governance Committee is contained in Exhibit 99.03 of this Annual Report.

 

Leadership Development and Compensation Committee

 

The purpose of our Leadership Development and Compensation Committee is to oversee our compensation programs. The committee may form and delegate authority to subcommittees or, with respect to compensation for employees and consultants who are not executive officers for purposes of Section 16 of the Exchange Act, to our officers, in either instance as the committee determines appropriate. The committee’s responsibilities include:

 

  ● Reviewing and approving our general compensation strategy.

 

  ● Establishing annual and long-term performance goals for our CEO and other executive officers.

 

37

 

 

  ● Conducting and reviewing with the board of directors an annual evaluation of the performance of the CEO and other executive officers.

 

  ● Evaluating the competitiveness of the compensation of the CEO and the other executive officers.

 

  ● Reviewing and making recommendations to the board of directors regarding the salary, bonuses, equity awards, perquisites and other compensation and benefit plans for the CEO.

 

  ● Reviewing and approving all salaries, bonuses, equity awards, perquisites and other compensation and benefit plans for our other executive officers.

 

  ● Reviewing and approving the terms of any offer letters, employment agreements, termination agreements or arrangements, change-in-control agreements, indemnification agreements and other material agreements between the company and our executive officers.

 

  ● Acting as the administering committee for our stock and bonus plans and for any equity or cash compensation arrangements that we may adopt from time to time.

 

  ● Providing oversight for our overall compensation plans and benefit programs, monitoring trends in executive and overall compensation and making recommendations to the board of directors with respect to improvements to such plans and programs or the adoption of new plans and programs.

 

  ● Reviewing and approving compensation programs as well as salaries, fees, bonuses and equity awards for non-employee members of the board of directors.

 

  ● Reviewing plans for the development, retention and succession of our executive officers.

 

  ● Reviewing executive education and development programs.

 

● Monitoring total equity usage for compensation and establishing appropriate equity dilution levels.

 

  ● Reporting regularly to the board of directors on the committee’s activities.

 

  ● Reviewing and discussing with management the required annual compensation discussion and analysis disclosure, if any, regarding named executive officer compensation and, based on this review and discussions, making a recommendation to include in our annual public filings.

 

  ● Preparing and approving any required committee report to be included in our annual public filings.

 

  ● Performing a review, at least annually, of the performance of the committee and its members and reporting to the board of directors on the results of this review.

 

  ● Investigating any matter brought to its attention, with full access to all our books, records, facilities and employees and obtaining advice, reports or opinions from internal or external counsel and expert advisors in order to help it perform its responsibilities.

 

Our Leadership Development and Compensation Committee is currently comprised of Claire Thom, who is a non-employee member of our board of directors. Dr. Thom is an “outside” director as defined in Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), and a “non-employee” director within the meaning of Rule 16b-3 of the Exchange Act. Our board of directors has determined that Dr. Thom is independent as defined in rule 5605(a)(2) of the Marketplace Rules of NASDAQ. A copy of the charter is contained in Exhibit 99.02 to this Annual Report.

 

38

 

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act requires our officers, directors, and stockholders owning more than ten percent of our common stock, to file reports of ownership and changes in ownership with the SEC and to furnish us with copies of such reports. Based solely on our review of Form 3, 4 and 5’s, the following table provides information regarding any of the reports which were filed late during the fiscal year ended December 31, 2022:

 

N/A

 

Limitation on Liability and Indemnification of Directors and Officers

 

Our certificate of incorporation states that, to the fullest extent permitted by the Delaware General Corporate Law, or the DGCL, no director shall be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as director; provided, however, that this provision eliminating personal liability of a director shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to us or our stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.

 

Section 174 of the DGCL provides, among other things, that a director who willfully and negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing the minutes of the meetings of the board of directors at the time the action occurred or immediately after the absent director receives notice of the unlawful acts.

 

Our certificate of incorporation and bylaws provide that we will indemnify our directors and officers and may indemnify our employees or agents to the fullest extent permitted by law against liabilities and expenses incurred in connection with litigation in which they may be involved because of their offices or positions with us. However, nothing in our certificate of incorporation or bylaws protects or indemnifies a director, officer, employee or agent against any liability to which that person would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of that person’s office or position. To the extent that a director has been successful in defending any proceeding brought against him, the Delaware General Corporation Law provides that the director shall be indemnified against reasonable expenses incurred by him in connection with the proceeding.

 

Diversity of Board of Directors

 

We do not have a formal policy with regard to the consideration of diversity in identifying director nominees, but the Nominating and Corporate Governance Committee strives to nominate Directors with a variety of complementary skills so that, as a group, the board of directors will possess the appropriate talent, skills, and expertise to oversee our businesses.

 

Code of Ethics

 

We have adopted a “Code of Ethics” that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of our code is attached to this Annual Report as Exhibit 14.01.

 

39

 

 

ITEM 11. EXECUTIVE COMPENSATION

 

Summary Compensation

 

The following table provides disclosure concerning all compensation paid for services to us in all capacities for our fiscal years ended December 31, 2022 and 2021 provided by (i) each person serving as our principal executive officer, or PEO, or acting in a similar capacity during our fiscal year ended December 31, 2022 (ii) our most highly compensated executive officers other than our PEO who were serving as executive officers on December 31, 2022 and whose total compensation exceeded $100,000 (collectively with the PEO referred to as the “named executive officers” in this Executive Compensation section); and (iii) our Principal Financial Officer.

 

Name & Principal Position   Year     Salary
($)		     Bonus
($)		     Stock
Awards
($)		     Option
Awards
($)		     Non-Equity
Incentive Plan
Compensation
($)		     Nonqualified
Deferred
Compensation
Earnings
($)		     All Other
Compensation
($)		     Total
($)		  
Raul Silvestre,   2022     - (1)      -       -       -       -       -       -       -  
Chief Executive Officer and Principal Accounting Officer   2021     - (1)      -       -       -       -       -       -       -  
                                                                     
Michael Cain,   2022     - (2)      -       -       -       -       -       -       -  
Chief Executive Officer and Principal Accounting Officer   2021     - (2)      -       -       -       -       -       -       -  

 

 
(1) Mr. Silvestre was appointed as principal executive and accounting officer, and as a member of the Board effective August 16, 2021. Mr. Silvestre does not receive any compensation for his services as an officer of the Company. Mr. Silvestre is the principal of Silvestre Law Group, P.C., the Company’s outside corporate counsel. We pay Silvestre Law Group $10,000 per month for legal services related to SEC compliance, which began in September of 2021. Additional legal work outside of the scope of the monthly legal services are being billed at Silvestre Law Group’s standard rates and have all been accrued. See “Related Party Transactions” in Part III, Item 13 of this Annual Report for additional information related to Silvestre Law Group.
(2) Mr. Cain became our chief executive officer and principal accounting officer effective July 26, 2019. Mr. Cain did not receive any compensation for his services. Mr. Cain resigned as chief executive officer and a member of the board effective June 16, 2021.

 

Outstanding Executive Equity Awards at Fiscal Year-End 2022

 

None.

 

Employment Agreements and Change in Control

 

Raul Silvestre

 

Raul Silvestre was appointed chief executive officer and chief financial officer / principal accounting officer of the Company effective August 16, 2021. He was also appointed as a member of the Board of Directors. Mr. Silvestre does not have an employment agreement covering his services and has not received any compensation for services as chief executive officer or principal accounting financial officer Mr. Silvestre is not subject to any compensation arrangements in the event that he is terminated or resigns as an officer for any reason.

 

Mr. Silvestre is the principal of Silvestre Law Group, P.C., the Company’s outside corporate counsel. The law firm receives payment from bona fide legal services that it provides to the Company.

 

40

 

 

Michael Cain

 

Michael Cain was appointed chief executive officer and chief financial officer / principal accounting officer of the Company effective July 26, 2019. Effective June 16, 2021, Mr. Cain resigned from all positions with the Company and as a member of the Board of Directors. During his tenure, the Company did not have any employment agreement covering Mr. Cain’s services and he did not receive any compensation as our chief executive officer or chief financial officer.

 

Equity Compensation Plans

 

For information related to our equity compensation plans for which our officers and directors are issued securities from, please see Equity Compensation Plan Information contained in Part III, Item 12 of this Annual Report.

 

Director Compensation

 

Current Amended Non-Employee Director Compensation Policy

 

Effective April 1, 2021, the Board of Directors amended its employee director compensation policy (“Amended Director Policy”). Pursuant to the Amended Director Policy, each Board member will receive $5,000 in cash per quarter of service on the Board of Directors, or such pro-rated portion for any partial quarter.

 

For the year end 2022, non-employee directors received the following:

 

Name   Fees
Earned
or Paid in
Cash
($)		     Stock
Awards
($)		     Option
Awards
($)		     Non-Equity
Incentive Plan
Compensation
($)		     Non-Qualified
Deferred
Compensation
Earnings
($)		     All Other
Compensation
($)		     Total
($)		  
Scott Ogilvie     20,000       -       -       -       -       -       20,000  
                                                         
Claire Thom     20,000       -       -       -       -       -       20,000  

 

41

 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Securities authorized for issuance under equity compensation plans

 

The following table sets forth information as of December 31, 2022 with respect to our compensation plans under which equity securities may be issued.

 

    (a)     (b)     (c)  
    Number of Securities
to be Issued
upon Exercise of
Outstanding
Options, Warrants
and Rights		     Weighted-Average
Exercise Price of
Outstanding
Options,
Warrants and
Rights		     Number of Securities
Remaining Available for
Future Issuance under
Equity Compensation Plans
(Excluding Securities
Reflected in Column (a))		  
Equity compensation plans approved by security holders:                        
N/A (1)                        
Equity compensation plans not approved by security holders:                        
N/A (1)                        
Total                        

 

 
(1) Our 2007 Equity Compensation Plan, 2009 Executive Compensation Plan, Inducement Award Stock Option Plan and 2017 Equity Compensation Plan have all expired or been terminated by the Board.

 

2007 Equity Compensation Plan

 

Our 2007 Equity Compensation Plan (“2007 Plan”) was administered by our board or any of its committees. The purposes of the 2007 Plan was to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants, and to promote the success of our business. The issuance of awards under our 2007 Plan was at the discretion of the administrator, which had the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2007 Plan, we were able to grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock based awards. All awards under the 2007 Plan have expired, been forfeited or converted into Common Stock pursuant to our holding company reorganization. The 2007 Plan was terminated by the Board and has no remaining shares authorized.

 

42

 

 

2009 Executive Compensation Plan

 

Our 2009 Executive Compensation Plan, as amended (“2009 Plan”) was administered by our Board or any of its committees. The purpose of our 2009 Plan was to advance the interests of the Company and our stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. The issuance of awards under our 2009 Plan was at the discretion of the administrator, which had the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2009 Plan, we were able to grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock-based awards. All awards under the 2009 Plan have expired, been forfeited or converted into Common Stock pursuant to our holding company reorganization. The 2009 Plan was terminated by the Board and has no remaining shares authorized.

 

Inducement Award Stock Option Plan

 

Our Inducement Award Stock Option Plan (“Inducement Plan”) was administered by our board or our compensation committee. The Plan is intended to be used in connection with the recruiting and inducement of senior management and employees. The issuance of wards under the Inducement Plan is at the discretion of the administrator which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. The Company did not seek approval of the Plan by our stockholders. All awards under the Inducement Plan have expired, been forfeited or converted into Common Stock pursuant to our holding company reorganization. The Inducement Plan was terminated by the Board and has no remaining shares authorized.

 

Inspyr Therapeutics 2017 Equity Compensation Plan

 

Our 2017 Equity Compensation Plan (“2017 Plan”) was administered by our board or any of its committees. The purposes of the 2017 Plan was to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants, and to promote the success of our business. The issuance of awards under our 2017 Plan was at the discretion of the administrator, which had the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2017 Plan, we were able to grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock based awards. All awards under the 2017 Plan have expired, been forfeited or converted into Common Stock pursuant to our holding company reorganization. The 2017 Plan was terminated by the Board and has no remaining shares authorized.

 

Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth, as of March 15, 2023, information regarding beneficial ownership of our capital stock by:

 

  ● each person, or group of affiliated persons, known by us to be the beneficial owner of 5% or more of any class of our voting securities;
     
  ● each of our current directors and nominees;
     
  ● each of our current named executive officers; and
     
  ● all current directors and named executive officers as a group.

 

43

 

 

Beneficial ownership is determined according to the rules of the SEC. Beneficial ownership means that a person has or shares voting or investment power of a security and includes any securities that person or group has the right to acquire within 60 days after the measurement date. This table is based on information supplied by officers, directors and principal stockholders. Except as otherwise indicated, we believe that each of the beneficial owners of the common stock listed below, based on the information such beneficial owner has given to us, has sole investment and voting power with respect to such beneficial owner’s shares, except where community property laws may apply.

 

Name and Address of Beneficial Owner(1)   Shares     Common Stock
Shares
Underlying
Convertible
Securities(2)		     Total     Percent of
Class(2)		  
Directors and named Executive Officers                                
Raul Silvestre(3)     2       1,687,643       1,687,645       4.99 %
Scott Ogilvie     1       -       1       *  
Claire Thom     1       -       1       *  
All directors and executive officers as a group (4 persons)     4       1,687,643       1,687,647       4.99 %
                                 
5% Shareholders                                
Ridgeway Therapeutics, Inc.(4)             866,667 (5)      866,667 (6)      2.70 %

 

 
* Less than one percent.

 

(1) Except as otherwise indicated, the persons named in this table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and to the information contained in the footnotes to this table. Unless otherwise indicated, the address of the beneficial owner is 2629 Townsgate Road #215, Westlake Village, CA 91361.
(2) Pursuant to Rules 13d-3 and 13d-5 of the Exchange Act, beneficial ownership includes any shares as to which a shareholder has sole or shared voting power or investment power, and also any shares which the shareholder has the right to acquire within 60 days, including upon exercise of common shares purchase options or warrants. There were 32,132,907 shares of common stock issued and outstanding as of March 15, 2023.
(3) All share amounts underlying convertible securities represent debentures held by Silvestre Law Group, P.C., of which Mr. Silvestre serves as its managing director. Excludes 32,355,568 shares of common stock underlying debentures held by Silvestre Law Group, P.C. that are subject to beneficial ownership limitations.
(4) 4085 Campbell Ave. #150, Menlo Park, CA 94025. Colin Hislop has voting and dispositive control with respect to the securities.
(5) Ridgeway Therapeutics additionally holds 8,000 shares of our Series F Convertible Preferred Stock that converts into Common Stock. The 8,000 shares of Series F Convertible Preferred Stock are convertible into an aggregate of 80% of the issued and outstanding Common Stock post-conversion on the conversion date. The Series F Preferred Stock votes on an as converted to Common Stock basis. Additionally, upon the termination, conversion or otherwise extinguishment of certain of our outstanding convertible debentures, the Series F Preferred Stock will automatically convert into Common Stock.

 

44

 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Information regarding disclosure of an employment relationship or transaction involving an executive officer and any related compensation solely resulting from that employment relationship or transaction is incorporated by reference from the section of this annual report entitled “Executive Compensation.”

 

Information regarding disclosure of compensation to a director is incorporated by reference from the section of this annual report entitled “Director Compensation.”

 

Related Party Transactions

 

  ● We have entered into an indemnification agreement with each of our directors and executive officers. The indemnification agreements and our certificate of incorporation and bylaws require us to indemnify our directors and executive officers to the fullest extent permitted by Delaware law. The indemnification agreements are substantially similar to those entered into with our executive officers and as a more fully described in the section of this annual report entitled “Employment Agreements and Change in Control.”
     
  ● On March 1, 2021, we entered into a settlement and release agreement with Claire Thom, one of our independent directors for the settlement of past due director fees and the mutual release of all claims. Pursuant to the agreement, Dr. Thom agreed to waive $204,500 in outstanding director fees in exchange for the following: (i) the payment of $40,000 (of which $20,000 was paid in November 2020 and $20,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021, a common stock purchase option with a Black Scholes’ value of $40,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. We also agreed to amend our non-employee director compensation policy such that on April 1, 2021, each director will be entitled to receive a quarterly Board fee of $5,000 in cash.

 

  ● On March 1, 2021, we entered into a settlement and release agreement with Scott Ogilvie, one of our independent directors for the settlement of all past due director fees and the mutual release of all claims. Pursuant to the agreement, Mr. Ogilvie agreed to waive $231,167 in outstanding director fees in exchange for the following: (i) the payment of $60,000 (of which $30,000 was paid in November 2020 and $30,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021, a common stock purchase option with a Black Scholes’ value of $60,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. We also agreed to amend our non-employee director compensation policy such that on April 1, 2021, each director will be entitled to receive a quarterly Board fee of $5,000 in cash.

 

  ● In September of 2021, we began paying $10,000 per month to Silvestre Law Group, P.C., our outside corporate counsel for our SEC compliance legal work (“Monthly Fee”). Mr. Silvestre, our CEO is a principal of Silvestre Law Group, P.C. Additionally, Silvestre Law Group bills us at their standard rates for additional services outside of the scope of the Monthly Fee, which unpaid portions are accrued as of the date of this Annual Report on Form 10-K. Between January 1, 2021 and August 15, 2021, we accrued $84,224 in legal fees to Silvestre Law Group. Beginning August 16, 2021 and December 31, 2021, we paid Silvestre Law Group $40,000 for the Monthly Fee and accrued an additional $54,141 in legal fees for other services not covered by the Monthly Fee. From January 1, 2022 through December 31, 2022, we paid $110,000 for the Monthly Fee and accrued an additional $15,844 for both Monthly Fee services and other services not covered by the Monthly Fee. Accordingly, The Company has a balance due to Silvestre Law Group of $309,848 at December 31, 2022. Silvestre Law Group also holds $290,000 of our convertible debentures at December 31, 2022 and December 31, 2021.

 

45

 

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

The following table summarizes the approximate aggregate fees billed to us or expected to be billed to us by our independent auditors for our 2022 and 2021 fiscal years:

 

Type of Fees   2022     2021  
Audit Fees   $ 39,603   $ 50,000  
Audit Related Fees     -       -  
Tax Fees     -       -  
All Other Fees     -       -  
Total Fees   $ 39,603   $ 50,000  

 

Pre-Approval of Independent Auditor Services and Fees

 

Our board of directors reviewed and pre-approved all audit and non-audit fees for services provided by independent registered accounting firm and has determined that the provision of such services to us during fiscal 2022 is compatible with and did not impair independence. It is the practice of the audit committee to consider and approve in advance all auditing and non-auditing services provided to us by our independent auditors in accordance with the applicable requirements of the SEC. Liggett & Webb, P.A. provided our audit for 2021 and RBSM LLP provided our audit for 2022. The firms engaged during 2022 and 2021, respectively provided no other services, other than those listed above for their respective years.

 

46

 

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

  1. Financial Statements: See “Index to Financial Statements” beginning on Page F-1 of this Form 10-K.

 

  2. Exhibits: The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Form 10-K.

 

Certain of the agreements filed as exhibits to this Form 10-K contain representations and warranties by the parties to the agreements that have been made solely for the benefit of the parties to the agreement. These representations and warranties:

 

  ● may have been qualified by disclosures that were made to the other parties in connection with the negotiation of the agreements, which disclosures are not necessarily reflected in the agreements;

 

  ● may apply standards of materiality that differ from those of a reasonable investor;

 

  ● and were made only as of specified dates contained in the agreements and are subject to later developments.

 

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time, and investors should not rely on them as statements of fact.

 

ITEM 16. FORM 10-K SUMMARY

 

None.

 

47

 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed by the undersigned hereunto duly authorized.

 

  REBUS HOLDINGS, INC.
   
Date: March 31, 2023 /s/ Raul Silvestre
  Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the following capacities and on the dates indicated.

 

Name   Title   Date
         
/s/ Raul Silvestre   Principal Executive Officer, Principal Accounting Officer   March 31, 2023
Raul Silvestre        
         
/s/ Scott Ogilvie   Director   March 31, 2023
Scott Ogilvie        
         
/s/ Claire Thom, PharmD   Director   March 31, 2023
Claire Thom, PharmD        

 

48

 

 

REBUS HOLDINGS, INC.

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

    Page
Report of RBSM LLP, Independent Registered Public Accounting Firm   F-2
     
Report of Liggett & Webb, P.A., Independent Registered Public Accounting Firm   F-3
     
Consolidated Balance Sheets   F-4
     
Consolidated Statements of Operations   F-5
     
Consolidated Statement of Stockholders’ Deficit   F-6
     
Consolidated Statements of Cash Flows   F-7
     
Notes to Consolidated Financial Statements   F-8

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

To the Board of Directors and Stockholders of

Rebus Holdings, Inc. and subsidiaries

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheet of Rebus Holdings, Inc. and subsidiaries (the Company) as of December 31, 2022, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the year ended December 31, 2022, and the related notes schedule (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

The Company's Ability to Continue as a Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the accompanying consolidated financial statements, the Company has not yet generated any significant revenue, has incurred recurring losses from operations, generated negative cash flows from operating activities and had an accumulated deficit that raises substantial doubt about the Company’s ability to continue as a going concern. Management's evaluation of the events and conditions and management’s plans in regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Valuation of Derivative Liabilities

 

As described in Note 7 to the consolidated financial statements, the Company measures fair value of derivative liabilities at fair value using level three inputs. To determine fair value of derivative liabilities, the Company determines the appropriate valuation methodology and assumptions, including unobservable inputs. The derivative liabilities are measured at fair value using a Black-Scholes valuation model that uses significant assumptions, including the Company’s stock price, historical volatility of the Company’s shares, risk-free interest rate and probability of conversion occurrence through maturity.

 

Auditing management’s estimate for the fair value of derivative liabilities was complex and highly judgmental as it involved our assessment of the significant assumptions used by management because the fair value calculations were sensitive to changes in assumptions described above, and certain inputs used in the determination of fair values were based on unobservable data, including, but not limited to, the historical volatility and probability of conversion.

 

To test the fair value of derivative liabilities, we performed audit procedures that included, among others, evaluating the methodologies used in the valuation model and the significant assumptions used by the Company.

 

/s/ RBSM LLP

We have served as the Company’s auditor since 2022.

PCAOB ID 587

New York, NY

March 31, 2023

 

F-2

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors of:

Rebus Holdings, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of Rebus Holdings, Inc. and Subsidiaries (the “Company”) as of December 31, 2021, the related consolidated statements of operations, changes in stockholders’ deficit and cash flows for the year ended December 31, 2021, and the related notes (collectively referred to as “the consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the year ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America.

 

Explanatory Paragraph – Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred losses since inception and has generated no revenues. The Company has a working capital deficit and an accumulated deficit. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal controls over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Valuation of Derivative Liabilities

 

As described in Note 7 to the consolidated financial statements, the Company measures fair value of derivative liabilities at fair value using level three inputs. To determine fair value of derivative liabilities, the Company determines the appropriate valuation methodology and assumptions, including unobservable inputs. The derivative liabilities are measured at fair value using a Black-Scholes valuation model that uses significant assumptions, including the Company’s stock price, historical volatility of the Company’s shares, risk-free interest rate and probability of conversion occurrence through maturity.

 

Auditing management’s estimate for the fair value of derivative liabilities was complex and highly judgmental as it involved our assessment of the significant assumptions used by management because the fair value calculations were sensitive to changes in assumptions described above, and certain inputs used in the determination of fair values were based on unobservable data, including, but not limited to, the historical volatility and probability of conversion.

 

To test the fair value of derivative liabilities, we performed audit procedures that included, among others, evaluating the methodologies used in the valuation model and the significant assumptions used by the Company.

 

/s/ Liggett & Webb, P.A.

 

We have served as the Company’s auditor since 2014.

 

Boynton Beach, Florida

 

March 31, 2022

PCAOB No. 287

 

F-3

 

 

REBUS HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

           
   December 31,   December 31, 
   2022   2021 
ASSETS          
           
Current assets:          
Cash  $5   $711 
Prepaid expenses   -    4 
Total current assets   5    715 
           
Total assets  $5   $715 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
Current liabilities:          
Accounts payable  $1,664   $1,801 
Accounts payable - related party   310    294 
Accrued expenses   2,078    2,004 
Convertible debentures, net of unamortized discount of $0 and $212   20    250 
Convertible debenture - related party, net of unamortized discount of $0 and $46   290    154 
Derivative liability   880    1,124 
Total current liabilities   5,242    5,627 
           
Long-term liabilities:          
Convertible debentures, net of current   -    20 
Convertible debentures - related party, net of current   -    90 
Total long-term liabilities   -    110 
           
Total liabilities   5,242    5,737 
           
Commitments and contingencies (Note 8)   -    - 
           
Stockholders’ deficit:          
Convertible preferred stock, undesignated, par value $.0001 per share; 29,978,846 shares authorized, no shares issued and outstanding, respectively   -    - 
Convertible preferred stock Series A, par value $.0001 per share; 1,854 shares authorized, 134 shares issued and outstanding, respectively   -    - 
Convertible preferred stock Series B, par value $.0001 per share; 1,000 shares authorized, 71 shares issued and outstanding, respectively   -    - 
Convertible preferred stock Series C, par value $.0001 per share; 300 shares authorized, 290 shares issued and outstanding, respectively   -    - 
Convertible preferred stock Series D, par value $.0001 per share; 5,000 shares authorized, 5,000 shares issued and outstanding, respectively   -    - 
Convertible preferred stock Series E, par value $.0001 per share; 5,000 shares authorized, 5,000 shares issued and outstanding, respectively   -    - 
Convertible preferred stock Series F, par value $.0001 per share; 8,000 shares authorized, 8,000 shares issued and outstanding, respectively   -    - 
Common stock, par value $.0001 per share; 1,000,000,000 shares authorized, 32,132,907 and 11,769,221 shares issued and outstanding, respectively   3    1 
Additional paid-in capital   60,057    59,254 
Accumulated deficit   (65,297)   (64,277)
Total stockholders’ deficit   (5,237)   (5,022)
           
Total liabilities and stockholders’ deficit  $5   $715 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

 

REBUS HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

 

           
   Years Ended
December 31,		 
   2022   2021 
Operating expenses:          
Research and development  $239   $494 
General and administrative   425    528 
Total operating expenses   664    1,022 
           
Loss from operations   (664)   (1,022)
           
Other income (expense):          
Gain (loss) on change in fair value of derivative liability   (263)   3,687 
Gain (loss) on conversion of debt   (24)   1,116 
Interest (expense), net   (69)   (1,083)
           
Income (loss) before provision for income taxes   (1,020)   2,698 
           
Provision for income taxes   -    - 
           
Net income (loss)  $(1,020)  $2,698 
           
Net income (loss) per common share, basic  $(0.03)  $0.35 
Net income (loss) per common share, diluted  $(0.03)  $(0.07)
           
Weighted average shares outstanding, basic   31,819,481    7,645,188 
Weighted average shares outstanding, diluted   31,819,481    21,132,450 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

 

REBUS HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

(in thousands, except share and per share data)

 

                                    
   Convertible           Additional         
   Preferred Stock   Common Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance, December 31, 2020   18,495   $-    2,478,848   $-   $54,472   $(66,975)  $(12,503)
                                    
Conversion of notes   -    -    9,290,364    1    4,446    -    4,447 
                                    
Director compensation waived   -    -    -    -    336    -    336 
                                    
Issuance of common stock in settlement of options, pursuant to merger   -    -    9    -    -    -    - 
                                    
Net income   -    -    -    -    -    2,698    2,698 
                                    
Balance, December 31, 2021   18,495    -    11,769,221    1    59,254    (64,277)   (5,022)
                                    
Conversion of notes   -    -    20,363,686    2    788    -    790 
                                    
Imputed interest on notes   -         -    -    15    -    15 
                                    
Net loss   -    -    -    -    -    (1,020)   (1,020)
                                    
Balance, December 31, 2022   18,495   $-    32,132,907   $3   $60,057   $(65,297)  $(5,237)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6

 

 

REBUS HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

           
   Years Ended
December 31,		 
   2022   2021 
Cash flows from operating activities:          
Net income (loss)  $(1,020)  $2,698 
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
(Gain) loss on change in fair value of derivative liability   263    (3,687)
(Gain) loss on conversion of debt   24    (1,116)
Amortization of debt discount   54    828 
Imputed interest on notes payable   15    - 
Finance cost   -    254 
Changes in operating assets and liabilities:          
Prepaid expenses   4    (4)
Accounts payable and accrued expenses   (62)   334 
Accounts payable- related party   16    - 
Cash used in operating activities   (706)   (693)
           
Cash flows from investing activities:   -    - 
           
Cash flows from financing activities:          
Proceeds from convertible notes   -    1,000 
Cash provided by financing activities   -    1,000 
           
Net increase (decrease) in cash   (706)   307 
Cash, beginning of year   711    404 
           
Cash, end of year  $5   $711 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-7

 

 

REBUS HOLDINGS, INC.

(FKA INSPYR THERAPEUTICS, INC.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022 AND 2021

 

NOTE 1 – BACKGROUND

 

Rebus Holdings, Inc. (“we”, “us”, “our company”, “our”, “Rebus,” “Rebus Holdings,” or the “Company”) (formerly known as Inspyr Therapeutics, Inc., see below) was formed under the laws of the State of Delaware in November 2003, and has its principal office in Westlake Village, California. We are focused on the research and development of novel targeted precision therapeutics for the treatment of cancer.

 

Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor A2B antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific targets found in each type of cancer.

 

The adenosine receptor modulators include A 2B antagonists, dual A 2A /A 2B antagonists, and A 2A antagonists that have broad development applicability including indications within immuno-oncology and inflammation. Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine receptor antagonists may boost the host immune response against the tumor as a single-agent and in combination with other existing immuno-oncology agents leading to enhanced tumor killing and inhibition of metastasis. Adenosine also has anti-inflammatory properties in the acute and chronic setting. Adenosine receptor antagonists may promote a decreased inflammatory response and can potentially treat a broad range of inflammatory and autoimmune based diseases and conditions (e.g., rheumatoid arthritis, joint injury, Crohn’s disease, psoriasis) as well as improve wound healing and decrease pain.

 

Pursuant to our recent termination of license with Ridgeway Therapeutics, Inc., a Delaware Corporation (“Ridgeway”), we reacquired the rights to certain intellectual property, discussed above, and are currently focusing on a pipeline of small molecule adenosine receptor modulators. In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.

 

Our ability to execute the business plan is contingent upon our ability to raise the necessary funds. During March 2020, we sold approximately $250,000 of debt securities and in October 2020, we sold $500,000 of debt securities for cash. In January 2021, we sold an additional $500,000 of debt securities for cash and in June 2021, we sold an additional $500,000 of debt securities for cash. We are currently using such funds to maintain our SEC reporting requirements, pay legal accounting and other professional fees, and to retain consultants and other personnel to develop the adenosine A2R antagonists and in preparation for an IND filing related to our unique delivery platform and portfolio of adenosine A2R antagonists for the treatment of certain solid tumors. Should we fail to further raise sufficient funds to execute our business plan, our priority would be to maintain our intellectual property portfolio and seek business development opportunities with potential development partners and/or acquirors.

 

Adoption of Agreement and Plan of Merger and Consummation of Reorganization

 

On September 28, 2021 the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) to implement a holding company reorganization, which became effective on October 11, 2021 at 5:00 p.m. Eastern Time (the “Effective Time”). The Merger Agreement was entered into by and among Inspyr Therapeutics, Inc., Rebus Holdings, Inc., and Rebus Sub, Inc., a wholly-owned subsidiary of Rebus Holdings which has resulted in Rebus becoming the direct parent company of Inspyr Therapeutics and replacing Inspyr Therapeutics as the public company trading on the OTC Markets (“OTC”) (the “Reorganization”). Further, the Company began trading under the symbol RBSH on November 9, 2021.

 

F-8

 

 

Upon consummation of the Reorganization (and the Reverse Stock Split as defined below), Inspyr stockholders automatically became stockholders of Rebus Holdings, on a one-for-one basis, with the same number and approximate ownership percentage of shares of the same class as they held in Inspyr immediately prior to the Effective Time. The Reorganization was intended to be a tax-free transaction for U.S. federal income tax purposes for Inspyr stockholders.

 

As a result of the Reorganization, Rebus Holdings became the successor issuer to Inspyr Therapeutics pursuant to Rule 12g-3(a) of the Exchange Act, and as a result, shares of Rebus Holdings Common Stock are deemed registered under Section 12(g) of the Exchange Act as the Common Stock of the successor issuer.

 

Reverse Stock Split

 

On September 1, 2021, the Board of Directors approved a one-for-seventy-five (1-for-75) reverse stock split of the Company’s Common Stock (“Reverse Stock Split”). The Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio. All share and per share data have been retroactively restated in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split.

 

Post Reverse Stock Split and Reorganization Information

 

The Company began trading on post Reverse Stock Split and Reorganization basis on the Pink Sheets of the OTC Markets Group on October 12, 2021. The symbol remained NSPX until November 9, 2021, at which time the Company began trading under the symbol RBSH.

 

The officers and members of the Board of Inspyr became the officers and members of the board of directors of the Rebus Holdings.

 

Pursuant to the Reorganization, Rebus Holdings has, on a consolidated basis, the same assets, businesses, and operations as Inspyr Therapeutics had immediately prior to the Reorganization.

 

Termination of License Agreement

 

On October 5, 2020, the Company entered into an agreement with Ridgeway (“Termination Agreement”) whereby the parties terminated the licensing agreement previously entered into on August 3, 2018 (“Licensing Agreement”), The Company had previously licensed certain technologies related to targeting adenosine receptor antagonists for the treatment of cancer (the “Licensed Assets”). As a result of the Termination Agreement, the Company reacquired full ownership and worldwide rights to all of the Licensed Assets as well as any improvements made thereto.

 

In exchange for entering into the Termination Agreement, the Company issued to Ridgeway: (i) 866,667 shares Common Stock, and (ii) 8,000 shares of Series F 0% Convertible Preferred Stock (“Series F Preferred Stock”). Additionally, the Company paid approximately $25,000 of Ridgeway’s expenses and costs.

 

Pursuant to the Certificate of Designation of the Series F Preferred Stock, each share of Series F Preferred Stock has a stated value of $10.00 per share and is convertible into Common Stock at any time at the election of the holder. In the aggregate, all of the Series F Preferred Stock issued to Ridgeway is convertible into such number of shares of Common Stock equal to eighty percent (80%) of the issued and outstanding shares of Common Stock, post-conversion, on the conversion date (taking into effect any forward or reverse stock splits or consolidations). The Series F Preferred Stock votes on an as if converted to Common Stock basis. Additionally, upon the Company’s outstanding Convertible Debentures (as such term is defined in the Certificate of Designation) being terminated, converted, or otherwise extinguished, the Series F Preferred Stock will automatically convert into Common Stock.

 

F-9

 

 

Pursuant to the Termination Agreement, in the event that the Company is unable to secure equity financing resulting in aggregate gross proceeds to the Company of at least $5,000,000 by October 5, 2023, or in the event that the Company ceases its operations, then the Termination Agreement will be deemed terminated and the Licensing Agreement will be reinstated in exchange for the return of the Common Shares and Series F Preferred Stock previously issued to Ridgeway.

 

As a result of the issuance of the Common Shares and Series F Preferred Stock, Ridgeway became the owner of approximately 54.14% of the Company’s issued and outstanding Common Stock as of the termination date. Furthermore, by virtue of the issuance of the Series F Preferred Stock, Ridgeway will vote its Series F Preferred Stock on an as if converted to Common Stock basis which shall be equal to eighty percent (80%) of the issued and outstanding Common Stock post-conversion. Accordingly, the Board of Directors determined that a change in control of the registrant had occurred. The Company did not have a prior relationship with Ridgeway, or any of its principals, except pursuant to the terms contained in the Termination Agreement and its previous relationship under the Licensing Agreement.

 

NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN

 

Basis of Presentation

 

The opinion of our independent registered accounting firm on our consolidated financial statements contains explanatory going concern language. We have prepared our consolidated financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred losses from operations since inception, we have a working capital deficit of $5.2 million and we have an accumulated deficit of $65 million as of December 31, 2022. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our therapeutic product candidates which are currently in development or we enter into cash flow positive business development transactions.

 

To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance our product candidates through development. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds.

 

Our cash balances at December 31, 2022 were approximately $5,000, representing 100% of our total assets. Based on our current expected level of operating expenditures, and including $500,000 that we raised in January 2021 and $500,000 that we raised in June 2021, pursuant to the sale of our senior convertible debentures, we expect to be able to fund our operations into the first quarter of 2023. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such financing will be available when needed in order to allow us to continue our operations, or if available, on terms favorable or acceptable to us.

 

In the event additional financing is not obtained, we may pursue cost cutting measures as well as explore the sale of assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on our business, results of operations, and financial condition. These factors raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

Our current cash level raises substantial doubt about our ability to continue as a going concern past the fourth quarter of 2022. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

 

F-10

 

 

NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the parent company, Rebus Holdings, Inc., (fka Inspyr Therapeutics, Inc.) and its wholly-owned subsidiaries, Inspyr Therapeutics, Inc., Lewis & Clark Pharmaceuticals, Inc. and Ridgeway Therapeutics, Inc. (a California corporation). All significant intercompany accounts and transactions have been eliminated.

 

Reverse Stock Split and Increase in Authorized Shares

 

The one for seventy-five (1-for-75) Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio.

 

All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split and the 2020 Reverse Stock Split.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.

 

Research and Development

 

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for pre-clinical research, toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs associated therewith.

 

We incurred research and development expenses of $0.2 million and $0.5 million for the years ended December 31, 2022 and 2021, respectively.

 

Cash Equivalents

 

For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did not have any cash equivalents at December 31, 2022 or 2021.

 

Concentrations of Credit Risk

 

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash was $5,000 and $0.7 million at December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, there was no cash over the federally insured limit.

 

F-11

 

 

Income (Loss) per Share

 

Basic income (loss) per share is calculated by dividing net income (loss) and net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding for the period.

 

The Company’s potentially dilutive securities are detailed in the table below. The potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2022 and 2021, as they would be anti-dilutive.

 

               
    Year Ended
December 31,		  
    2022     2021  
Shares underlying warrants outstanding     1       23  
Shares underlying convertible notes outstanding     49,569,961       35,204,931  
Shares underlying convertible preferred stock outstanding     131,804,100       47,172,096  
      181,374,062       82,377,050  

 

Diluted loss per share for the year ended December 31, 2021 is calculated as follows:

 

       
    Year ended  
    December 31,  
    2021  
Net income attributable to common shareholders   $ 2,698  
Income attributable to convertible instruments     (4,928 )
Expense attributable to convertible instruments     829  
Diluted loss attributable to common shareholders   $ (1,401 )
         
Basic shares outstanding     7,645,186  
Dilutive convertible instruments     13,487,262  
Diluted shares outstanding     21,132,448  
         
Diluted loss per share   $ (0.07 )

 

Derivative Liability

 

The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.

 

Fair Value of Financial Instruments

 

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of one year or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

 

The derivative liabilities consist of our convertible notes and Series F preferred stock with variable conversion features. The Company uses the Black-Scholes option-pricing model to value its derivative liabilities which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

 

F-12

 

 

Fair Value Measurements

 

The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

 

The Company has recorded a derivative liability for its convertible notes and preferred stock with variable conversion features as of December 31, 2022 and 2021. The tables below summarize the fair values of our financial liabilities as of December 31, 2022 and 2021 (in thousands):

 

                               
    Fair Value at
December 31,		     Fair Value Measurement Using  
    2022     Level 1     Level 2     Level 3  
Convertible notes   $ 285       -       -     $ 285  
Preferred stock     595       -       -       595  
Derivative liability   $ 880     $ -     $ -     $ 880  

 

    Fair Value at
December 31,		     Fair Value Measurement Using  
    2021     Level 1     Level 2     Level 3  
Convertible notes   $ 518       -       -     $ 518  
Preferred stock     606       -       -       606  
Derivative liability   $ 1,124     $ -     $ -     $ 1,124  

 

The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

 

               
    Year ended
December 31,		  
    2022     2021  
Balance at beginning of year   $ 1,124     $ 6,828  
Additions to derivative instruments     -       1,354  
Reclassification on conversion     (507 )     (3,371 )
Loss (gain) on change in fair value of derivative liability     263       (3,687 )
Balance at end of year   $ 880     $ 1,124  

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.

 

F-13

 

 

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment.

 

Other Comprehensive Income

 

The Company does not have any activity that results in Other Comprehensive Income.

 

Recent Accounting Pronouncements

 

There have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2022 that are of significance or potential significance to the Company.

 

NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION

 

The following table contains additional information for the periods reported (in thousands).

 

               
    Year Ended
December 31,		  
    2022     2021  
Non-cash financial activities:                
Common stock issued on conversion of notes payable and derivative liability   $ 790     $ 4,447  
Debentures converted to common stock     462       2,694  
Derivative liability extinguished upon conversion of notes payable     507       3,371  
Derivative liability issued     -       1,354  
Accounts payable paid through issuance of debentures     -       100  
Accrued director fees forgiven and credited to paid in capital     -       336  

 

There was no cash paid for interest and income taxes for the years ended December 31, 2022 and 2021.

 

NOTE 5 – INTELLECTUAL PROPERTY

 

We solely own or have exclusive licenses to all of our patents and patent applications. Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $212,000 in cash and common stock. As a result of these payments and pursuant to the agreements, we acquired worldwide, exclusive, fully paid up rights in know-how, pre-clinical data, development data and certain patent portfolios that relate to, and form the basis of, our technology. Under these agreements, we are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to JHU, UC, or the Assignee Co-Founders.

 

Intangibles have been fully amortized at December 31, 2022 and 2021.

 

F-14

 

 

NOTE 6 – ACCRUED EXPENSES

 

Accrued expenses consist of the following (in thousands):

 

               
    December 31,  
    2022     2021  
Accrued compensation and benefits   $ 1,326     $ 1,326  
Accrued research and development     233       233  
Accrued other     519       445  
Total accrued expenses   $ 2,078     $ 2,004  

 

NOTE 7 – DERIVATIVE LIABILITY

 

We account for equity-linked financial instruments, such as our convertible preferred stock, convertible debentures and our common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the respective agreement. Equity-linked financial instruments are accounted for as derivative liabilities, in accordance with ASC Topic 815 – Derivatives and Hedging, if the instrument allows for cash settlement or issuance of a variable number of shares. We classify derivative liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.

 

We have issued convertible debentures and preferred stock which contain variable conversion features, anti-dilution protection and other conversion price adjustment provisions. As a result, the Company assessed its outstanding equity-linked financial instruments and concluded that the convertible notes and preferred stock are subject to derivative accounting. The fair value of the conversion feature is classified as a liability in the consolidated financial statements, with the change in fair value during the periods presented recorded in the consolidated statement of losses.

 

During the years ended December 31, 2022 and 2021, we recorded loss of approximately $0.3 million and gain of approximately $3.7 million, respectively, related to the change in fair value of the derivative liabilities during the periods. For purpose of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuations of the derivatives for the years ended December 31, 2022 and 2021 are as follows:

 

       
   

For the Years Ended

December 31

    2022   2021
Expected dividends   0%   0%
Expected volatility   198% - 260%   205% - 262%
Risk free interest rate   0.22% - 4.76%   0.06% - 0.19%
Expected term   3 – 12 Months   3 – 6 Months

 

As of December 31, 2022 and 2021, the derivative liability recognized in the financial statements was approximately $0.9 million and $1.1 million, respectively.

 

F-15

 

 

NOTE 8 – COMMITMENTS AND CONTINGENCIES

 

Operating Leases

 

The Company currently does not have any ongoing leases for office space. It has availability to office space on an as needed basis. Its employees work on a remote basis.

 

There was no rent expense for the years ended December 31, 2022 and 2021, respectively.

 

Legal Matters

 

The Company is subject at times to legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

 

Uncertainty Due to Geopolitical Events

 

Due to Russia’s invasion of Ukraine, which began in February 2022, and the resulting sanctions and other actions against Russia and Belarus, there has been uncertainty and disruption in the global economy. Although the Russian war against Ukraine did not have a material adverse impact on the Company’s financial results for the year ended December 31, 2022, at this time the Company is unable to fully assess the aggregate impact the Russian war against Ukraine will have on its business due to various uncertainties, which include, but are not limited to, the duration of the war, the war’s effect on the economy, its impact to the business of the Company, and actions that may be taken by governmental authorities related to the war.

 

COVID-19 Uncertainty

 

On March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The extent of the public-health impact of the outbreak is currently unknown and rapidly evolving, and the related health crisis could adversely affect the global economy, resulting in an economic downturn. Any disruption of the Company’s facilities or those of our suppliers could likely adversely impact the Company’s operations. At this time, there is significant uncertainty relating to the potential effect of the novel coronavirus on our business.

 

NOTE 9 – CAPITAL STOCK AND STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

The Company is authorized to issue 30,000,000 shares of preferred stock. As of December 31, 2022 and 2021, there were outstanding 133.8 shares of Series A Preferred Stock, 71 shares of Series B Preferred Stock, 290.4 shares of Series C Preferred Stock, 5,000 shares of Series D Preferred Stock, 5,000 shares of Series E Preferred Stock and 8,000 shares of Series F Preferred Stock.

 

Series F Preferred Stock

 

On October 6, 2020, the Company filed a certificate of designation of Series F Preferred Stock (“Series F COD”) with the Secretary of State of the State of Delaware that contains the rights, preferences, and privileges of the Series F Preferred Stock. Pursuant to the Series F COD, each share of Series F Preferred Stock has a stated value of $10.00 per share and is convertible into Common Stock at any time at the election of the holder. We issued all 8,000 shares of the Series F stock to Ridgeway Therapeutics, Inc. in connection with the Termination Agreement described in Note 1. In the aggregate, all of the Series F Preferred Stock issued to Ridgeway is convertible into such number of shares of Common Stock equal to eighty percent (80%) of the issued and outstanding shares of Common Stock, post-conversion, on the conversion date (taking into effect any forward or reverse stock splits or consolidations). As the number of shares of common stock issuable upon conversion is variable, the related contingent liability is accounted as a derivative liability. The Series F Preferred Stock votes on an as if converted to common stock basis. Additionally, upon the Company’s outstanding Convertible Debentures (as such term is defined in the Series F COD) being terminated, converted, or otherwise extinguished, the Series F Preferred Stock will automatically convert into Common Stock. The Series F preferred stock is accounted for as equity classification.

 

Series E Preferred Stock

 

On May 2, 2020, we sold 5,000 shares of Series E 0% Convertible Preferred Stock to an accredited investor at a price per share of $1.00 for aggregate gross proceeds of $5,000. Pursuant to the certificate of designation of Series E Preferred Stock (“Series E COD”), each share of Series E Preferred Stock has stated value of $1.00 and is convertible, at any time after the Original Issue Date (as such term is defined in the Series E COD) at the option of the Holder into that number of shares of Common Stock (Subject to the limitations set forth in Section 6(d) of Series E COD), determined by dividing the stated value by the then in effect conversion price. As of December 31, 2022, the conversion price is $22.50 per share.

 

F-16

 

 

As provided for in the Series E COD, with respect to a vote of stockholders to approve a reverse split of the Common Stock to occur no later than December 31, 2022 only, each share of Series E Preferred Stock held by a holder, as such, is entitled to 1,333 votes. On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series E Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series E Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series E Preferred Stock shall vote together with the holders of Common Stock as a single class. The Series E preferred stock is accounted for as equity classification.

 

Series D Preferred Stock

 

During December 2018, we designated 5,000 shares of preferred stock as Series D 0% Convertible Preferred Stock (the “Series D Preferred Stock”). Each share of Preferred Stock has a par value of $0.0001 per share and a stated value equal to $1.00. During January 2019, we issued the 5,000 shares of Series D Convertible Preferred Stock for proceeds of $5,000. Pursuant to the certificate of designation of Series D Preferred stock (“Series D COD”), each share of Series D Preferred Stock shall be convertible, at any time and from time to time from and after its original issue date at the option of the holder thereof, into that number of shares of Common Stock (subject to beneficial ownership limitations contained in Section 6(d) of the Series D COD) determined by dividing the stated value of such share of Series D Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $281.25 per share of Series D Preferred Stock. The Series D preferred stock is accounted for as equity classification.

 

On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series D Preferred Stock shall vote together with the holders of Common Stock as a single class.

 

Series C Preferred Stock

 

In March and April 2017, we issued 290.43148 shares of Series C 0% Convertible Preferred Stock (the “Series C Preferred Stock”). Pursuant to the certificate of designation of Series C Preferred Stock (“Series C COD”), the Series C Preferred Stock has a stated value of $1,000. Pursuant to the Series C COD, the Series C Preferred Stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series C COD) determined by dividing the stated value of such Series C Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $1,125.00 per share for 200 shares of Series C Preferred Stock and $562.50 per shares for 90.43418 shares of Series C preferred, subject to certain beneficial ownership limitations and subject to adjustment pursuant to stock splits and dividends. The Series C preferred stock is accounted for as equity classification.

 

Series B Preferred Stock

 

In December 2016, we issued 1,000 shares of our Series B 0% Convertible Preferred Stock (the “Series B Preferred Stock”). Pursuant to the certificate of designation of the Series B Preferred Stock (“Series B COD”), the Series B Preferred Stock has a stated value of $1,000 per share. Pursuant to the Series B COD, the Series B Preferred stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series B COD), determined by dividing the stated value of such Series B Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $0.0217 per share, subject to adjustment pursuant to stock splits and dividends, and subject to adjustment pursuant to anti-dilution protection for subsequent equity sales and other conversion price adjustments. The Series B preferred stock is accounted for as equity classification.

 

F-17

 

 

Series A Preferred Stock

 

In December 2015, we issued 1,853 shares of our Series A 0% Convertible Preferred Stock (the “Series A Preferred Stock”). Pursuant to the certificate of designation of Series A Preferred Stock (“Series A COD”), the Series A Preferred Stock has a stated value of $1,000 per share. Pursuant to the Series A COD, the Series A Preferred Stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series A COD), determined by dividing the stated value of such Series A Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $29,812.50 per share, subject to adjustment pursuant to stock splits and dividends. The Series A preferred stock is accounted for as equity classification.

 

As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2022, (ii) our Series B Preferred Stock has been reduced to $0.0217 per share at December 31, 2022, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2022, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2022.

 

Common Stock

 

The Company is authorized to issue 1,000,000,000 shares of common stock. There were 32,132,907 and 11,769,221 shares of common stock outstanding at December 31, 2022 and 2021, respectively.

 

Reverse Stock Split

 

On September 1, 2021, the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split. The Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio.

 

All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split.

 

Common Stock Activity

 

During the year ended December 31, 2022, we issued a total of 20,363,686 shares of common stock, valued at $789,699, upon the conversion of $461,972 principal amount of our convertible debentures. We recorded loss on conversion of debt of $23,746 during the year ended December 31, 2022.

 

During the year ended December 31, 2021, we issued a total of 9,290,364 shares of common stock, valued at $4,447,246, upon the conversion of $2,693,596 principal amount of our convertible debentures. We recorded gain on conversion of debt of $1,116,424 during the year ended December 31, 2021.

 

During the year ended December 31, 2021, we issued a total of 9 shares of common stock in settlement of outstanding options, pursuant to the merger discussed in Note 1.

 

During the three months ended March 31, 2021, we entered into settlement and release agreements with two of our independent directors for the settlement of past due director fees and the mutual release of all claims. Pursuant to the agreements, the directors agreed to waive an aggregate of $435,667 in outstanding director fees in exchange for the following: (i) the aggregate payment of $100,000 (of which $50,000 was paid in November 2020 and $50,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021 (which has yet to occur), common stock purchase options with an aggregate Black Scholes’ value of $80,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. The difference between the amount waived of $435,667 and the cash paid of $100,000 has been credited to paid in capital during 2021.

 

F-18

 

 

NOTE 10 – STOCK OPTIONS

 

Deferred Compensation Plan

 

In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded “top hat” plan which is maintained primarily to provide deferred compensation benefits for a select group of our “management or highly compensated employees” within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards.

 

Company Compensation Plans

 

The Company’s 2007 Equity Compensation Plan (2007 Plan), 2009 Executive Compensation Plan (2009 Plan), 2017 Equity Compensation Plan (2017 Plan), and the Inducement Award Stock Option Plan (Inducement Plan) (together, the Plans) provided for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of the Company and its stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans were administered by a committee of non-employee directors (the Committee). The Committee determined: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award.

 

Termination of Compensation Plans

 

Our 2007 Equity Compensation Plan, 2009 Executive Compensation Plan, Inducement Award Stock Option Plan and 2017 Equity Compensation Plan have all expired or been terminated by the Board as of December 31, 2021.

 

The following table summarizes stock option activity for the year ended December 31, 2021:

 

                       
    Number of
shares		     Weighted- average
exercise price		     Weighted- average
remaining contractual term
(in years)		  
Outstanding at December 31, 2020     16     $ 355,342          
Granted     -     $ -          
Settled with shares pursuant to merger     (9 )   $ 477,238          
Forfeited     (7 )   $ 198,619          
Outstanding at December 31, 2021     -     $ -       -  

 

No options were issued or exercised during the years ended December 31, 2022 and 2021. As of December 31, 2022, there were no options outstanding.

 

F-19

 

 

NOTE 11 – WARRANTS

 

Transactions involving our warrants are summarized as follows:

 

                       
    Number of
shares		     Weighted- average
exercise price		     Weighted- average
remaining contractual term
(in years)		  
Outstanding at December 31, 2020     53     $ 5,033          
Granted     -     $ -          
Forfeited     (30 )   $ 22          
Outstanding at December 31, 2021     23     $ 11,568       0.3  
Granted     -     $ -          
Forfeited     (22 )   $ 972          
Outstanding at December 31, 2022     1     $ 244,688       0.6  
                         
Exercisable at December 31, 2022     1     $ 244,688       0.6  

 

No warrants were issued or exercised during the years ended December 31, 2022 and 2021. The warrants had no intrinsic value at December 31, 2022.

 

The following table summarizes outstanding common stock purchase warrants as of December 31, 2022:

 

               
    Number of
shares		     Weighted- average
exercise price		     Expiration
Issued to consultants   1     $ 244,688     August 2023

 

NOTE 12 – CONVERTIBLE DEBENTURES AND NOTES

 

June 2021 Debentures

 

On June 18, 2021, the Company sold an aggregate of $600,000 of senior convertible debentures (“June Debentures”) for (i) $500,000 in cash and (ii) $100,000 in cancellation of outstanding indebtedness to existing accredited and institutional investors of the Company. The June Debentures (i) are non-interest bearing, (ii) have a maturity date of June 18, 2022, (iii) are convertible into shares of Common Stock at the election of the holders at any time, subject to a beneficial ownership limitation of 9.99%, and (iv) have a conversion price equal to the lesser of $24.75 and 85% of the lowest Volume Weighted Average Price (VWAP) during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein. The maturity date of the debentures has been extended to December 31, 2023. There were no other modifications to the June 2021 Debentures.

 

The June Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investors also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the June Debentures contains anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the June Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the June Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the June Debentures.

 

F-20

 

 

During the year ended December 31, 2022, $461,972 of June Debentures have been converted to Common Stock and $100,000 remains outstanding at December 31, 2022.

 

During the year ended December 31, 2021, $38,028 of June Debentures have been converted to Common Stock.

 

We recorded an initial derivative liability of $644,457 related to the fair value of the derivative liability associated with the June Debentures. We recorded debt discount of $600,000, which will be amortized to interest expense over the term of the June Debentures, and we charged $44,457 to interest expense upon issue. We have amortized $54,292 of discount to interest expense during the year ended December 31, 2022 and $203,458 of discount has been charged off against loss upon the conversion of the June Debentures during 2022. We have amortized $324,561 of discount to interest expense during the year December 31, 2021 and $17,689 has been charged off against gain upon the conversion of the June Debentures during the year ended December 31, 2021. There was no unamortized discount at December 31, 2022.

 

January 2021 Debenture

 

On January 12, 2021, we sold a $500,000 senior convertible debenture (“January Debenture”) for $500,000 in cash to an existing institutional investor of the Company. The January Debenture (i) is non-interest bearing, (ii) has a maturity date of January 12, 2022, (iii) is convertible into shares of Common Stock at the election of the holder at any time, subject to a beneficial ownership limitation of 9.99%, and (iv) has a conversion price equal to the lesser of $24.75 and 85% of the lowest VWAP during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein.

 

The January Debenture also contains provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investor also has the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the January Debentures contains anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the January Debenture is no longer outstanding. Additionally, the Company has the option to redeem some or all of the January Debenture for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the January Debenture.

 

The January Debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

We recorded an initial derivative liability of $709,835 related to the fair value of the derivative liability associated with the January debenture. We recorded debt discount of $500,000, which will be amortized to interest expense over the term of the January debenture, and we charged $209,835 to interest expense upon issue. We have amortized $327,450 of discount to interest expense during the year ended December 31, 2021 and $172,550 has been charged off against gain upon the conversion of the October Debentures during the year ended December 31, 2021.

 

October 2020 Debentures

 

On October 23, 2020, the Company sold an aggregate of $600,000 of senior convertible debentures (“October Debentures”) for (i) $500,000 in cash and (ii) $100,000 in cancellation of outstanding indebtedness to existing accredited and institutional investors of the Company.

 

The October Debentures (i) are non-interest bearing, (ii) have a maturity date of October 23, 2021, (iii) are convertible into shares of common stock at the election of the holders at any time, subject to a beneficial ownership limitation of 9.99%, and (iv) have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to December 31, 2023. There were no other modifications to the October Debentures.

 

The October Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The holders also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the October Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the October Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the October Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the October Debentures.

 

F-21

 

 

Without the approval of the October Debenture holders holding at least 67% of the then outstanding principal amount of the October Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any holder, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company.

 

During the year ended December 31, 2021, $500,000 of October Debentures have been converted to common stock and $100,000 remains outstanding at December 31, 2022.

 

We had recorded debt discount of $600,000 related to the October Debentures, which will be amortized to interest expense over the term of the October Debentures. We have amortized $176,389 of discount to interest expense during the year ended December 31, 2021 and $311,111 has been charged off against gain upon the conversion of the October Debentures during the year ended December 31, 2021. We recorded an initial derivative liability of $619,627 related to the fair value of the derivative liability associated with the debentures, of which $600,000 was recorded as discount and $19,627 was charged to interest expense upon issue.

 

March 2020 Debentures

 

On March 6, 2020, the Company sold an aggregate of $250,000 of senior convertible debentures (the “March Debentures”) for cash to existing accredited institutional investors of the Company (the “March 2020 Offering”). The March Debentures issued (i) are non-interest bearing, (ii) have a maturity date of July 16, 2020 and (iii) are convertible into shares of common stock of the Company at the election of the holder at any time, subject to a beneficial ownership limitation of 9.99%. The March Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to June 30, 2021.

 

The March Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The holders will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the March Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the March Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the March Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the March Debentures.

 

Furthermore, without the approval of the debenture holders holding at least 67% of the then outstanding principal amount of the March Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any investor, (ii) repay or repurchase or acquire shares of its common stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company.

 

The March Debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

November 2019 Debentures

 

Sabby Volatility Warrant Master Fund, Ltd. has paid certain of our accounts payable in the amount of $26,235. We issued $26,235 in new debentures with substantially the same terms as those issued in our Debenture Offerings. The debentures were issued in November 2019. The debentures originally matured November 20, 2020. The maturity date of the debentures has been extended to June 30, 2021.

 

The debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

F-22

 

 

October 2019 Debentures

 

Effective September 30 2019, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures and notes issued in our Debenture Offerings and extended the maturity date of such debentures until March 31, 2020 in exchange for the issuance of $96,000 in new debentures with substantially the same terms as those issued in our Debenture Offerings. The debentures were issued in October 2019. The debentures originally matured on October 1, 2020. The maturity date of the debentures has been extended to June 30, 2021.

 

The debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

July 2019 Debentures

 

On July 16, 2019, we entered into securities purchase agreements with certain institutional investors. Pursuant to the securities purchase agreement, we issued an aggregate of $154,000 of senior convertible debentures (the “July 2019 Debentures”) in exchange for the extension of the maturity date of our December 2018 convertible notes and certain of our July 2018 and September 2017 convertible debentures, and the waiver of certain default provisions of our July 2018 and September 2017 convertible debentures. We charged $154,000 to finance cost at the date of issuance.

 

The July 2019 Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the investor upon 61 days’ notice. The July 2019 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The July 2019 Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the July 2019 Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the July 2019 Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the July 2019 Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the July 2019 Debentures. The maturity date of the July 2019 has been extended to June 30, 2021.

 

Furthermore, without the approval of the investors holding at least 67% of the then outstanding principal amount of the July 2019 Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also obligated under the Securities Purchase Agreement to pay investors, as partial liquidated damages, a fee of 2.0% of each investor’s initial principal amount of such investor’s July 2019 Debenture in cash upon our failure to have current public information available beginning six (6) months after the issuance date of the Debentures.

 

The July 2019 Debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

December 2018 Notes

 

On December 13, 2018 we issued an aggregate of $25,000 in convertible promissory notes (“Notes”) for cash proceeds of $25,000. The Notes will mature on the earlier of (i) June 30, 2019 or (ii) such time as we raise capital in exchange for the sale of securities (“Note Maturity Date”) and bear interest at 10% per year, payable on the Note Maturity Date. Pursuant to the terms of the Notes, the Notes may be converted into shares of common stock upon an Event of Default (as such term is defined in the Notes) or upon the Maturity Date at the election of the holder at a price per share equal to 75% of the lowest trade price of our common stock on the trading day immediately prior to the date such exchange is exercised by the holder. The Note Maturity Date has been extended to June 30, 2021.

 

The Notes were fully converted to Common Stock during the year ended December 31, 2021.

 

F-23

 

 

July 2018 Debentures

 

On July 3, 2018, we entered into securities purchase agreements with certain institutional investors. Pursuant to the securities purchase agreement, we sold an aggregate of $515,000 of senior convertible debentures (“July 2018 Debentures”) consisting of $500,000 in cash and the cancellation of $15,000 of obligations of the Company. Pursuant to the terms of the securities purchase agreement, we issued $515,000 in principal amount of July 2018 Debentures. The July 2018 Debentures have substantially the same terms as the July 2019 Debentures. The maturity date of the July 2018 Debentures has been extended to June 30, 2021.

 

The July 2018 Debentures were fully converted to common stock during the year ended December 31, 2021.

 

September 2017 Debentures

 

On September 12, 2017, we entered into an exchange agreement (“Exchange Agreement”) with certain holders of our Series A Preferred Stock and Series B Preferred Stock. Pursuant to the terms of the Exchange Agreement, we issued to the investors approximately $2.5 million in principal amount of senior convertible debentures (the “September 2017 Debentures”) in exchange for 1,614.8125 shares of Series A Preferred Stock with a stated value of approximately $1.6 million and 890 shares of Series B Preferred Stock with a stated value of approximately $0.9 million.

 

On September 12, 2017, we sold an aggregate of $320,000 of our September 2017 Debentures. The sale consisted of $250,000 in cash and the cancellation of $70,000 of obligations of the Company.

 

The September 2017 Debentures have substantially the same terms as the July 2019 Debentures.

 

During the year ended December 31, 2021 $589,334 of debenture were converted to common stock and $110,072 remains outstanding at December 31, 2022. The remaining outstanding debentures have been extended to December 31, 2023. There were no other modifications to the September 2017 Debentures.

 

During 2022, we recorded imputed interest on the outstanding September 2017, October 2020 and June 2021 debentures in the amount of $15,500. This amount has been credited to additional paid-in capital.

 

NOTE 13 — RELATED PARTY TRANSACTIONS

 

In September of 2021, we began paying $10,000 per month to Silvestre Law Group, P.C., our outside corporate counsel, for our SEC compliance legal work (“Monthly Fee”). Mr. Silvestre, our CEO since August 16, 2021, is a principal of Silvestre Law Group, P.C. Additionally, Silvestre Law Group bills us at their standard rates for additional services outside of the scope of the Monthly Fee. For the year ended December 31, 2022, we accrued $125,844 in legal fees to Silvestre Law Group. We paid Silvestre Law Group $110,000 for the Monthly Fee and recorded an additional $15,844 in legal fees for other services not covered by the Monthly Fee during 2022. Between January 1, 2021 and August 15, 2021, we accrued $84,224 in legal fees to Silvestre Law Group. From August 16, 2021 through December 31, 2021, we paid Silvestre Law Group $40,000 for the Monthly Fee and recorded an additional $54,141 in legal fees for other services not covered by the Monthly Fee.

 

The company had a balance due to Silvestre Law Group of $309,848 and $294,005 at December 31, 2022 and 2021, respectively. Silvestre Law Group also holds $290,000 of our convertible debentures at December 31, 2022 and 2021. During 2022, we recorded imputed interest of $14,500 on the debentures.

 

F-24

 

 

NOTE 14 — INCOME TAXES

 

The Company had, subject to limitation, $44 million of net operating loss carryforwards (“NOL”) at December 31, 2022, of which $39.9 million will expire at various dates through 2037. In addition, the Company has research and development tax credits of approximately $496,000 at December 31, 2022 available to offset future taxable income, which will expire from 2028 through 2042. We have provided a 100% valuation allowance for the deferred tax benefits resulting from the net operating loss carryover and our tax credits due to our lack of earnings history. In addressing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The valuation allowance decreased by approximately $1.7 million and increased by approximately $306,000 for the years ended December 31, 2022 and 2021, respectively. Significant components of deferred tax assets and liabilities are as follows (in thousands): 

 

               
    2022     2021  
Deferred tax assets:                
Net operating loss carryover   $ 9,525     $ 9,343  
Stock-based compensation     -       1,920  
Accrued compensation     334       334  
Other     30       30  
Tax credits     496       485  
Total deferred tax assets     10,385       12,112  
Less: valuation allowance     (10,385 )     (12,112 )
Net deferred tax assets   $ -     $ -  

 

The above NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL carryforward that can be utilized to offset future taxable income. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. The Company has not completed an IRC Section 382/383 analysis. If a change in ownership were to have occurred, NOL carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company’s effective tax rate.

 

The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2022 and 2021 (computed by applying the U.S. Federal Corporate tax rate of 21% to income before taxes) are as follows:

 

               
    2021     2020  
Statutory federal income tax rate     (21.0 )%     (21.0 )%
State income taxes, net of federal benefits     (7.0 )%     (7.0 )%
Non-deductible items     (240.8 )%     38.3 %
Valuation allowance     268.8 %     (10.3 )%
Effective income tax rate     - %     - %

 

The Company’s tax returns for the previous six years remain open for audit by the respective tax jurisdictions.

 

F-25

 

 

INDEX TO EXHIBITS

 

            Incorporated by Reference  
Exhibit No.   Description   Filed
Herewith		   Form   Exhibit
No.		   File
No.		   Filing
Date		  
2.01   Form of agreement and Plan of Merger among Inspyr Therapeutics, Inc., Rebus Holdings, Inc., and Rebus Sub, Inc. dated September 28, 2021.       8-K   3.01   000-55331   10/4/21  
                           
3.01(i)   Amended and Restated Certificate of Incorporation dated September 4, 2013       8-K   3.01   333-153829   9/6/13  
                           
3.02(i)   Amendment to the Amended and Restated Certificate of Incorporation, effective August 1, 2016       8-K   3.01   333-153829   8/2/16  
                           
3.03(i)   Amended and Restated Certificate of Incorporation dated October 21, 2016       8-K   3.01(i)   000-55331   11/10/16  
                           
3.04(i)   Amended and Restated Certificate of Incorporation, effective September 30, 2019       8-K   3.01(i)   000-55331   9/30/19  
                           
3.05(i)   Amended and Restated Certificate of Incorporation, effective June 26, 2020       8-K   3.01(i)   000-55331   6/29/20  
                           
3.06(ii)   Amended and Restated Bylaws       8-K   3.02   333-153829   1/11/10  
                           
3.07(i)   Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock       8-K   3.01   000-55331   12/23/15  
                           
3.08(i)   Certificate of Designation of Preferences, Rights and Limitations of Series B 0% Convertible Preferred Stock       8-K   3.01   000-55331   12/12/16  
                           
3.09(i)   Certificate of Designation of Preferences, Rights and Limitations of Series C 0% Convertible Preferred Stock       8-K   3.01   000-55331   3/20/17  
                           
3.10(i)   Certificate of Designation of Preferences, Rights and Limitations of Series D 0% Convertible Preferred Stock       10-K   3.08(i)   000-55331   4/26/19  
                           
3.11(i)   Certificate of Designation of Preferences, Rights and Limitations of Series E 0% Convertible Preferred Stock       10-K   3.10(i)   000-55331   5/14/20  
                           
3.12(i)   Certificate of Designation of Preferences, Rights and Limitations of Series F 0% Convertible Preferred Stock       8-K   3.01(i)   000-55331   10/8/20  
                           
3.13(i)   Amended and Restated Certificate of Incorporation Effective November 27, 2020       8-K   3.01(i)   000-55331   11/27/20  

 

49

 

 

3.14(i)   Amended and Restated Certificate of Incorporation of Inspyr Therapeutics, Inc. effecting 1-for-75 Reverse Stock Split       8-K   3.01(i)   000-55331   10/4/21  
                           
3.15(i)   Certificate of Merger between Inspyr Therapeutics, Inc. and Rebus Sub, Inc.       8-K   3.02(i)   000-55331   10/4/21  
                           
3.16(ii)   Rebus Holdings Bylaws dated November 11, 2021       10-Q   3.16(ii)   000-55331   11/12/21  
                           
4.01   Specimen of Common Stock Certificate       S-1   4.01   333-153829   10/03/08  
                           
4.02   Form of Series A Preferred Stock Certificate       8-K   4.01   000-55331   12/23/15  
                           
4.03   Form of Series B Preferred Stock Certificate       8-K   4.01   000-55331   12/12/16  
                           
4.04   Form of Series C Preferred Stock Certificate       8-K   4.01   000-55331   3/20/17  
                           
4.05   Form of Series D and E Common Stock Purchase Warrants for July 2015 Private Placement       8-K   10.03   000-55331   7/6/15  
                           
4.06   Form of Securities Purchase Agreement for December 2016 Private Placement       8-K   10.01   000-55331   12/12/16  
                           
4.07   Form of Series J, K and L Warrants for December 2016 Private Placement       8-K   10.03   000-55331   12/12/16  
                           
4.08   Form of Securities Purchase Agreement for March 2017 – April 2017 Private Placement       8-K   10.01   000-55331   3/20/16  
                           
4.09   Form of Series M, N and O warrants for March 2017 – April 2017 Private Placement       8-K   10.02   000-55331   3/20/17  
                           
4.10   Form of Series D Preferred Stock Certificate       10-K   4.45   000-55331   4/26/19  
                           
4.11   Form of Series E Preferred Stock Certificate       10-K   4.36   000-55331   5/14/20  
                           
10.01   Exclusive Supply Agreement between GenSpera and Thapsibiza dated April 2012 that expires April 6, 2022       10-K   10.01   333-153829   3/29/13  
                           
10.02   Form of Indemnification Agreement with Directors and Officers       8-K   10.01   000-55331   9/12/16  

 

10.03   Form of Proprietary Information, Inventions and Competition Agreement       8-K   10.02   000-55331   8/10/16  
                           
10.04   Form of Share Exchange Agreement between Inspyr Therapeutics and Lewis & Clark Pharmaceuticals       8-K   10.01   000-55331   8/03/17  

 

50

 

 

10.05   Form of Exchange Agreement for September 2017 Private Placement       8-K   10.01   000-55331   9/12/17  
                           
10.06   Form of Senior Convertible Debenture initially due 9/12/18 issued pursuant to Exchange Agreement       8-K   10.02   000-55331   9/12/17  
                           
10.07   Form of Securities Purchase Agreement for September 2017 Private Placement       8-K   10.01   000-55331   9/12/17  
                           
10.08   Form of Senior Convertible Debenture initially due 9/12/18 issued pursuant to Securities Purchase Agreement       8-K   10.02   000-55331   9/12/17  
                           
10.10   Form of Securities Purchase Agreement for July 2018 Private Placement       8-K   10.01   000-55331   7/3/18  
                           
10.11   Form of Debenture for July 2018 Private Placement       8-K   10.02   000-55331   7/3/18  
                           
10.12   Form of Securities Purchase Agreement for January 2019 Preferred Stock Offering       10-K   10.23   000-55331   4/26/19  
                           
10.13   Form of Debenture for March 2020 Private Placement       8-K   10.01   000-55331   3/6/20  
                           
10.14   Form of Securities Purchase Agreement for May 2020 Preferred Stock Offering       10-K   10.25   000-55331   5/14/20  
                           
10.15   Termination of Licensing Agreement with Ridgeway Therapeutics, Inc. dated October 5, 2020       8-K   10.01   000-55331   10/8/20  
                           
10.16   Form of Debenture for October 2020 Private Placement       8-K   10.01   000-55331   10/29/20  
                           
10.17   Conversion Price Adjustment Agreement with Sabby Entities dated November 25, 2020       8-K   10.01   000-55331   11/27/20  
                           
10.18   Form of Convertible Debenture for January 2021 Private Placement       8-K   10.01   000-55331   1/12/21  
                           
10.19   Form of Convertible Debenture for June 2021 Private Placement       8-K   10.01   000-55331   6/21/21  

 

14.01   Code of Ethics       10-K   14.01   000-55331   4/26/19  
                           
21.01   List of Subsidiaries of Registrant       10-K   21.01   000-55331   3/31/23  
                           
31.1   Certification of the Principal Executive Officer Pursuant to Section 3.02 of the Sarbanes-Oxley Act of 2002.   *                  

 

51

 

 

31.2   Certification of the Principal Financial Officer Pursuant to Section 3.02 of the Sarbanes-Oxley Act of 2002.   *                  
                           
32.1   Certification of Principal Executive Officer pursuant to 18 U.S.C § 1350.                      
                           
32.2   Certification of Principal Financial Officer pursuant to 18 U.S.C § 1350.                      
                           
99.01   Audit Committee Charter       10-K   99.01   000-55331   4/26/19  
                           
99.02   Leadership Development and Compensation Committee Charter       10-K   99.02   000-55331   4/26/19  
                           
99.03   Nominating and Governance Committee Charter       10-K   99.03   000-55331   4/26/19  
                           
101.INS   XBRL Instance Document   *                  
                           
101.SCH   XBRL Taxonomy Extension Schema   *                  
                           
101.INS   XBRL Taxonomy Extension Calculation Linkbase   *                  
                           
101.INS   XBRL Taxonomy Extension Definition Linkbase   *                  
                           
101.INS   XBRL Taxonomy Extension Label Linkbase   *                  
                           
101.INS   XBRL Taxonomy Extension Presentation Linkbase   *                  

 

 
* Filed Herein
** Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.

 

52

 EX-31.1 2 rebusholdings_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

SECTION 302

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

 

I, Raul Silvestre, certify that:

 

(1) I have reviewed this Annual Report on Form 10-K of Rebus Holdings, Inc.;

 

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

(4) The registrant’s other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its unconsolidated investments, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2023 By: /s/ Raul Silvestre
    Raul Silvestre, Chief Executive Officer

 

 

 EX-31.2 3 rebusholdings_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

SECTION 302

CERTIFICATION OF THE PRINCIPAL ACCOUNTING OFFICER

 

I, Raul Silvestre, certify that:

 

(1) I have reviewed this Annual Report on Form 10-K of Rebus Holdings Inc.;

 

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

(4) The registrant’s other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its unconsolidated investments, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 31, 2023 By: /s/ Raul Silvestre
    Raul Silvestre, Principal Accounting Officer

 

 

 EX-32.1 4 rebusholdings_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350 AND EXCHANGE ACT RULES 13a-14(b) AND 15d-14(b)

(Section 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with the Annual Report of Rebus Holdings, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Raul Silvestre, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operation of the Company.

 

Date: March 31, 2023  
   
/s/ Raul Silvestre  
Chief Executive Officer  
Rebus Holdings, Inc.  

 

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 EX-32.2 5 rebusholdings_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER PURSUANT TO

18 U.S.C. SECTION 1350 AND EXCHANGE ACT RULES 13a-14(b) AND 15d-14(b)

(Section 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with the Annual Report of Rebus Holdings, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Raul Silvestre, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operation of the Company.

 

Date: March 31, 2023  
   
/s/ Raul Silvestre  
Chief Executive Officer  
(Principal Financial and Principal Accounting Officer)  
Rebus Holdings, Inc.  

 

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 EX-101.SCH 6 rbsh-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - BACKGROUND link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - INTELLECTUAL PROPERTY link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - DERIVATIVE LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - CAPITAL STOCK AND STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCK OPTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - CONVERTIBLE DEBENTURES AND NOTES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - DERIVATIVE LIABILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - STOCK OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - BACKGROUND (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - INTELLECTUAL PROPERTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - DERIVATIVE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - DERIVATIVE LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - CAPITAL STOCK AND STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - STOCK OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - STOCK OPTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - WARRANTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - CONVERTIBLE DEBENTURES AND NOTES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rbsh-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 rbsh-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 rbsh-20221231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Series F Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Finite-Lived Intangible Assets by Major Class [Axis] Intellectual Property [Member] Cash and Cash Equivalents [Axis] Cash [Member] Series F Preferred Stocks [Member] Warrant [Member] Short-Term Debt, Type [Axis] Convertible Debt [Member] Convertible Preferred Stock [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Measurement Input Type [Axis] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Price Volatility [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Term [Member] Related Party [Axis] Ridgeway Therapeutics, Inc [Member] Series E 0% Convertible Preferred Stock [Member] Derivative Instrument [Axis] Equity Option [Member] Consultant [Member] Debt Instrument [Axis] June 2021 Debenture [Member] January 2021 Debenture [Member] October 2020 Debentures [Member] March 2020 Debentures [Member] November 2019 Debentures [Member] October 2019 Debentures [Member] July 2019 Debenture [Member] December 2018 Debentures [Member] July 2018 Debentures [Member] September 2017 Debentures [Member] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Silvestre Law Group P C [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Name Auditor Firm ID Auditor Location Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Prepaid expenses Total current assets Total assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable Accounts payable - related party Accrued expenses Convertible debentures, net of unamortized discount of $0 and $212 Convertible debenture - related party, net of unamortized discount of $0 and $46 Derivative liability Total current liabilities Long-term liabilities: Convertible debentures, net of current Convertible debentures - related party, net of current Total long-term liabilities Total liabilities Commitments and contingencies (Note 8) Stockholders’ deficit: Convertible preferred stock Common stock, par value $.0001 per share; 1,000,000,000 shares authorized, 32,132,907 and 11,769,221 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total stockholders’ deficit Total liabilities and stockholders’ deficit Net of unamortized discount, convertible debentures Unamortized discount Convertible preferred stock, par value (in dollars per share) Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Other income (expense): Gain (loss) on change in fair value of derivative liability Gain (loss) on conversion of debt Interest (expense), net Income (loss) before provision for income taxes Provision for income taxes Net income (loss) Net income (loss) per common share, basic Net income (loss) per common share, diluted Weighted average shares outstanding, basic Weighted average shares outstanding, diluted Beginning balance, value Beginning balance, shares Conversion of notes Conversion of notes, shares Director compensation waived Issuance of common stock in settlement of options, pursuant to merger Issuance of common stock in settlement of options, pursuant to merger, shares Net loss Imputed interest on notes Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: (Gain) loss on change in fair value of derivative liability (Gain) loss on conversion of debt Amortization of debt discount Imputed interest on notes payable Finance cost Changes in operating assets and liabilities: Prepaid expenses Accounts payable and accrued expenses Accounts payable- related party Cash used in operating activities Cash flows from investing activities: Cash flows from financing activities: Proceeds from convertible notes Cash provided by financing activities Net increase (decrease) in cash Cash, beginning of year Cash, end of year Organization, Consolidation and Presentation of Financial Statements [Abstract] BACKGROUND Managements Plans To Continue As Going Concern MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN Accounting Policies [Abstract] SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES Supplemental Cash Flow Elements [Abstract] SUPPLEMENTAL CASH FLOW INFORMATION Goodwill and Intangible Assets Disclosure [Abstract] INTELLECTUAL PROPERTY Payables and Accruals [Abstract] ACCRUED EXPENSES Derivative Instruments and Hedging Activities Disclosure [Abstract] DERIVATIVE LIABILITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] CAPITAL STOCK AND STOCKHOLDERS’ EQUITY Share-Based Payment Arrangement [Abstract] STOCK OPTIONS Warrants WARRANTS Convertible Debentures And Notes CONVERTIBLE DEBENTURES AND NOTES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Income Tax Disclosure [Abstract] INCOME TAXES Principles of Consolidation Reverse Stock Split and Increase in Authorized Shares Use of Estimates Research and Development Cash Equivalents Concentrations of Credit Risk Income (Loss) per Share Derivative Liability Fair Value of Financial Instruments Fair Value Measurements Income Taxes Stock-Based Compensation Other Comprehensive Income Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Diluted loss per share Schedule of fair values of financial liabilities Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs Schedule of additional information of cash flow Schedule of accrued expenses Schedule of black scholes valuations of derivatives Schedule of stock option activity Schedule of transactions involving of warrants Schedule of outstanding common stock purchase warrants Schedule of deferred tax assets and liabilities Schedule of actual tax benefit differs from the expected tax benefit Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Description of cancellation of a license agreement Debt securities sold Reverse stock split Common stock shares issued Convertible preferred stock Payment for expenses and costs Proceeds from equity financing Percentage of issued and outstanding shares of common stock Working capital deficit Accumulated deficit Cash balances Percentage of total assets Amount raised Shares underlying, outstanding Net income attributable to common shareholders Income attributable to convertible instruments Expense attributable to convertible instruments Diluted loss attributable to common shareholders Basic shares outstanding Dilutive convertible instruments Diluted shares outstanding Diluted loss per share DerivativeLiabilityTable [Table] DerivativeLiabilityDisclosure [Line Items] Convertible notes Preferred stock Balance at beginning of year Additions to derivative instruments Reclassification on conversion Loss (gain) on change in fair value of derivative liability Balance at end of year Reverse stock split, description Research and development Cash equivalents Cash Uninsured amount Non-cash financial activities: Common stock issued on conversion of notes payable and derivative liability Debentures converted to common stock Derivative liability extinguished upon conversion of notes payable Derivative liability issued Accounts payable paid through issuance of debentures Accrued director fees forgiven and credited to paid in capital Payments in cash and common stock Accrued compensation and benefits Accrued research and development Accrued other Total accrued expenses Derivative [Table] Derivative [Line Items] Derivative liability measurement input Derivative liability measurement input Derivative liability measurement input Derivative liability term Gain and loss on change in fair value of the derivative liability Derivative Liability Rental expenses Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock, shares outstanding Preferred stock, stated value Stock issued during period, shares Sale of stock, shares Sale of stock value Sale of stock, price per share Conversion price per share Preferred Stock, Voting Rights Preferred stock, shares authorized Preferred stock, par value Preferred stock, stated value Preferred stock shares issued Proceeds of preferred stock [custom:PreferredStockSharesValued-0] [custom:BeneficialOwnershipLimitation] Conversion price, description Common stock shares issued activity Common stock valued activity Principal amount activity convertible Gain of conversion of debt activity Directors fees waived Directors fees waived description Offsetting Assets [Table] Offsetting Assets [Line Items] Number of shares outstanding at beginning Weighted average exercise price outstanding at beginning Number of shares granted Weighted average exercise price granted Settled with shares pursuant to merger Weighted average exercise price, Settled with shares pursuant to merger Number of shares Forfeited Weighted average exercise price forfeited Number of shares outstanding at ending Weighted average exercise price outstanding at ending Number of share option outstanding Number of shares outstanding at beginning Weighted average exercise price outstanding at beginning Weighted- average remaining contractual term at beginning Number of shares granted Weighted average exercise price granted Number of shares forfeited Weighted average exercise price forfeited Number of shares outstanding at ending Weighted average exercise price outstanding at ending Weighted- average remaining contractual term at ending Warrant exercisable Weighted average exercise price warrant exercisable Weighted- average remaining contractual term, exercisable Number of shares Weighted Average Exercise price Expiration date ending Principal amount Cash received Cancellation amount Beneficial ownership limitation percentage Maturity date Converted debentures Debentures remaining amount Derivative liability Debt discount Interest Expense, Debt Debt discount Amortization of debt charged off Unamortized of debt discount Gain on charged off conversion of debentures Debt conversion amount Debt conversion amount remains outstanding Fair value intial derivative liability Interest expense Accounts payable Interest rate Trading price Remaining debt outstanding Stated value of the preferred shares Stated value of the preferred shares Preferred shares exchanged Imputed interest on debenture Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Payment to related parties Legal fees Payment for monthly fee Amount due to related party Convertible debentures Imputed interest on debentures Deferred tax assets: Net operating loss carryover Stock-based compensation Accrued compensation Other Tax credits Total deferred tax assets Less: valuation allowance Net deferred tax assets Statutory federal income tax rate State income taxes, net of federal benefits Non-deductible items Valuation allowance Effective income tax rate Net operating loss carryforwards Net operating loss carryforwards expire amount Expiration period Research and development tax credits Expiration period for tax credit Change in valuation allowance Director compensation waived. Debt securities sold. Percentage of issued and outstanding shares of common stock. Percentage of total assets. Amount raised. Income attributable to convertible debentures and preferred stock. Preferred stock. It refers to the amount of liability reclassified as fair value. Derivative liability extinguished upon conversion of notes payable. Derivative liability issued. Accounts payable paid through issuance of debentures. Accrued directors fees forgiven and credited to paid in capital. Carrying value as of the balance sheet date of obligations incurred and payable for research and development. Preferred stock, stated value. Preferred stock, par value. Directors fees waived. Directors fees waived description. Information by type of related party. It represents as a operating loss carryforwards expiration period. Information about the expiration period for tax credits. Amount of cancellation. Percentage of beneficial ownership limitation. Discount recorded at issuance. Amount of discount charged off against the gain on conversion. Information by type of debt instrument, including, but not limited to, draws against credit facilities. Preferred shares exchanged. Information by type of debt instrument, including, but not limited to, draws against credit facilities. Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding LossGainOnChangeInFairValueOfDerivativeLiability GainLossOnConversionOfDebt Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Preferred Stock, Convertible, Shares Issuable DilutedLossPerShare Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Research and Development Expense DerivativeLiabilitiesMeasurementInputPercentages DerivativeLiabilityMeasurementsInputPercentages Derivative Liability [Default Label] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share Amortization of Debt Discount (Premium) Accounts Payable Deferred Tax Assets, Valuation Allowance Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent EX-101.PRE 10 rbsh-20221231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 30, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 000-55331    
Entity Registrant Name REBUS HOLDINGS INC.    
Entity Central Index Key 0001421204    
Entity Tax Identification Number 20-0438951    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 2629 Townsgate Road    
Entity Address, Address Line Two Suite 215    
Entity Address, City or Town Westlake Village    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91361    
City Area Code (818)    
Local Phone Number 597-7552    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 766,023
Entity Common Stock, Shares Outstanding   32,132,907  
ICFR Auditor Attestation Flag false    
Auditor Name RBSM LLP    
Auditor Firm ID 587    
Auditor Location New York, NY    
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash $ 5 $ 711
Prepaid expenses 4
Total current assets 5 715
Total assets 5 715
Current liabilities:    
Accounts payable 1,664 1,801
Accounts payable - related party 310 294
Accrued expenses 2,078 2,004
Convertible debentures, net of unamortized discount of $0 and $212 20 250
Convertible debenture - related party, net of unamortized discount of $0 and $46 290 154
Derivative liability 880 1,124
Total current liabilities 5,242 5,627
Long-term liabilities:    
Convertible debentures, net of current 20
Convertible debentures - related party, net of current 90
Total long-term liabilities 110
Total liabilities 5,242 5,737
Commitments and contingencies (Note 8)
Stockholders’ deficit:    
Common stock, par value $.0001 per share; 1,000,000,000 shares authorized, 32,132,907 and 11,769,221 shares issued and outstanding, respectively 3 1
Additional paid-in capital 60,057 59,254
Accumulated deficit (65,297) (64,277)
Total stockholders’ deficit (5,237) (5,022)
Total liabilities and stockholders’ deficit 5 715
Series A Preferred Stock [Member]    
Stockholders’ deficit:    
Convertible preferred stock
Series B Preferred Stock [Member]    
Stockholders’ deficit:    
Convertible preferred stock
Series C Preferred Stock [Member]    
Stockholders’ deficit:    
Convertible preferred stock
Series D Preferred Stock [Member]    
Stockholders’ deficit:    
Convertible preferred stock
Series E Preferred Stock [Member]    
Stockholders’ deficit:    
Convertible preferred stock
Series F Preferred Stock [Member]    
Stockholders’ deficit:    
Convertible preferred stock
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Net of unamortized discount, convertible debentures $ 0 $ 212
Unamortized discount $ 0 $ 46
Convertible preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock, shares authorized 29,978,846 29,978,846
Convertible preferred stock, shares issued 0 0
Convertible preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 32,132,907 11,769,221
Common stock, shares outstanding 32,132,907 11,769,221
Series A Preferred Stock [Member]    
Convertible preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock, shares authorized 1,854 1,854
Convertible preferred stock, shares issued 134 134
Convertible preferred stock, shares outstanding 134 134
Series B Preferred Stock [Member]    
Convertible preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock, shares authorized 1,000 1,000
Convertible preferred stock, shares issued 71 71
Convertible preferred stock, shares outstanding 71 71
Series C Preferred Stock [Member]    
Convertible preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock, shares authorized 300 300
Convertible preferred stock, shares issued 290 290
Convertible preferred stock, shares outstanding 290 290
Series D Preferred Stock [Member]    
Convertible preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock, shares authorized 5,000 5,000
Convertible preferred stock, shares issued 5,000 5,000
Convertible preferred stock, shares outstanding 5,000 5,000
Series E Preferred Stock [Member]    
Convertible preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock, shares authorized 5,000 5,000
Convertible preferred stock, shares issued 5,000 5,000
Convertible preferred stock, shares outstanding 5,000 5,000
Series F Preferred Stock [Member]    
Convertible preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock, shares authorized 8,000 8,000
Convertible preferred stock, shares issued 8,000 8,000
Convertible preferred stock, shares outstanding 8,000 8,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development $ 239 $ 494
General and administrative 425 528
Total operating expenses 664 1,022
Loss from operations (664) (1,022)
Other income (expense):    
Gain (loss) on change in fair value of derivative liability (263) 3,687
Gain (loss) on conversion of debt (24) 1,116
Interest (expense), net (69) (1,083)
Income (loss) before provision for income taxes (1,020) 2,698
Provision for income taxes
Net income (loss) $ (1,020) $ 2,698
Net income (loss) per common share, basic $ (0.03) $ 0.35
Net income (loss) per common share, diluted $ (0.03) $ (0.07)
Weighted average shares outstanding, basic 31,819,481 7,645,188
Weighted average shares outstanding, diluted 31,819,481 21,132,450
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 54,472 $ (66,975) $ (12,503)
Beginning balance, shares at Dec. 31, 2020 18,495 2,478,848      
Conversion of notes $ 1 4,446 4,447
Conversion of notes, shares   9,290,364      
Director compensation waived 336 336
Issuance of common stock in settlement of options, pursuant to merger
Issuance of common stock in settlement of options, pursuant to merger, shares   9      
Net loss 2,698 2,698
Ending balance, value at Dec. 31, 2021 $ 1 59,254 (64,277) (5,022)
Ending balance, shares at Dec. 31, 2021 18,495 11,769,221      
Conversion of notes $ 2 788 790
Conversion of notes, shares   20,363,686      
Net loss (1,020) (1,020)
Imputed interest on notes   15 15
Ending balance, value at Dec. 31, 2022 $ 3 $ 60,057 $ (65,297) $ (5,237)
Ending balance, shares at Dec. 31, 2022 18,495 32,132,907      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net income (loss) $ (1,020) $ 2,698
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
(Gain) loss on change in fair value of derivative liability 263 (3,687)
(Gain) loss on conversion of debt 24 (1,116)
Amortization of debt discount 54 828
Imputed interest on notes payable 15
Finance cost 254
Changes in operating assets and liabilities:    
Prepaid expenses 4 (4)
Accounts payable and accrued expenses (62) 334
Accounts payable- related party 16
Cash used in operating activities (706) (693)
Cash flows from investing activities:
Cash flows from financing activities:    
Proceeds from convertible notes 1,000
Cash provided by financing activities 1,000
Net increase (decrease) in cash (706) 307
Cash, beginning of year 711 404
Cash, end of year $ 5 $ 711
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
BACKGROUND
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BACKGROUND

NOTE 1 – BACKGROUND

 

Rebus Holdings, Inc. (“we”, “us”, “our company”, “our”, “Rebus,” “Rebus Holdings,” or the “Company”) (formerly known as Inspyr Therapeutics, Inc., see below) was formed under the laws of the State of Delaware in November 2003, and has its principal office in Westlake Village, California. We are focused on the research and development of novel targeted precision therapeutics for the treatment of cancer.

 

Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor A2B antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific targets found in each type of cancer.

 

The adenosine receptor modulators include A 2B antagonists, dual A 2A /A 2B antagonists, and A 2A antagonists that have broad development applicability including indications within immuno-oncology and inflammation. Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine receptor antagonists may boost the host immune response against the tumor as a single-agent and in combination with other existing immuno-oncology agents leading to enhanced tumor killing and inhibition of metastasis. Adenosine also has anti-inflammatory properties in the acute and chronic setting. Adenosine receptor antagonists may promote a decreased inflammatory response and can potentially treat a broad range of inflammatory and autoimmune based diseases and conditions (e.g., rheumatoid arthritis, joint injury, Crohn’s disease, psoriasis) as well as improve wound healing and decrease pain.

 

Pursuant to our recent termination of license with Ridgeway Therapeutics, Inc., a Delaware Corporation (“Ridgeway”), we reacquired the rights to certain intellectual property, discussed above, and are currently focusing on a pipeline of small molecule adenosine receptor modulators. In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.

 

Our ability to execute the business plan is contingent upon our ability to raise the necessary funds. During March 2020, we sold approximately $250,000 of debt securities and in October 2020, we sold $500,000 of debt securities for cash. In January 2021, we sold an additional $500,000 of debt securities for cash and in June 2021, we sold an additional $500,000 of debt securities for cash. We are currently using such funds to maintain our SEC reporting requirements, pay legal accounting and other professional fees, and to retain consultants and other personnel to develop the adenosine A2R antagonists and in preparation for an IND filing related to our unique delivery platform and portfolio of adenosine A2R antagonists for the treatment of certain solid tumors. Should we fail to further raise sufficient funds to execute our business plan, our priority would be to maintain our intellectual property portfolio and seek business development opportunities with potential development partners and/or acquirors.

 

Adoption of Agreement and Plan of Merger and Consummation of Reorganization

 

On September 28, 2021 the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) to implement a holding company reorganization, which became effective on October 11, 2021 at 5:00 p.m. Eastern Time (the “Effective Time”). The Merger Agreement was entered into by and among Inspyr Therapeutics, Inc., Rebus Holdings, Inc., and Rebus Sub, Inc., a wholly-owned subsidiary of Rebus Holdings which has resulted in Rebus becoming the direct parent company of Inspyr Therapeutics and replacing Inspyr Therapeutics as the public company trading on the OTC Markets (“OTC”) (the “Reorganization”). Further, the Company began trading under the symbol RBSH on November 9, 2021.

 

Upon consummation of the Reorganization (and the Reverse Stock Split as defined below), Inspyr stockholders automatically became stockholders of Rebus Holdings, on a one-for-one basis, with the same number and approximate ownership percentage of shares of the same class as they held in Inspyr immediately prior to the Effective Time. The Reorganization was intended to be a tax-free transaction for U.S. federal income tax purposes for Inspyr stockholders.

 

As a result of the Reorganization, Rebus Holdings became the successor issuer to Inspyr Therapeutics pursuant to Rule 12g-3(a) of the Exchange Act, and as a result, shares of Rebus Holdings Common Stock are deemed registered under Section 12(g) of the Exchange Act as the Common Stock of the successor issuer.

 

Reverse Stock Split

 

On September 1, 2021, the Board of Directors approved a one-for-seventy-five (1-for-75) reverse stock split of the Company’s Common Stock (“Reverse Stock Split”). The Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio. All share and per share data have been retroactively restated in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split.

 

Post Reverse Stock Split and Reorganization Information

 

The Company began trading on post Reverse Stock Split and Reorganization basis on the Pink Sheets of the OTC Markets Group on October 12, 2021. The symbol remained NSPX until November 9, 2021, at which time the Company began trading under the symbol RBSH.

 

The officers and members of the Board of Inspyr became the officers and members of the board of directors of the Rebus Holdings.

 

Pursuant to the Reorganization, Rebus Holdings has, on a consolidated basis, the same assets, businesses, and operations as Inspyr Therapeutics had immediately prior to the Reorganization.

 

Termination of License Agreement

 

On October 5, 2020, the Company entered into an agreement with Ridgeway (“Termination Agreement”) whereby the parties terminated the licensing agreement previously entered into on August 3, 2018 (“Licensing Agreement”), The Company had previously licensed certain technologies related to targeting adenosine receptor antagonists for the treatment of cancer (the “Licensed Assets”). As a result of the Termination Agreement, the Company reacquired full ownership and worldwide rights to all of the Licensed Assets as well as any improvements made thereto.

 

In exchange for entering into the Termination Agreement, the Company issued to Ridgeway: (i) 866,667 shares Common Stock, and (ii) 8,000 shares of Series F 0% Convertible Preferred Stock (“Series F Preferred Stock”). Additionally, the Company paid approximately $25,000 of Ridgeway’s expenses and costs.

 

Pursuant to the Certificate of Designation of the Series F Preferred Stock, each share of Series F Preferred Stock has a stated value of $10.00 per share and is convertible into Common Stock at any time at the election of the holder. In the aggregate, all of the Series F Preferred Stock issued to Ridgeway is convertible into such number of shares of Common Stock equal to eighty percent (80%) of the issued and outstanding shares of Common Stock, post-conversion, on the conversion date (taking into effect any forward or reverse stock splits or consolidations). The Series F Preferred Stock votes on an as if converted to Common Stock basis. Additionally, upon the Company’s outstanding Convertible Debentures (as such term is defined in the Certificate of Designation) being terminated, converted, or otherwise extinguished, the Series F Preferred Stock will automatically convert into Common Stock.

 

Pursuant to the Termination Agreement, in the event that the Company is unable to secure equity financing resulting in aggregate gross proceeds to the Company of at least $5,000,000 by October 5, 2023, or in the event that the Company ceases its operations, then the Termination Agreement will be deemed terminated and the Licensing Agreement will be reinstated in exchange for the return of the Common Shares and Series F Preferred Stock previously issued to Ridgeway.

 

As a result of the issuance of the Common Shares and Series F Preferred Stock, Ridgeway became the owner of approximately 54.14% of the Company’s issued and outstanding Common Stock as of the termination date. Furthermore, by virtue of the issuance of the Series F Preferred Stock, Ridgeway will vote its Series F Preferred Stock on an as if converted to Common Stock basis which shall be equal to eighty percent (80%) of the issued and outstanding Common Stock post-conversion. Accordingly, the Board of Directors determined that a change in control of the registrant had occurred. The Company did not have a prior relationship with Ridgeway, or any of its principals, except pursuant to the terms contained in the Termination Agreement and its previous relationship under the Licensing Agreement.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN
 12 Months Ended
Dec. 31, 2022
Managements Plans To Continue As Going Concern  
MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN

NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN

 

Basis of Presentation

 

The opinion of our independent registered accounting firm on our consolidated financial statements contains explanatory going concern language. We have prepared our consolidated financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred losses from operations since inception, we have a working capital deficit of $5.2 million and we have an accumulated deficit of $65 million as of December 31, 2022. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our therapeutic product candidates which are currently in development or we enter into cash flow positive business development transactions.

 

To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance our product candidates through development. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds.

 

Our cash balances at December 31, 2022 were approximately $5,000, representing 100% of our total assets. Based on our current expected level of operating expenditures, and including $500,000 that we raised in January 2021 and $500,000 that we raised in June 2021, pursuant to the sale of our senior convertible debentures, we expect to be able to fund our operations into the first quarter of 2023. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such financing will be available when needed in order to allow us to continue our operations, or if available, on terms favorable or acceptable to us.

 

In the event additional financing is not obtained, we may pursue cost cutting measures as well as explore the sale of assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on our business, results of operations, and financial condition. These factors raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

Our current cash level raises substantial doubt about our ability to continue as a going concern past the fourth quarter of 2022. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES

NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the parent company, Rebus Holdings, Inc., (fka Inspyr Therapeutics, Inc.) and its wholly-owned subsidiaries, Inspyr Therapeutics, Inc., Lewis & Clark Pharmaceuticals, Inc. and Ridgeway Therapeutics, Inc. (a California corporation). All significant intercompany accounts and transactions have been eliminated.

 

Reverse Stock Split and Increase in Authorized Shares

 

The one for seventy-five (1-for-75) Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio.

 

All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split and the 2020 Reverse Stock Split.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.

 

Research and Development

 

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for pre-clinical research, toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs associated therewith.

 

We incurred research and development expenses of $0.2 million and $0.5 million for the years ended December 31, 2022 and 2021, respectively.

 

Cash Equivalents

 

For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did not have any cash equivalents at December 31, 2022 or 2021.

 

Concentrations of Credit Risk

 

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash was $5,000 and $0.7 million at December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, there was no cash over the federally insured limit.

 

Income (Loss) per Share

 

Basic income (loss) per share is calculated by dividing net income (loss) and net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding for the period.

 

The Company’s potentially dilutive securities are detailed in the table below. The potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2022 and 2021, as they would be anti-dilutive.

 

               
    Year Ended
December 31,		  
    2022     2021  
Shares underlying warrants outstanding     1       23  
Shares underlying convertible notes outstanding     49,569,961       35,204,931  
Shares underlying convertible preferred stock outstanding     131,804,100       47,172,096  
      181,374,062       82,377,050  

 

Diluted loss per share for the year ended December 31, 2021 is calculated as follows:

 

       
    Year ended  
    December 31,  
    2021  
Net income attributable to common shareholders   $ 2,698  
Income attributable to convertible instruments     (4,928 )
Expense attributable to convertible instruments     829  
Diluted loss attributable to common shareholders   $ (1,401 )
         
Basic shares outstanding     7,645,186  
Dilutive convertible instruments     13,487,262  
Diluted shares outstanding     21,132,448  
         
Diluted loss per share   $ (0.07 )

 

Derivative Liability

 

The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.

 

Fair Value of Financial Instruments

 

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of one year or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

 

The derivative liabilities consist of our convertible notes and Series F preferred stock with variable conversion features. The Company uses the Black-Scholes option-pricing model to value its derivative liabilities which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

 

Fair Value Measurements

 

The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

 

The Company has recorded a derivative liability for its convertible notes and preferred stock with variable conversion features as of December 31, 2022 and 2021. The tables below summarize the fair values of our financial liabilities as of December 31, 2022 and 2021 (in thousands):

 

                               
    Fair Value at
December 31,		     Fair Value Measurement Using  
    2022     Level 1     Level 2     Level 3  
Convertible notes   $ 285       -       -     $ 285  
Preferred stock     595       -       -       595  
Derivative liability   $ 880     $ -     $ -     $ 880  

 

    Fair Value at
December 31,		     Fair Value Measurement Using  
    2021     Level 1     Level 2     Level 3  
Convertible notes   $ 518       -       -     $ 518  
Preferred stock     606       -       -       606  
Derivative liability   $ 1,124     $ -     $ -     $ 1,124  

 

The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

 

               
    Year ended
December 31,		  
    2022     2021  
Balance at beginning of year   $ 1,124     $ 6,828  
Additions to derivative instruments     -       1,354  
Reclassification on conversion     (507 )     (3,371 )
Loss (gain) on change in fair value of derivative liability     263       (3,687 )
Balance at end of year   $ 880     $ 1,124  

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.

 

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment.

 

Other Comprehensive Income

 

The Company does not have any activity that results in Other Comprehensive Income.

 

Recent Accounting Pronouncements

 

There have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2022 that are of significance or potential significance to the Company.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
SUPPLEMENTAL CASH FLOW INFORMATION
 12 Months Ended
Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]  
SUPPLEMENTAL CASH FLOW INFORMATION

NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION

 

The following table contains additional information for the periods reported (in thousands).

 

               
    Year Ended
December 31,		  
    2022     2021  
Non-cash financial activities:                
Common stock issued on conversion of notes payable and derivative liability   $ 790     $ 4,447  
Debentures converted to common stock     462       2,694  
Derivative liability extinguished upon conversion of notes payable     507       3,371  
Derivative liability issued     -       1,354  
Accounts payable paid through issuance of debentures     -       100  
Accrued director fees forgiven and credited to paid in capital     -       336  

 

There was no cash paid for interest and income taxes for the years ended December 31, 2022 and 2021.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
INTELLECTUAL PROPERTY
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTELLECTUAL PROPERTY

NOTE 5 – INTELLECTUAL PROPERTY

 

We solely own or have exclusive licenses to all of our patents and patent applications. Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $212,000 in cash and common stock. As a result of these payments and pursuant to the agreements, we acquired worldwide, exclusive, fully paid up rights in know-how, pre-clinical data, development data and certain patent portfolios that relate to, and form the basis of, our technology. Under these agreements, we are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to JHU, UC, or the Assignee Co-Founders.

 

Intangibles have been fully amortized at December 31, 2022 and 2021.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES
 12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

NOTE 6 – ACCRUED EXPENSES

 

Accrued expenses consist of the following (in thousands):

 

               
    December 31,  
    2022     2021  
Accrued compensation and benefits   $ 1,326     $ 1,326  
Accrued research and development     233       233  
Accrued other     519       445  
Total accrued expenses   $ 2,078     $ 2,004  

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITY
 12 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE LIABILITY

NOTE 7 – DERIVATIVE LIABILITY

 

We account for equity-linked financial instruments, such as our convertible preferred stock, convertible debentures and our common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the respective agreement. Equity-linked financial instruments are accounted for as derivative liabilities, in accordance with ASC Topic 815 – Derivatives and Hedging, if the instrument allows for cash settlement or issuance of a variable number of shares. We classify derivative liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.

 

We have issued convertible debentures and preferred stock which contain variable conversion features, anti-dilution protection and other conversion price adjustment provisions. As a result, the Company assessed its outstanding equity-linked financial instruments and concluded that the convertible notes and preferred stock are subject to derivative accounting. The fair value of the conversion feature is classified as a liability in the consolidated financial statements, with the change in fair value during the periods presented recorded in the consolidated statement of losses.

 

During the years ended December 31, 2022 and 2021, we recorded loss of approximately $0.3 million and gain of approximately $3.7 million, respectively, related to the change in fair value of the derivative liabilities during the periods. For purpose of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuations of the derivatives for the years ended December 31, 2022 and 2021 are as follows:

 

       
   

For the Years Ended

December 31

    2022   2021
Expected dividends   0%   0%
Expected volatility   198% - 260%   205% - 262%
Risk free interest rate   0.22% - 4.76%   0.06% - 0.19%
Expected term   3 – 12 Months   3 – 6 Months

 

As of December 31, 2022 and 2021, the derivative liability recognized in the financial statements was approximately $0.9 million and $1.1 million, respectively.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 8 – COMMITMENTS AND CONTINGENCIES

 

Operating Leases

 

The Company currently does not have any ongoing leases for office space. It has availability to office space on an as needed basis. Its employees work on a remote basis.

 

There was no rent expense for the years ended December 31, 2022 and 2021, respectively.

 

Legal Matters

 

The Company is subject at times to legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

 

Uncertainty Due to Geopolitical Events

 

Due to Russia’s invasion of Ukraine, which began in February 2022, and the resulting sanctions and other actions against Russia and Belarus, there has been uncertainty and disruption in the global economy. Although the Russian war against Ukraine did not have a material adverse impact on the Company’s financial results for the year ended December 31, 2022, at this time the Company is unable to fully assess the aggregate impact the Russian war against Ukraine will have on its business due to various uncertainties, which include, but are not limited to, the duration of the war, the war’s effect on the economy, its impact to the business of the Company, and actions that may be taken by governmental authorities related to the war.

 

COVID-19 Uncertainty

 

On March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The extent of the public-health impact of the outbreak is currently unknown and rapidly evolving, and the related health crisis could adversely affect the global economy, resulting in an economic downturn. Any disruption of the Company’s facilities or those of our suppliers could likely adversely impact the Company’s operations. At this time, there is significant uncertainty relating to the potential effect of the novel coronavirus on our business.

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
CAPITAL STOCK AND STOCKHOLDERS’ EQUITY
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
CAPITAL STOCK AND STOCKHOLDERS’ EQUITY

NOTE 9 – CAPITAL STOCK AND STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

The Company is authorized to issue 30,000,000 shares of preferred stock. As of December 31, 2022 and 2021, there were outstanding 133.8 shares of Series A Preferred Stock, 71 shares of Series B Preferred Stock, 290.4 shares of Series C Preferred Stock, 5,000 shares of Series D Preferred Stock, 5,000 shares of Series E Preferred Stock and 8,000 shares of Series F Preferred Stock.

 

Series F Preferred Stock

 

On October 6, 2020, the Company filed a certificate of designation of Series F Preferred Stock (“Series F COD”) with the Secretary of State of the State of Delaware that contains the rights, preferences, and privileges of the Series F Preferred Stock. Pursuant to the Series F COD, each share of Series F Preferred Stock has a stated value of $10.00 per share and is convertible into Common Stock at any time at the election of the holder. We issued all 8,000 shares of the Series F stock to Ridgeway Therapeutics, Inc. in connection with the Termination Agreement described in Note 1. In the aggregate, all of the Series F Preferred Stock issued to Ridgeway is convertible into such number of shares of Common Stock equal to eighty percent (80%) of the issued and outstanding shares of Common Stock, post-conversion, on the conversion date (taking into effect any forward or reverse stock splits or consolidations). As the number of shares of common stock issuable upon conversion is variable, the related contingent liability is accounted as a derivative liability. The Series F Preferred Stock votes on an as if converted to common stock basis. Additionally, upon the Company’s outstanding Convertible Debentures (as such term is defined in the Series F COD) being terminated, converted, or otherwise extinguished, the Series F Preferred Stock will automatically convert into Common Stock. The Series F preferred stock is accounted for as equity classification.

 

Series E Preferred Stock

 

On May 2, 2020, we sold 5,000 shares of Series E 0% Convertible Preferred Stock to an accredited investor at a price per share of $1.00 for aggregate gross proceeds of $5,000. Pursuant to the certificate of designation of Series E Preferred Stock (“Series E COD”), each share of Series E Preferred Stock has stated value of $1.00 and is convertible, at any time after the Original Issue Date (as such term is defined in the Series E COD) at the option of the Holder into that number of shares of Common Stock (Subject to the limitations set forth in Section 6(d) of Series E COD), determined by dividing the stated value by the then in effect conversion price. As of December 31, 2022, the conversion price is $22.50 per share.

 

As provided for in the Series E COD, with respect to a vote of stockholders to approve a reverse split of the Common Stock to occur no later than December 31, 2022 only, each share of Series E Preferred Stock held by a holder, as such, is entitled to 1,333 votes. On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series E Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series E Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series E Preferred Stock shall vote together with the holders of Common Stock as a single class. The Series E preferred stock is accounted for as equity classification.

 

Series D Preferred Stock

 

During December 2018, we designated 5,000 shares of preferred stock as Series D 0% Convertible Preferred Stock (the “Series D Preferred Stock”). Each share of Preferred Stock has a par value of $0.0001 per share and a stated value equal to $1.00. During January 2019, we issued the 5,000 shares of Series D Convertible Preferred Stock for proceeds of $5,000. Pursuant to the certificate of designation of Series D Preferred stock (“Series D COD”), each share of Series D Preferred Stock shall be convertible, at any time and from time to time from and after its original issue date at the option of the holder thereof, into that number of shares of Common Stock (subject to beneficial ownership limitations contained in Section 6(d) of the Series D COD) determined by dividing the stated value of such share of Series D Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $281.25 per share of Series D Preferred Stock. The Series D preferred stock is accounted for as equity classification.

 

On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series D Preferred Stock shall vote together with the holders of Common Stock as a single class.

 

Series C Preferred Stock

 

In March and April 2017, we issued 290.43148 shares of Series C 0% Convertible Preferred Stock (the “Series C Preferred Stock”). Pursuant to the certificate of designation of Series C Preferred Stock (“Series C COD”), the Series C Preferred Stock has a stated value of $1,000. Pursuant to the Series C COD, the Series C Preferred Stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series C COD) determined by dividing the stated value of such Series C Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $1,125.00 per share for 200 shares of Series C Preferred Stock and $562.50 per shares for 90.43418 shares of Series C preferred, subject to certain beneficial ownership limitations and subject to adjustment pursuant to stock splits and dividends. The Series C preferred stock is accounted for as equity classification.

 

Series B Preferred Stock

 

In December 2016, we issued 1,000 shares of our Series B 0% Convertible Preferred Stock (the “Series B Preferred Stock”). Pursuant to the certificate of designation of the Series B Preferred Stock (“Series B COD”), the Series B Preferred Stock has a stated value of $1,000 per share. Pursuant to the Series B COD, the Series B Preferred stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series B COD), determined by dividing the stated value of such Series B Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $0.0217 per share, subject to adjustment pursuant to stock splits and dividends, and subject to adjustment pursuant to anti-dilution protection for subsequent equity sales and other conversion price adjustments. The Series B preferred stock is accounted for as equity classification.

 

Series A Preferred Stock

 

In December 2015, we issued 1,853 shares of our Series A 0% Convertible Preferred Stock (the “Series A Preferred Stock”). Pursuant to the certificate of designation of Series A Preferred Stock (“Series A COD”), the Series A Preferred Stock has a stated value of $1,000 per share. Pursuant to the Series A COD, the Series A Preferred Stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series A COD), determined by dividing the stated value of such Series A Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $29,812.50 per share, subject to adjustment pursuant to stock splits and dividends. The Series A preferred stock is accounted for as equity classification.

 

As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2022, (ii) our Series B Preferred Stock has been reduced to $0.0217 per share at December 31, 2022, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2022, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2022.

 

Common Stock

 

The Company is authorized to issue 1,000,000,000 shares of common stock. There were 32,132,907 and 11,769,221 shares of common stock outstanding at December 31, 2022 and 2021, respectively.

 

Reverse Stock Split

 

On September 1, 2021, the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split. The Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio.

 

All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split.

 

Common Stock Activity

 

During the year ended December 31, 2022, we issued a total of 20,363,686 shares of common stock, valued at $789,699, upon the conversion of $461,972 principal amount of our convertible debentures. We recorded loss on conversion of debt of $23,746 during the year ended December 31, 2022.

 

During the year ended December 31, 2021, we issued a total of 9,290,364 shares of common stock, valued at $4,447,246, upon the conversion of $2,693,596 principal amount of our convertible debentures. We recorded gain on conversion of debt of $1,116,424 during the year ended December 31, 2021.

 

During the year ended December 31, 2021, we issued a total of 9 shares of common stock in settlement of outstanding options, pursuant to the merger discussed in Note 1.

 

During the three months ended March 31, 2021, we entered into settlement and release agreements with two of our independent directors for the settlement of past due director fees and the mutual release of all claims. Pursuant to the agreements, the directors agreed to waive an aggregate of $435,667 in outstanding director fees in exchange for the following: (i) the aggregate payment of $100,000 (of which $50,000 was paid in November 2020 and $50,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021 (which has yet to occur), common stock purchase options with an aggregate Black Scholes’ value of $80,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. The difference between the amount waived of $435,667 and the cash paid of $100,000 has been credited to paid in capital during 2021.

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK OPTIONS
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
STOCK OPTIONS

NOTE 10 – STOCK OPTIONS

 

Deferred Compensation Plan

 

In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded “top hat” plan which is maintained primarily to provide deferred compensation benefits for a select group of our “management or highly compensated employees” within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards.

 

Company Compensation Plans

 

The Company’s 2007 Equity Compensation Plan (2007 Plan), 2009 Executive Compensation Plan (2009 Plan), 2017 Equity Compensation Plan (2017 Plan), and the Inducement Award Stock Option Plan (Inducement Plan) (together, the Plans) provided for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of the Company and its stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans were administered by a committee of non-employee directors (the Committee). The Committee determined: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award.

 

Termination of Compensation Plans

 

Our 2007 Equity Compensation Plan, 2009 Executive Compensation Plan, Inducement Award Stock Option Plan and 2017 Equity Compensation Plan have all expired or been terminated by the Board as of December 31, 2021.

 

The following table summarizes stock option activity for the year ended December 31, 2021:

 

                       
    Number of
shares		     Weighted- average
exercise price		     Weighted- average
remaining contractual term
(in years)		  
Outstanding at December 31, 2020     16     $ 355,342          
Granted     -     $ -          
Settled with shares pursuant to merger     (9 )   $ 477,238          
Forfeited     (7 )   $ 198,619          
Outstanding at December 31, 2021     -     $ -       -  

 

No options were issued or exercised during the years ended December 31, 2022 and 2021. As of December 31, 2022, there were no options outstanding.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS
 12 Months Ended
Dec. 31, 2022
Warrants  
WARRANTS

NOTE 11 – WARRANTS

 

Transactions involving our warrants are summarized as follows:

 

                       
    Number of
shares		     Weighted- average
exercise price		     Weighted- average
remaining contractual term
(in years)		  
Outstanding at December 31, 2020     53     $ 5,033          
Granted     -     $ -          
Forfeited     (30 )   $ 22          
Outstanding at December 31, 2021     23     $ 11,568       0.3  
Granted     -     $ -          
Forfeited     (22 )   $ 972          
Outstanding at December 31, 2022     1     $ 244,688       0.6  
                         
Exercisable at December 31, 2022     1     $ 244,688       0.6  

 

No warrants were issued or exercised during the years ended December 31, 2022 and 2021. The warrants had no intrinsic value at December 31, 2022.

 

The following table summarizes outstanding common stock purchase warrants as of December 31, 2022:

 

               
    Number of
shares		     Weighted- average
exercise price		     Expiration
Issued to consultants   1     $ 244,688     August 2023

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE DEBENTURES AND NOTES
 12 Months Ended
Dec. 31, 2022
Convertible Debentures And Notes  
CONVERTIBLE DEBENTURES AND NOTES

NOTE 12 – CONVERTIBLE DEBENTURES AND NOTES

 

June 2021 Debentures

 

On June 18, 2021, the Company sold an aggregate of $600,000 of senior convertible debentures (“June Debentures”) for (i) $500,000 in cash and (ii) $100,000 in cancellation of outstanding indebtedness to existing accredited and institutional investors of the Company. The June Debentures (i) are non-interest bearing, (ii) have a maturity date of June 18, 2022, (iii) are convertible into shares of Common Stock at the election of the holders at any time, subject to a beneficial ownership limitation of 9.99%, and (iv) have a conversion price equal to the lesser of $24.75 and 85% of the lowest Volume Weighted Average Price (VWAP) during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein. The maturity date of the debentures has been extended to December 31, 2023. There were no other modifications to the June 2021 Debentures.

 

The June Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investors also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the June Debentures contains anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the June Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the June Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the June Debentures.

 

During the year ended December 31, 2022, $461,972 of June Debentures have been converted to Common Stock and $100,000 remains outstanding at December 31, 2022.

 

During the year ended December 31, 2021, $38,028 of June Debentures have been converted to Common Stock.

 

We recorded an initial derivative liability of $644,457 related to the fair value of the derivative liability associated with the June Debentures. We recorded debt discount of $600,000, which will be amortized to interest expense over the term of the June Debentures, and we charged $44,457 to interest expense upon issue. We have amortized $54,292 of discount to interest expense during the year ended December 31, 2022 and $203,458 of discount has been charged off against loss upon the conversion of the June Debentures during 2022. We have amortized $324,561 of discount to interest expense during the year December 31, 2021 and $17,689 has been charged off against gain upon the conversion of the June Debentures during the year ended December 31, 2021. There was no unamortized discount at December 31, 2022.

 

January 2021 Debenture

 

On January 12, 2021, we sold a $500,000 senior convertible debenture (“January Debenture”) for $500,000 in cash to an existing institutional investor of the Company. The January Debenture (i) is non-interest bearing, (ii) has a maturity date of January 12, 2022, (iii) is convertible into shares of Common Stock at the election of the holder at any time, subject to a beneficial ownership limitation of 9.99%, and (iv) has a conversion price equal to the lesser of $24.75 and 85% of the lowest VWAP during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein.

 

The January Debenture also contains provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investor also has the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the January Debentures contains anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the January Debenture is no longer outstanding. Additionally, the Company has the option to redeem some or all of the January Debenture for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the January Debenture.

 

The January Debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

We recorded an initial derivative liability of $709,835 related to the fair value of the derivative liability associated with the January debenture. We recorded debt discount of $500,000, which will be amortized to interest expense over the term of the January debenture, and we charged $209,835 to interest expense upon issue. We have amortized $327,450 of discount to interest expense during the year ended December 31, 2021 and $172,550 has been charged off against gain upon the conversion of the October Debentures during the year ended December 31, 2021.

 

October 2020 Debentures

 

On October 23, 2020, the Company sold an aggregate of $600,000 of senior convertible debentures (“October Debentures”) for (i) $500,000 in cash and (ii) $100,000 in cancellation of outstanding indebtedness to existing accredited and institutional investors of the Company.

 

The October Debentures (i) are non-interest bearing, (ii) have a maturity date of October 23, 2021, (iii) are convertible into shares of common stock at the election of the holders at any time, subject to a beneficial ownership limitation of 9.99%, and (iv) have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to December 31, 2023. There were no other modifications to the October Debentures.

 

The October Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The holders also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the October Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the October Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the October Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the October Debentures.

 

Without the approval of the October Debenture holders holding at least 67% of the then outstanding principal amount of the October Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any holder, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company.

 

During the year ended December 31, 2021, $500,000 of October Debentures have been converted to common stock and $100,000 remains outstanding at December 31, 2022.

 

We had recorded debt discount of $600,000 related to the October Debentures, which will be amortized to interest expense over the term of the October Debentures. We have amortized $176,389 of discount to interest expense during the year ended December 31, 2021 and $311,111 has been charged off against gain upon the conversion of the October Debentures during the year ended December 31, 2021. We recorded an initial derivative liability of $619,627 related to the fair value of the derivative liability associated with the debentures, of which $600,000 was recorded as discount and $19,627 was charged to interest expense upon issue.

 

March 2020 Debentures

 

On March 6, 2020, the Company sold an aggregate of $250,000 of senior convertible debentures (the “March Debentures”) for cash to existing accredited institutional investors of the Company (the “March 2020 Offering”). The March Debentures issued (i) are non-interest bearing, (ii) have a maturity date of July 16, 2020 and (iii) are convertible into shares of common stock of the Company at the election of the holder at any time, subject to a beneficial ownership limitation of 9.99%. The March Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to June 30, 2021.

 

The March Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The holders will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the March Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the March Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the March Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the March Debentures.

 

Furthermore, without the approval of the debenture holders holding at least 67% of the then outstanding principal amount of the March Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any investor, (ii) repay or repurchase or acquire shares of its common stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company.

 

The March Debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

November 2019 Debentures

 

Sabby Volatility Warrant Master Fund, Ltd. has paid certain of our accounts payable in the amount of $26,235. We issued $26,235 in new debentures with substantially the same terms as those issued in our Debenture Offerings. The debentures were issued in November 2019. The debentures originally matured November 20, 2020. The maturity date of the debentures has been extended to June 30, 2021.

 

The debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

October 2019 Debentures

 

Effective September 30 2019, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures and notes issued in our Debenture Offerings and extended the maturity date of such debentures until March 31, 2020 in exchange for the issuance of $96,000 in new debentures with substantially the same terms as those issued in our Debenture Offerings. The debentures were issued in October 2019. The debentures originally matured on October 1, 2020. The maturity date of the debentures has been extended to June 30, 2021.

 

The debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

July 2019 Debentures

 

On July 16, 2019, we entered into securities purchase agreements with certain institutional investors. Pursuant to the securities purchase agreement, we issued an aggregate of $154,000 of senior convertible debentures (the “July 2019 Debentures”) in exchange for the extension of the maturity date of our December 2018 convertible notes and certain of our July 2018 and September 2017 convertible debentures, and the waiver of certain default provisions of our July 2018 and September 2017 convertible debentures. We charged $154,000 to finance cost at the date of issuance.

 

The July 2019 Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the investor upon 61 days’ notice. The July 2019 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The July 2019 Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the July 2019 Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the July 2019 Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the July 2019 Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the July 2019 Debentures. The maturity date of the July 2019 has been extended to June 30, 2021.

 

Furthermore, without the approval of the investors holding at least 67% of the then outstanding principal amount of the July 2019 Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also obligated under the Securities Purchase Agreement to pay investors, as partial liquidated damages, a fee of 2.0% of each investor’s initial principal amount of such investor’s July 2019 Debenture in cash upon our failure to have current public information available beginning six (6) months after the issuance date of the Debentures.

 

The July 2019 Debentures were fully converted to Common Stock during the year ended December 31, 2021.

 

December 2018 Notes

 

On December 13, 2018 we issued an aggregate of $25,000 in convertible promissory notes (“Notes”) for cash proceeds of $25,000. The Notes will mature on the earlier of (i) June 30, 2019 or (ii) such time as we raise capital in exchange for the sale of securities (“Note Maturity Date”) and bear interest at 10% per year, payable on the Note Maturity Date. Pursuant to the terms of the Notes, the Notes may be converted into shares of common stock upon an Event of Default (as such term is defined in the Notes) or upon the Maturity Date at the election of the holder at a price per share equal to 75% of the lowest trade price of our common stock on the trading day immediately prior to the date such exchange is exercised by the holder. The Note Maturity Date has been extended to June 30, 2021.

 

The Notes were fully converted to Common Stock during the year ended December 31, 2021.

 

July 2018 Debentures

 

On July 3, 2018, we entered into securities purchase agreements with certain institutional investors. Pursuant to the securities purchase agreement, we sold an aggregate of $515,000 of senior convertible debentures (“July 2018 Debentures”) consisting of $500,000 in cash and the cancellation of $15,000 of obligations of the Company. Pursuant to the terms of the securities purchase agreement, we issued $515,000 in principal amount of July 2018 Debentures. The July 2018 Debentures have substantially the same terms as the July 2019 Debentures. The maturity date of the July 2018 Debentures has been extended to June 30, 2021.

 

The July 2018 Debentures were fully converted to common stock during the year ended December 31, 2021.

 

September 2017 Debentures

 

On September 12, 2017, we entered into an exchange agreement (“Exchange Agreement”) with certain holders of our Series A Preferred Stock and Series B Preferred Stock. Pursuant to the terms of the Exchange Agreement, we issued to the investors approximately $2.5 million in principal amount of senior convertible debentures (the “September 2017 Debentures”) in exchange for 1,614.8125 shares of Series A Preferred Stock with a stated value of approximately $1.6 million and 890 shares of Series B Preferred Stock with a stated value of approximately $0.9 million.

 

On September 12, 2017, we sold an aggregate of $320,000 of our September 2017 Debentures. The sale consisted of $250,000 in cash and the cancellation of $70,000 of obligations of the Company.

 

The September 2017 Debentures have substantially the same terms as the July 2019 Debentures.

 

During the year ended December 31, 2021 $589,334 of debenture were converted to common stock and $110,072 remains outstanding at December 31, 2022. The remaining outstanding debentures have been extended to December 31, 2023. There were no other modifications to the September 2017 Debentures.

 

During 2022, we recorded imputed interest on the outstanding September 2017, October 2020 and June 2021 debentures in the amount of $15,500. This amount has been credited to additional paid-in capital.

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 13 — RELATED PARTY TRANSACTIONS

 

In September of 2021, we began paying $10,000 per month to Silvestre Law Group, P.C., our outside corporate counsel, for our SEC compliance legal work (“Monthly Fee”). Mr. Silvestre, our CEO since August 16, 2021, is a principal of Silvestre Law Group, P.C. Additionally, Silvestre Law Group bills us at their standard rates for additional services outside of the scope of the Monthly Fee. For the year ended December 31, 2022, we accrued $125,844 in legal fees to Silvestre Law Group. We paid Silvestre Law Group $110,000 for the Monthly Fee and recorded an additional $15,844 in legal fees for other services not covered by the Monthly Fee during 2022. Between January 1, 2021 and August 15, 2021, we accrued $84,224 in legal fees to Silvestre Law Group. From August 16, 2021 through December 31, 2021, we paid Silvestre Law Group $40,000 for the Monthly Fee and recorded an additional $54,141 in legal fees for other services not covered by the Monthly Fee.

 

The company had a balance due to Silvestre Law Group of $309,848 and $294,005 at December 31, 2022 and 2021, respectively. Silvestre Law Group also holds $290,000 of our convertible debentures at December 31, 2022 and 2021. During 2022, we recorded imputed interest of $14,500 on the debentures.

 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 14 — INCOME TAXES

 

The Company had, subject to limitation, $44 million of net operating loss carryforwards (“NOL”) at December 31, 2022, of which $39.9 million will expire at various dates through 2037. In addition, the Company has research and development tax credits of approximately $496,000 at December 31, 2022 available to offset future taxable income, which will expire from 2028 through 2042. We have provided a 100% valuation allowance for the deferred tax benefits resulting from the net operating loss carryover and our tax credits due to our lack of earnings history. In addressing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The valuation allowance decreased by approximately $1.7 million and increased by approximately $306,000 for the years ended December 31, 2022 and 2021, respectively. Significant components of deferred tax assets and liabilities are as follows (in thousands): 

 

               
    2022     2021  
Deferred tax assets:                
Net operating loss carryover   $ 9,525     $ 9,343  
Stock-based compensation     -       1,920  
Accrued compensation     334       334  
Other     30       30  
Tax credits     496       485  
Total deferred tax assets     10,385       12,112  
Less: valuation allowance     (10,385 )     (12,112 )
Net deferred tax assets   $ -     $ -  

 

The above NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL carryforward that can be utilized to offset future taxable income. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. The Company has not completed an IRC Section 382/383 analysis. If a change in ownership were to have occurred, NOL carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company’s effective tax rate.

 

The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2022 and 2021 (computed by applying the U.S. Federal Corporate tax rate of 21% to income before taxes) are as follows:

 

               
    2021     2020  
Statutory federal income tax rate     (21.0 )%     (21.0 )%
State income taxes, net of federal benefits     (7.0 )%     (7.0 )%
Non-deductible items     (240.8 )%     38.3 %
Valuation allowance     268.8 %     (10.3 )%
Effective income tax rate     - %     - %

 

The Company’s tax returns for the previous six years remain open for audit by the respective tax jurisdictions.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the parent company, Rebus Holdings, Inc., (fka Inspyr Therapeutics, Inc.) and its wholly-owned subsidiaries, Inspyr Therapeutics, Inc., Lewis & Clark Pharmaceuticals, Inc. and Ridgeway Therapeutics, Inc. (a California corporation). All significant intercompany accounts and transactions have been eliminated.

 
Reverse Stock Split and Increase in Authorized Shares

Reverse Stock Split and Increase in Authorized Shares

 

The one for seventy-five (1-for-75) Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio.

 

All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split and the 2020 Reverse Stock Split.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.

 
Research and Development

Research and Development

 

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for pre-clinical research, toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs associated therewith.

 

We incurred research and development expenses of $0.2 million and $0.5 million for the years ended December 31, 2022 and 2021, respectively.

 
Cash Equivalents

Cash Equivalents

 

For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did not have any cash equivalents at December 31, 2022 or 2021.

 
Concentrations of Credit Risk

Concentrations of Credit Risk

 

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash was $5,000 and $0.7 million at December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, there was no cash over the federally insured limit.

 
Income (Loss) per Share

Income (Loss) per Share

 

Basic income (loss) per share is calculated by dividing net income (loss) and net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding for the period.

 

The Company’s potentially dilutive securities are detailed in the table below. The potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2022 and 2021, as they would be anti-dilutive.

 

               
    Year Ended
December 31,		  
    2022     2021  
Shares underlying warrants outstanding     1       23  
Shares underlying convertible notes outstanding     49,569,961       35,204,931  
Shares underlying convertible preferred stock outstanding     131,804,100       47,172,096  
      181,374,062       82,377,050  

 

Diluted loss per share for the year ended December 31, 2021 is calculated as follows:

 

       
    Year ended  
    December 31,  
    2021  
Net income attributable to common shareholders   $ 2,698  
Income attributable to convertible instruments     (4,928 )
Expense attributable to convertible instruments     829  
Diluted loss attributable to common shareholders   $ (1,401 )
         
Basic shares outstanding     7,645,186  
Dilutive convertible instruments     13,487,262  
Diluted shares outstanding     21,132,448  
         
Diluted loss per share   $ (0.07 )

 
Derivative Liability

Derivative Liability

 

The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of one year or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

 

The derivative liabilities consist of our convertible notes and Series F preferred stock with variable conversion features. The Company uses the Black-Scholes option-pricing model to value its derivative liabilities which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

 
Fair Value Measurements

Fair Value Measurements

 

The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

 

The Company has recorded a derivative liability for its convertible notes and preferred stock with variable conversion features as of December 31, 2022 and 2021. The tables below summarize the fair values of our financial liabilities as of December 31, 2022 and 2021 (in thousands):

 

                               
    Fair Value at
December 31,		     Fair Value Measurement Using  
    2022     Level 1     Level 2     Level 3  
Convertible notes   $ 285       -       -     $ 285  
Preferred stock     595       -       -       595  
Derivative liability   $ 880     $ -     $ -     $ 880  

 

    Fair Value at
December 31,		     Fair Value Measurement Using  
    2021     Level 1     Level 2     Level 3  
Convertible notes   $ 518       -       -     $ 518  
Preferred stock     606       -       -       606  
Derivative liability   $ 1,124     $ -     $ -     $ 1,124  

 

The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

 

               
    Year ended
December 31,		  
    2022     2021  
Balance at beginning of year   $ 1,124     $ 6,828  
Additions to derivative instruments     -       1,354  
Reclassification on conversion     (507 )     (3,371 )
Loss (gain) on change in fair value of derivative liability     263       (3,687 )
Balance at end of year   $ 880     $ 1,124  

 
Income Taxes

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.

 
Stock-Based Compensation

Stock-Based Compensation

 

We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment.

 
Other Comprehensive Income

Other Comprehensive Income

 

The Company does not have any activity that results in Other Comprehensive Income.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

There have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2022 that are of significance or potential significance to the Company.

 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
               
    Year Ended
December 31,		  
    2022     2021  
Shares underlying warrants outstanding     1       23  
Shares underlying convertible notes outstanding     49,569,961       35,204,931  
Shares underlying convertible preferred stock outstanding     131,804,100       47,172,096  
      181,374,062       82,377,050  
Diluted loss per share
       
    Year ended  
    December 31,  
    2021  
Net income attributable to common shareholders   $ 2,698  
Income attributable to convertible instruments     (4,928 )
Expense attributable to convertible instruments     829  
Diluted loss attributable to common shareholders   $ (1,401 )
         
Basic shares outstanding     7,645,186  
Dilutive convertible instruments     13,487,262  
Diluted shares outstanding     21,132,448  
         
Diluted loss per share   $ (0.07 )
Schedule of fair values of financial liabilities
                               
    Fair Value at
December 31,		     Fair Value Measurement Using  
    2022     Level 1     Level 2     Level 3  
Convertible notes   $ 285       -       -     $ 285  
Preferred stock     595       -       -       595  
Derivative liability   $ 880     $ -     $ -     $ 880  

 

    Fair Value at
December 31,		     Fair Value Measurement Using  
    2021     Level 1     Level 2     Level 3  
Convertible notes   $ 518       -       -     $ 518  
Preferred stock     606       -       -       606  
Derivative liability   $ 1,124     $ -     $ -     $ 1,124  
Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs
               
    Year ended
December 31,		  
    2022     2021  
Balance at beginning of year   $ 1,124     $ 6,828  
Additions to derivative instruments     -       1,354  
Reclassification on conversion     (507 )     (3,371 )
Loss (gain) on change in fair value of derivative liability     263       (3,687 )
Balance at end of year   $ 880     $ 1,124  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
SUPPLEMENTAL CASH FLOW INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]  
Schedule of additional information of cash flow
               
    Year Ended
December 31,		  
    2022     2021  
Non-cash financial activities:                
Common stock issued on conversion of notes payable and derivative liability   $ 790     $ 4,447  
Debentures converted to common stock     462       2,694  
Derivative liability extinguished upon conversion of notes payable     507       3,371  
Derivative liability issued     -       1,354  
Accounts payable paid through issuance of debentures     -       100  
Accrued director fees forgiven and credited to paid in capital     -       336  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES (Tables)
 12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
Schedule of accrued expenses
               
    December 31,  
    2022     2021  
Accrued compensation and benefits   $ 1,326     $ 1,326  
Accrued research and development     233       233  
Accrued other     519       445  
Total accrued expenses   $ 2,078     $ 2,004  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITY (Tables)
 12 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of black scholes valuations of derivatives
       
   

For the Years Ended

December 31

    2022   2021
Expected dividends   0%   0%
Expected volatility   198% - 260%   205% - 262%
Risk free interest rate   0.22% - 4.76%   0.06% - 0.19%
Expected term   3 – 12 Months   3 – 6 Months
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK OPTIONS (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of stock option activity
                       
    Number of
shares		     Weighted- average
exercise price		     Weighted- average
remaining contractual term
(in years)		  
Outstanding at December 31, 2020     16     $ 355,342          
Granted     -     $ -          
Settled with shares pursuant to merger     (9 )   $ 477,238          
Forfeited     (7 )   $ 198,619          
Outstanding at December 31, 2021     -     $ -       -  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS (Tables)
 12 Months Ended
Dec. 31, 2022
Warrants  
Schedule of transactions involving of warrants
                       
    Number of
shares		     Weighted- average
exercise price		     Weighted- average
remaining contractual term
(in years)		  
Outstanding at December 31, 2020     53     $ 5,033          
Granted     -     $ -          
Forfeited     (30 )   $ 22          
Outstanding at December 31, 2021     23     $ 11,568       0.3  
Granted     -     $ -          
Forfeited     (22 )   $ 972          
Outstanding at December 31, 2022     1     $ 244,688       0.6  
                         
Exercisable at December 31, 2022     1     $ 244,688       0.6  
Schedule of outstanding common stock purchase warrants
               
    Number of
shares		     Weighted- average
exercise price		     Expiration
Issued to consultants   1     $ 244,688     August 2023
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of deferred tax assets and liabilities
               
    2022     2021  
Deferred tax assets:                
Net operating loss carryover   $ 9,525     $ 9,343  
Stock-based compensation     -       1,920  
Accrued compensation     334       334  
Other     30       30  
Tax credits     496       485  
Total deferred tax assets     10,385       12,112  
Less: valuation allowance     (10,385 )     (12,112 )
Net deferred tax assets   $ -     $ -  
Schedule of actual tax benefit differs from the expected tax benefit
               
    2021     2020  
Statutory federal income tax rate     (21.0 )%     (21.0 )%
State income taxes, net of federal benefits     (7.0 )%     (7.0 )%
Non-deductible items     (240.8 )%     38.3 %
Valuation allowance     268.8 %     (10.3 )%
Effective income tax rate     - %     - %
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
BACKGROUND (Details Narrative) - USD ($)
 12 Months Ended
Sep. 02, 2021
Dec. 31, 2022
Jun. 30, 2021
Jan. 31, 2021
Oct. 31, 2020
Mar. 31, 2020
Finite-Lived Intangible Assets [Line Items]            
Debt securities sold           $ 250,000
Reverse stock split the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split. 1-for-75        
Common stock shares issued   866,667        
Payment for expenses and costs   $ 25,000        
Proceeds from equity financing   $ 5,000,000        
Percentage of issued and outstanding shares of common stock   54.14%        
Series F Preferred Stocks [Member]            
Finite-Lived Intangible Assets [Line Items]            
Convertible preferred stock   8,000        
Cash [Member]            
Finite-Lived Intangible Assets [Line Items]            
Debt securities sold     $ 500,000 $ 500,000 $ 500,000  
Intellectual Property [Member]            
Finite-Lived Intangible Assets [Line Items]            
Description of cancellation of a license agreement   In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.        
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN (Details Narrative) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2021
Jan. 31, 2021
Managements Plans To Continue As Going Concern        
Working capital deficit $ 5,200,000      
Accumulated deficit 65,297,000 $ 64,277,000    
Cash balances $ 5,000 $ 700,000    
Percentage of total assets 100.00%      
Amount raised     $ 500,000 $ 500,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Shares underlying, outstanding 181,374,062 82,377,050
Convertible Preferred Stock [Member]    
Shares underlying, outstanding 131,804,100 47,172,096
Convertible Debt [Member]    
Shares underlying, outstanding 49,569,961 35,204,931
Warrant [Member]    
Shares underlying, outstanding 1 23
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1)
 12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Accounting Policies [Abstract]  
Net income attributable to common shareholders $ 2,698
Income attributable to convertible instruments (4,928)
Expense attributable to convertible instruments 829
Diluted loss attributable to common shareholders $ (1,401)
Basic shares outstanding | shares 7,645,186
Dilutive convertible instruments | shares 13,487,262
Diluted shares outstanding | shares 21,132,448
Diluted loss per share | $ / shares $ (0.07)
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
DerivativeLiabilityDisclosure [Line Items]    
Convertible notes $ 285 $ 518
Preferred stock 595 606
Derivative liability 880 1,124
Fair Value, Inputs, Level 1 [Member]    
DerivativeLiabilityDisclosure [Line Items]    
Convertible notes
Preferred stock
Derivative liability
Fair Value, Inputs, Level 2 [Member]    
DerivativeLiabilityDisclosure [Line Items]    
Convertible notes
Preferred stock
Derivative liability
Fair Value, Inputs, Level 3 [Member]    
DerivativeLiabilityDisclosure [Line Items]    
Convertible notes 285 518
Preferred stock 595 606
Derivative liability $ 880 $ 1,124
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Balance at beginning of year $ 1,124 $ 6,828
Additions to derivative instruments 1,354
Reclassification on conversion (507) (3,371)
Loss (gain) on change in fair value of derivative liability 263 (3,687)
Balance at end of year $ 880 $ 1,124
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Narrative) - USD ($)
 12 Months Ended
Sep. 02, 2021
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Reverse stock split, description the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split. 1-for-75  
Research and development   $ 200,000 $ 500,000
Cash equivalents   0 0
Cash   5,000 700,000
Uninsured amount   $ 0 $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Non-cash financial activities:    
Common stock issued on conversion of notes payable and derivative liability $ 790 $ 4,447
Debentures converted to common stock 462 2,694
Derivative liability extinguished upon conversion of notes payable 507 3,371
Derivative liability issued 1,354
Accounts payable paid through issuance of debentures 100
Accrued director fees forgiven and credited to paid in capital $ 336
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
INTELLECTUAL PROPERTY (Details Narrative)
 12 Months Ended
Dec. 31, 2022
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Payments in cash and common stock $ 212,000
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued compensation and benefits $ 1,326 $ 1,326
Accrued research and development 233 233
Accrued other 519 445
Total accrued expenses $ 2,078 $ 2,004
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITY (Details)
Dec. 31, 2022
Dec. 31, 2021
Measurement Input, Expected Dividend Rate [Member]    
Derivative [Line Items]    
Derivative liability measurement input 0.00% 0.00%
Measurement Input, Price Volatility [Member] | Minimum [Member]    
Derivative [Line Items]    
Derivative liability measurement input 198.00% 205.00%
Measurement Input, Price Volatility [Member] | Maximum [Member]    
Derivative [Line Items]    
Derivative liability measurement input 260.00% 262.00%
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]    
Derivative [Line Items]    
Derivative liability measurement input 0.22% 0.06%
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]    
Derivative [Line Items]    
Derivative liability measurement input 4.76% 0.19%
Measurement Input, Expected Term [Member] | Minimum [Member]    
Derivative [Line Items]    
Derivative liability term 3 months 3 months
Measurement Input, Expected Term [Member] | Maximum [Member]    
Derivative [Line Items]    
Derivative liability term 12 months 6 months
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITY (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gain and loss on change in fair value of the derivative liability $ 300 $ 3,700
Derivative Liability $ 900 $ 1,100
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]    
Rental expenses $ 0 $ 0
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
CAPITAL STOCK AND STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 02, 2021
Oct. 06, 2020
May 02, 2020
Dec. 31, 2018
Apr. 30, 2017
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2016
Dec. 31, 2015
Class of Stock [Line Items]                    
Preferred stock, shares outstanding             0 0    
Preferred stock, shares authorized             29,978,846 29,978,846    
Preferred stock, stated value             $ 0.0001 $ 0.0001    
Preferred stock shares issued             0 0    
Conversion price, description             As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2022, (ii) our Series B Preferred Stock has been reduced to $0.0217 per share at December 31, 2022, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2022, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2022.      
Common stock, shares authorized             1,000,000,000 1,000,000,000    
Common stock, shares outstanding             32,132,907 11,769,221    
Reverse stock split, description the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split.           1-for-75      
Common stock shares issued activity             20,363,686 9,290,364    
Common stock valued activity             $ 789,699 $ 4,447,246    
Principal amount activity convertible             461,972 2,693,596    
Gain of conversion of debt activity             $ 23,746 $ 1,116,424    
Directors fees waived           $ 435,667        
Directors fees waived description           the aggregate payment of $100,000 (of which $50,000 was paid in November 2020 and $50,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021 (which has yet to occur), common stock purchase options with an aggregate Black Scholes’ value of $80,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. The difference between the amount waived of $435,667 and the cash paid of $100,000 has been credited to paid in capital during 2021.        
Series A Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares outstanding             134 134    
Conversion price per share                   $ 29,812.50
Preferred stock, shares authorized             1,854 1,854    
Preferred stock, stated value             $ 0.0001 $ 0.0001   $ 1,000
Preferred stock shares issued             134 134   1,853
Series B Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares outstanding             71 71    
Conversion price per share                 $ 0.0217  
Preferred stock, shares authorized             1,000 1,000    
Preferred stock, stated value             $ 0.0001 $ 0.0001 $ 1,000  
Preferred stock shares issued             71 71 1,000  
Series C Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares outstanding             290 290    
Conversion price per share         $ 1,125.00          
Preferred stock, shares authorized             300 300    
Preferred stock, stated value         $ 1,000   $ 0.0001 $ 0.0001    
Preferred stock shares issued         290.43148   290 290    
[custom:PreferredStockSharesValued-0]         $ 562.50          
[custom:BeneficialOwnershipLimitation]         90.43418          
Series D Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares outstanding             5,000 5,000    
Conversion price per share       $ 281.25            
Preferred stock, shares authorized       5,000     5,000 5,000    
Preferred stock, par value       $ 0.0001            
Preferred stock, stated value       $ 1.00     $ 0.0001 $ 0.0001    
Preferred stock shares issued       5,000     5,000 5,000    
Proceeds of preferred stock       $ 5,000            
Series E Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares outstanding             5,000 5,000    
Preferred stock, shares authorized             5,000 5,000    
Preferred stock, stated value             $ 0.0001 $ 0.0001    
Preferred stock shares issued             5,000 5,000    
Series F Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares outstanding             8,000 8,000    
Preferred stock, stated value   $ 10.00                
Preferred stock, shares authorized             8,000 8,000    
Preferred stock, stated value             $ 0.0001 $ 0.0001    
Preferred stock shares issued             8,000 8,000    
Series F Preferred Stock [Member] | Ridgeway Therapeutics, Inc [Member]                    
Class of Stock [Line Items]                    
Stock issued during period, shares   8,000                
Series E 0% Convertible Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, stated value     $ 1.00              
Sale of stock, shares     5,000              
Sale of stock value     $ 5,000              
Sale of stock, price per share     $ 1.00              
Conversion price per share     $ 22.50              
Preferred Stock, Voting Rights     each share of Series E Preferred Stock held by a holder, as such, is entitled to 1,333 votes.              
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK OPTIONS (Details) - Equity Option [Member]
 12 Months Ended
Dec. 31, 2021
$ / shares
shares
Offsetting Assets [Line Items]  
Number of shares outstanding at beginning | shares 16
Weighted average exercise price outstanding at beginning | $ / shares $ 355,342
Number of shares granted | shares
Weighted average exercise price granted | $ / shares
Settled with shares pursuant to merger | shares (9)
Weighted average exercise price, Settled with shares pursuant to merger | $ / shares $ 477,238
Number of shares Forfeited | shares (7)
Weighted average exercise price forfeited | $ / shares $ 198,619
Number of shares outstanding at ending | shares
Weighted average exercise price outstanding at ending | $ / shares
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK OPTIONS (Details Narrative)
Dec. 31, 2022
shares
Share-Based Payment Arrangement [Abstract]  
Number of share option outstanding 0
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS (Details) - Warrant [Member] - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Number of shares outstanding at beginning 23 53
Weighted average exercise price outstanding at beginning $ 11,568 $ 5,033
Weighted- average remaining contractual term at beginning 3 months 18 days  
Number of shares granted
Weighted average exercise price granted
Number of shares forfeited (22) (30)
Weighted average exercise price forfeited $ 972 $ 22
Number of shares outstanding at ending 1 23
Weighted average exercise price outstanding at ending $ 244,688 $ 11,568
Weighted- average remaining contractual term at ending 7 months 6 days  
Warrant exercisable $ 1  
Weighted average exercise price warrant exercisable $ 244,688  
Weighted- average remaining contractual term, exercisable 7 months 6 days  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
WARRANTS (Details 1) - Warrant [Member] - Consultant [Member]
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Number of shares | shares 1
Weighted Average Exercise price | $ / shares $ 244,688
Expiration date ending August 2023
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE DEBENTURES AND NOTES (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 12, 2021
Mar. 06, 2020
Dec. 13, 2018
Jul. 03, 2018
Sep. 12, 2017
Sep. 12, 2017
Jun. 18, 2021
Oct. 23, 2020
Jul. 16, 2019
Dec. 31, 2022
Dec. 31, 2021
Conversion price, description                   As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2022, (ii) our Series B Preferred Stock has been reduced to $0.0217 per share at December 31, 2022, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2022, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2022.  
Derivative liability                   $ 900,000 $ 1,100,000
Unamortized of debt discount                   0 212,000
Debt conversion amount                   462,000 2,694,000
Finance cost                   254,000
Remaining debt outstanding                   285,000 518,000
Imputed interest on debenture                   15,500  
June 2021 Debenture [Member]                      
Principal amount             $ 600,000        
Cash received             500,000        
Cancellation amount             $ 100,000        
Beneficial ownership limitation percentage             9.99%        
Conversion price, description             have a conversion price equal to the lesser of $24.75 and 85% of the lowest Volume Weighted Average Price (VWAP) during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein.        
Maturity date             Dec. 31, 2023        
Converted debentures                   461,972 38,028
Debentures remaining amount                   100,000  
Derivative liability             $ 644,457        
Debt discount             600,000        
Interest Expense, Debt             $ 44,457        
Debt discount                   54,292 324,561
Amortization of debt charged off                   203,458 $ 17,689
Unamortized of debt discount                   0  
January 2021 Debenture [Member]                      
Principal amount $ 500,000                    
Cash received $ 500,000                    
Beneficial ownership limitation percentage 9.99%                    
Conversion price, description has a conversion price equal to the lesser of $24.75 and 85% of the lowest VWAP during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein.                    
Maturity date Jan. 12, 2022                    
Derivative liability $ 709,835                    
Debt discount 500,000                    
Interest Expense, Debt $ 209,835                    
Debt discount                   327,450  
Gain on charged off conversion of debentures                   172,550  
October 2020 Debentures [Member]                      
Principal amount               $ 600,000      
Cash received               500,000      
Cancellation amount               $ 100,000      
Beneficial ownership limitation percentage               9.99%      
Conversion price, description               have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion.      
Maturity date               Oct. 23, 2021      
Debt discount                   600,000  
Debt discount                   176,389  
Gain on charged off conversion of debentures                   311,111  
Debt conversion amount                   500,000  
Debt conversion amount remains outstanding                   100,000  
Fair value intial derivative liability                   619,627  
Interest expense                   19,627  
March 2020 Debentures [Member]                      
Principal amount   $ 250,000                  
Beneficial ownership limitation percentage   9.99%                  
Conversion price, description   Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to June 30, 2021.                  
Maturity date   Jul. 16, 2020                  
November 2019 Debentures [Member]                      
Debt conversion amount                   26,235  
Accounts payable                   26,235  
October 2019 Debentures [Member]                      
Debt conversion amount                   $ 96,000  
July 2019 Debenture [Member]                      
Principal amount                 $ 154,000    
Conversion price, description                   by the investor upon 61 days’ notice. The July 2019 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion.  
Finance cost                 $ 154,000    
July 2019 Debenture [Member] | Minimum [Member]                      
Beneficial ownership limitation percentage                   4.99%  
July 2019 Debenture [Member] | Maximum [Member]                      
Beneficial ownership limitation percentage                   9.99%  
December 2018 Debentures [Member]                      
Principal amount     $ 25,000                
Cash received     $ 25,000                
Maturity date     Jun. 30, 2019                
Interest rate     10.00%                
Trading price     75.00%                
July 2018 Debentures [Member]                      
Principal amount       $ 515,000              
Cash received       500,000              
Cancellation amount       15,000              
Debt conversion amount       $ 515,000              
September 2017 Debentures [Member]                      
Principal amount         $ 320,000            
Cash received         250,000            
Cancellation amount         70,000 $ 70,000          
Debt conversion amount                   $ 589,334  
Remaining debt outstanding         $ 2,500,000 $ 2,500,000       $ 110,072  
Stated value of the preferred shares           1,614          
Preferred shares exchanged         890 890          
September 2017 Debentures [Member] | Series A Convertible Preferred Stock [Member]                      
Stated value of the preferred shares         $ 1,600,000 $ 1,600,000          
September 2017 Debentures [Member] | Series B Convertible Preferred Stock [Member]                      
Stated value of the preferred shares         $ 900,000 $ 900,000          
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 5 Months Ended 12 Months Ended
Aug. 15, 2015
Dec. 31, 2021
Dec. 31, 2022
Sep. 30, 2021
Related Party Transaction [Line Items]        
Legal fees     $ 15,844  
Convertible debentures   $ 20,000  
Imputed interest on debentures     14,500  
Silvestre Law Group P C [Member]        
Related Party Transaction [Line Items]        
Payment to related parties       $ 10,000
Legal fees $ 84,224 54,141 125,844  
Payment for monthly fee   40,000 110,000  
Amount due to related party   $ 294,005 309,848  
Convertible debentures     $ 290,000  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Deferred tax assets:    
Net operating loss carryover $ 9,525 $ 9,343
Stock-based compensation 1,920
Accrued compensation 334 334
Other 30 30
Tax credits 496 485
Total deferred tax assets 10,385 12,112
Less: valuation allowance (10,385) (12,112)
Net deferred tax assets
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details 1)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Statutory federal income tax rate (21.00%) (21.00%)
State income taxes, net of federal benefits (7.00%) (7.00%)
Non-deductible items (240.80%) 38.30%
Valuation allowance 268.80% (10.30%)
Effective income tax rate
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards $ 44,000,000  
Net operating loss carryforwards expire amount $ 39,900,000  
Expiration period expire at various dates through 2037.  
Research and development tax credits $ 496,000  
Expiration period for tax credit expire from 2028 through 2042.  
Change in valuation allowance $ 1,700,000 $ 306,000
XML 62 rebusholdings_10k_htm.xml IDEA: XBRL DOCUMENT 0001421204 2022-01-01 2022-12-31 0001421204 2022-06-30 0001421204 2023-03-30 0001421204 2022-12-31 0001421204 2021-12-31 0001421204 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesEPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001421204 us-gaap:SeriesFPreferredStockMember 2022-12-31 0001421204 us-gaap:SeriesFPreferredStockMember 2021-12-31 0001421204 2021-01-01 2021-12-31 0001421204 us-gaap:PreferredStockMember 2020-12-31 0001421204 us-gaap:CommonStockMember 2020-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001421204 us-gaap:RetainedEarningsMember 2020-12-31 0001421204 2020-12-31 0001421204 us-gaap:PreferredStockMember 2021-12-31 0001421204 us-gaap:CommonStockMember 2021-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001421204 us-gaap:RetainedEarningsMember 2021-12-31 0001421204 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001421204 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001421204 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001421204 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001421204 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001421204 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001421204 us-gaap:PreferredStockMember 2022-12-31 0001421204 us-gaap:CommonStockMember 2022-12-31 0001421204 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001421204 us-gaap:RetainedEarningsMember 2022-12-31 0001421204 us-gaap:IntellectualPropertyMember 2022-01-01 2022-12-31 0001421204 2020-03-31 0001421204 us-gaap:CashMember 2020-10-31 0001421204 us-gaap:CashMember 2021-01-31 0001421204 us-gaap:CashMember 2021-06-30 0001421204 RBSH:SeriesFPreferredStocksMember 2022-12-31 0001421204 2021-01-31 0001421204 2021-06-30 0001421204 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001421204 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001421204 us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0001421204 us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0001421204 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001421204 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001421204 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001421204 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001421204 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001421204 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001421204 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001421204 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001421204 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001421204 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001421204 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001421204 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001421204 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001421204 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001421204 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001421204 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001421204 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001421204 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001421204 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001421204 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001421204 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001421204 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001421204 us-gaap:SeriesFPreferredStockMember 2020-10-06 0001421204 RBSH:RidgewayTherapeuticsIncMember us-gaap:SeriesFPreferredStockMember 2020-10-01 2020-10-06 0001421204 RBSH:SeriesE0ConvertiblePreferredStockMember 2020-05-01 2020-05-02 0001421204 RBSH:SeriesE0ConvertiblePreferredStockMember 2020-05-02 0001421204 us-gaap:SeriesDPreferredStockMember 2018-12-31 0001421204 us-gaap:SeriesDPreferredStockMember 2018-12-01 2018-12-31 0001421204 us-gaap:SeriesCPreferredStockMember 2017-04-30 0001421204 us-gaap:SeriesCPreferredStockMember 2017-04-01 2017-04-30 0001421204 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001421204 us-gaap:SeriesAPreferredStockMember 2015-12-31 0001421204 2021-08-29 2021-09-02 0001421204 2021-01-01 2021-03-31 0001421204 us-gaap:StockOptionMember 2020-12-31 0001421204 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001421204 us-gaap:StockOptionMember 2021-12-31 0001421204 us-gaap:WarrantMember 2020-12-31 0001421204 us-gaap:WarrantMember 2021-12-31 0001421204 us-gaap:WarrantMember 2022-12-31 0001421204 RBSH:ConsultantMember us-gaap:WarrantMember 2022-12-31 0001421204 RBSH:ConsultantMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001421204 RBSH:June2021DebentureMember 2021-06-01 2021-06-18 0001421204 RBSH:June2021DebentureMember 2021-06-18 0001421204 RBSH:June2021DebentureMember 2022-01-01 2022-12-31 0001421204 RBSH:June2021DebentureMember 2021-01-01 2021-12-31 0001421204 RBSH:June2021DebentureMember 2022-12-31 0001421204 RBSH:January2021DebentureMember 2021-01-01 2021-01-12 0001421204 RBSH:January2021DebentureMember 2021-01-12 0001421204 RBSH:January2021DebentureMember 2022-01-01 2022-12-31 0001421204 RBSH:October2020DebenturesMember 2020-10-01 2020-10-23 0001421204 RBSH:October2020DebenturesMember 2020-10-23 0001421204 RBSH:October2020DebenturesMember 2022-01-01 2022-12-31 0001421204 RBSH:March2020DebenturesMember 2020-03-01 2020-03-06 0001421204 RBSH:November2019DebenturesMember 2022-01-01 2022-12-31 0001421204 RBSH:November2019DebenturesMember 2022-12-31 0001421204 RBSH:October2019DebenturesMember 2022-01-01 2022-12-31 0001421204 RBSH:July2019DebentureMember 2019-07-01 2019-07-16 0001421204 srt:MinimumMember RBSH:July2019DebentureMember 2022-01-01 2022-12-31 0001421204 srt:MaximumMember RBSH:July2019DebentureMember 2022-01-01 2022-12-31 0001421204 RBSH:July2019DebentureMember 2022-01-01 2022-12-31 0001421204 RBSH:December2018DebenturesMember 2018-12-01 2018-12-13 0001421204 RBSH:July2018DebenturesMember 2018-07-01 2018-07-03 0001421204 RBSH:July2018DebenturesMember 2018-07-03 0001421204 RBSH:September2017DebenturesMember 2017-09-12 0001421204 RBSH:September2017DebenturesMember 2017-09-01 2017-09-12 0001421204 RBSH:September2017DebenturesMember RBSH:SeriesAConvertiblePreferredStockMember 2017-09-12 0001421204 RBSH:September2017DebenturesMember RBSH:SeriesBConvertiblePreferredStockMember 2017-09-12 0001421204 RBSH:September2017DebenturesMember 2017-09-05 2017-09-12 0001421204 RBSH:September2017DebenturesMember 2022-01-01 2022-12-31 0001421204 RBSH:September2017DebenturesMember 2022-12-31 0001421204 RBSH:SilvestreLawGroupPCMember 2021-09-30 0001421204 RBSH:SilvestreLawGroupPCMember 2022-01-01 2022-12-31 0001421204 RBSH:SilvestreLawGroupPCMember 2015-08-01 2015-08-15 0001421204 RBSH:SilvestreLawGroupPCMember 2021-08-16 2021-12-31 0001421204 RBSH:SilvestreLawGroupPCMember 2022-12-31 0001421204 RBSH:SilvestreLawGroupPCMember 2021-12-31 iso4217:USD shares iso4217:USD shares pure 0001421204 false FY 2022 10-K true 2022-12-31 --12-31 false 000-55331 REBUS HOLDINGS INC. DE 20-0438951 2629 Townsgate Road Suite 215 Westlake Village CA 91361 (818) 597-7552 No No Yes Yes Non-accelerated Filer true false false false 766023 32132907 RBSM LLP 587 New York, NY 5000 711000 4000 5000 715000 5000 715000 1664000 1801000 310000 294000 2078000 2004000 0 212000 20000 250000 0 46000 290000 154000 880000 1124000 5242000 5627000 20000 90000 110000 5242000 5737000 0.0001 0.0001 29978846 29978846 0 0 0 0 0.0001 0.0001 1854 1854 134 134 134 134 0.0001 0.0001 1000 1000 71 71 71 71 0.0001 0.0001 300 300 290 290 290 290 0.0001 0.0001 5000 5000 5000 5000 5000 5000 0.0001 0.0001 5000 5000 5000 5000 5000 5000 0.0001 0.0001 8000 8000 8000 8000 8000 8000 0.0001 0.0001 1000000000 1000000000 32132907 32132907 11769221 11769221 3000 1000 60057000 59254000 -65297000 -64277000 -5237000 -5022000 5000 715000 239000 494000 425000 528000 664000 1022000 -664000 -1022000 -263000 3687000 -24000 1116000 -69000 -1083000 -1020000 2698000 -1020000 2698000 -0.03 0.35 -0.03 -0.07 31819481 7645188 31819481 21132450 18495 2478848 54472000 -66975000 -12503000 9290364 1000 4446000 4447000 336000 336000 9 2698000 2698000 18495 11769221 1000 59254000 -64277000 -5022000 20363686 2000 788000 790000 15000 15000 -1020000 -1020000 18495 32132907 3000 60057000 -65297000 -5237000 -1020000 2698000 -263000 3687000 -24000 1116000 54000 828000 15000 254000 -4000 4000 -62000 334000 16000 -706000 -693000 1000000 1000000 -706000 307000 711000 404000 5000 711000 <p id="xdx_809_eus-gaap--NatureOfOperations_z9NFmbrjnmrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82A_zuIa0lZTotb6">BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rebus Holdings, Inc. (“we”, “us”, “our company”, “our”, “Rebus,” “Rebus Holdings,” or the “Company”) (formerly known as Inspyr Therapeutics, Inc., see below) was formed under the laws of the State of Delaware in November 2003, and has its principal office in Westlake Village, California. We are focused on the research and development of novel targeted precision therapeutics for the treatment of cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor A2B antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific targets found in each type of cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The adenosine receptor modulators include A 2B antagonists, dual A 2A /A 2B antagonists, and A 2A antagonists that have broad development applicability including indications within immuno-oncology and inflammation. Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine receptor antagonists may boost the host immune response against the tumor as a single-agent and in combination with other existing immuno-oncology agents leading to enhanced tumor killing and inhibition of metastasis. Adenosine also has anti-inflammatory properties in the acute and chronic setting. Adenosine receptor antagonists may promote a decreased inflammatory response and can potentially treat a broad range of inflammatory and autoimmune based diseases and conditions (e.g., rheumatoid arthritis, joint injury, Crohn’s disease, psoriasis) as well as improve wound healing and decrease pain.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to our recent termination of license with Ridgeway Therapeutics, Inc., a Delaware Corporation (“Ridgeway”), we reacquired the rights to certain intellectual property, discussed above, and are currently focusing on a pipeline of small molecule adenosine receptor modulators. <span id="xdx_909_eus-gaap--BroadcastersLicenseAgreementCommitmentsDescription_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember" title="Description of cancellation of a license agreement">In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to execute the business plan is contingent upon our ability to raise the necessary funds. During March 2020, we sold approximately $<span id="xdx_90C_ecustom--DebtSecuritiesSold_iI_pp0p0_c20200331_zPcFgKDwTTFd" title="Debt securities sold">250,000</span> of debt securities and in October 2020, we sold $<span id="xdx_90A_ecustom--DebtSecuritiesSold_c20201031__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" title="Debt securities sold">500,000</span> of debt securities for cash. In January 2021, we sold an additional $<span id="xdx_90B_ecustom--DebtSecuritiesSold_c20210131__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" title="Debt securities sold">500,000</span> of debt securities for cash and in June 2021, we sold an additional $<span id="xdx_90F_ecustom--DebtSecuritiesSold_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" title="Debt securities sold">500,000</span> of debt securities for cash. We are currently using such funds to maintain our SEC reporting requirements, pay legal accounting and other professional fees, and to retain consultants and other personnel to develop the adenosine A2R antagonists and in preparation for an IND filing related to our unique delivery platform and portfolio of adenosine A2R antagonists for the treatment of certain solid tumors. Should we fail to further raise sufficient funds to execute our business plan, our priority would be to maintain our intellectual property portfolio and seek business development opportunities with potential development partners and/or acquirors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adoption of Agreement and Plan of Merger and Consummation of Reorganization</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 28, 2021 the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) to implement a holding company reorganization, which became effective on October 11, 2021 at 5:00 p.m. Eastern Time (the “Effective Time”). The Merger Agreement was entered into by and among Inspyr Therapeutics, Inc., Rebus Holdings, Inc., and Rebus Sub, Inc., a wholly-owned subsidiary of Rebus Holdings which has resulted in Rebus becoming the direct parent company of Inspyr Therapeutics and replacing Inspyr Therapeutics as the public company trading on the OTC Markets (“OTC”) (the “Reorganization”). Further, the Company began trading under the symbol RBSH on November 9, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon consummation of the Reorganization (and the Reverse Stock Split as defined below), Inspyr stockholders automatically became stockholders of Rebus Holdings, on a one-for-one basis, with the same number and approximate ownership percentage of shares of the same class as they held in Inspyr immediately prior to the Effective Time. The Reorganization was intended to be a tax-free transaction for U.S. federal income tax purposes for Inspyr stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the Reorganization, Rebus Holdings became the successor issuer to Inspyr Therapeutics pursuant to Rule 12g-3(a) of the Exchange Act, and as a result, shares of Rebus Holdings Common Stock are deemed registered under Section 12(g) of the Exchange Act as the Common Stock of the successor issuer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Reverse Stock Split</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2021, the Board of Directors approved a one-for-seventy-five (<span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231" title="Reverse stock split">1-for-75</span>) reverse stock split of the Company’s Common Stock (“Reverse Stock Split”). The Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio. All share and per share data have been retroactively restated in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post Reverse Stock Split and Reorganization Information</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company began trading on post Reverse Stock Split and Reorganization basis on the Pink Sheets of the OTC Markets Group on October 12, 2021. The symbol remained NSPX until November 9, 2021, at which time the Company began trading under the symbol RBSH.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The officers and members of the Board of Inspyr became the officers and members of the board of directors of the Rebus Holdings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Reorganization, Rebus Holdings has, on a consolidated basis, the same assets, businesses, and operations as Inspyr Therapeutics had immediately prior to the Reorganization.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Termination of License Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 5, 2020, the Company entered into an agreement with Ridgeway (“Termination Agreement”) whereby the parties terminated the licensing agreement previously entered into on August 3, 2018 (“Licensing Agreement”), The Company had previously licensed certain technologies related to targeting adenosine receptor antagonists for the treatment of cancer (the “Licensed Assets”). As a result of the Termination Agreement, the Company reacquired full ownership and worldwide rights to all of the Licensed Assets as well as any improvements made thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In exchange for entering into the Termination Agreement, the Company issued to Ridgeway: (i) <span id="xdx_902_eus-gaap--CommonStockDividendsShares_pid_c20220101__20221231_zPmr2m7oRUuh" title="Common stock shares issued">866,667</span> shares Common Stock, and (ii) <span id="xdx_90B_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesFPreferredStocksMember_zKdMVAW1ZG21" title="Convertible preferred stock">8,000</span> shares of Series F 0% Convertible Preferred Stock (“Series F Preferred Stock”). Additionally, the Company paid approximately $<span id="xdx_901_eus-gaap--CostsAndExpenses_c20220101__20221231_pp0p0" title="Payment for expenses and costs">25,000</span> of Ridgeway’s expenses and costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Certificate of Designation of the Series F Preferred Stock, each share of Series F Preferred Stock has a stated value of $10.00 per share and is convertible into Common Stock at any time at the election of the holder. In the aggregate, all of the Series F Preferred Stock issued to Ridgeway is convertible into such number of shares of Common Stock equal to eighty percent (80%) of the issued and outstanding shares of Common Stock, post-conversion, on the conversion date (taking into effect any forward or reverse stock splits or consolidations). The Series F Preferred Stock votes on an as if converted to Common Stock basis. Additionally, upon the Company’s outstanding Convertible Debentures (as such term is defined in the Certificate of Designation) being terminated, converted, or otherwise extinguished, the Series F Preferred Stock will automatically convert into Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Termination Agreement, in the event that the Company is unable to secure equity financing resulting in aggregate gross proceeds to the Company of at least $<span id="xdx_904_eus-gaap--ProceedsFromOtherEquity_c20220101__20221231_pp0p0" title="Proceeds from equity financing">5,000,000</span> by October 5, 2023, or in the event that the Company ceases its operations, then the Termination Agreement will be deemed terminated and the Licensing Agreement will be reinstated in exchange for the return of the Common Shares and Series F Preferred Stock previously issued to Ridgeway.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the issuance of the Common Shares and Series F Preferred Stock, Ridgeway became the owner of approximately <span id="xdx_90E_ecustom--PercentageOfIssuedAndOutstandingSharesOfCommonstock_iI_pid_dp_c20221231_zo0raWLWSx0c" title="Percentage of issued and outstanding shares of common stock">54.14</span>% of the Company’s issued and outstanding Common Stock as of the termination date. Furthermore, by virtue of the issuance of the Series F Preferred Stock, Ridgeway will vote its Series F Preferred Stock on an as if converted to Common Stock basis which shall be equal to eighty percent (80%) of the issued and outstanding Common Stock post-conversion. Accordingly, the Board of Directors determined that a change in control of the registrant had occurred. The Company did not have a prior relationship with Ridgeway, or any of its principals, except pursuant to the terms contained in the Termination Agreement and its previous relationship under the Licensing Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development. 250000 500000 500000 500000 1-for-75 866667 8000 25000 5000000 0.5414 <p id="xdx_807_ecustom--ManagementPlansToContinueAsGoingConcernDisclosureTextBlock_zFJTlObrcx3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82B_zQnmOPS6YPma">MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The opinion of our independent registered accounting firm on our consolidated financial statements contains explanatory going concern language. We have prepared our consolidated financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred losses from operations since inception, we have a working capital deficit of $<span id="xdx_90C_ecustom--WorkingCapitalDeficit_iI_pn3n3_dm_c20221231_zcT2sCBP4Byj" title="Working capital deficit">5.2</span> million and we have an accumulated deficit of $65 <span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_dmi_c20221231_z66SaIy9twU5" style="display: none" title="Accumulated deficit">65,297</span> million as of December 31, 2022. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our therapeutic product candidates which are currently in development or we enter into cash flow positive business development transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance our product candidates through development. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our cash balances at December 31, 2022 were approximately $<span id="xdx_904_eus-gaap--Cash_iI_pp0p0_c20221231_zOQatJkvCtL7" title="Cash balances">5,000</span>, representing <span id="xdx_907_ecustom--PercentageOfTotalAssets_iI_pid_dp_c20221231_z4n0937Gu3t9" title="Percentage of total assets">100</span>% of our total assets. Based on our current expected level of operating expenditures, and including $<span id="xdx_904_ecustom--AmountRaised_iI_pp0p0_c20210131_z8DSjpBwRup6" title="Amount raised">500,000</span> that we raised in January 2021 and $<span id="xdx_906_ecustom--AmountRaised_iI_pp0p0_c20210630_zJJwv2gXHpY5" title="Amount raised">500,000</span> that we raised in June 2021, pursuant to the sale of our senior convertible debentures, we expect to be able to fund our operations into the first quarter of 2023. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such financing will be available when needed in order to allow us to continue our operations, or if available, on terms favorable or acceptable to us.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event additional financing is not obtained, we may pursue cost cutting measures as well as explore the sale of assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on our business, results of operations, and financial condition. These factors raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current cash level raises substantial doubt about our ability to continue as a going concern past the fourth quarter of 2022. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 5200000 -65297000 5000 1 500000 500000 <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z4nTRGO4abfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_828_ziY714TNvxB">SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zPsfduA5jnhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zwyOVUQoAp2d">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the parent company, Rebus Holdings, Inc., (fka Inspyr Therapeutics, Inc.) and its wholly-owned subsidiaries, Inspyr Therapeutics, Inc., Lewis &amp; Clark Pharmaceuticals, Inc. and Ridgeway Therapeutics, Inc. (a California corporation). All significant intercompany accounts and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_ecustom--ReverseStockSplitAndIncreaseInAuthorizedSharesPolicyTextBlock_zytSXyjFkIfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zbguKSHV5S7l">Reverse Stock Split and Increase in Authorized Shares</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The one for seventy-five (<span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_zmwGfElKh1Rc" title="Reverse stock split, description">1-for-75</span>) Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split and the 2020 Reverse Stock Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_z9bNFTXjbCvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_ztv32CJj6OYi">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zHX0ZK9BMBCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z9T0e7GtPNQi">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for pre-clinical research, toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs associated therewith.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We incurred research and development expenses of $<span id="xdx_901_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_dm_c20220101__20221231_zEYnLD8MXXx5" title="Research and development">0.2</span> million and $<span id="xdx_90B_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_dm_c20210101__20211231_zaHv0vwUmh56" title="Research and development">0.5</span> million for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm1sKZ3Ec8ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zrb8BP77MXeh">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did <span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_dmo_c20221231_zVs5AdntSw88" title="Cash equivalents"><span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_dmo_c20211231_zvykpSBBZdi8" title="Cash equivalents">no</span></span>t have any cash equivalents at December 31, 2022 or 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zqDjDdiQUqZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zRFvDwDX89b8">Concentrations of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash was $<span id="xdx_903_eus-gaap--Cash_iI_pp0p0_c20221231_z0x79YCADhc4" title="Cash">5,000</span> and $<span id="xdx_90E_eus-gaap--Cash_iI_pn3n3_dm_c20211231_zwzQr9yA57ub" title="Cash">0.7</span> million at December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, there was <span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_pp0p0_dmo_c20221231_z49BB0DKbfhi" title="Uninsured amount"><span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_pp0p0_do_c20211231_z651CtX7weTl" title="Uninsured amount">no</span></span> cash over the federally insured limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zDS461PR1y91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zOlQQZOtQ32a">Income (Loss) per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic income (loss) per share is calculated by dividing net income (loss) and net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding for the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s potentially dilutive securities are detailed in the table below. The potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2022 and 2021, as they would be anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zCN0rQunOg6j" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BC_zXdoEbsYvmU8" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ended<br/> December 31,</b></td> <td style="padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td> <td style="padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Shares underlying warrants outstanding</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="width: 9%; text-align: right" title="Shares underlying, outstanding">1</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="width: 9%; text-align: right" title="Shares underlying, outstanding">23</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shares underlying convertible notes outstanding</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" style="text-align: right" title="Shares underlying, outstanding">49,569,961</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" style="text-align: right" title="Shares underlying, outstanding">35,204,931</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Shares underlying convertible preferred stock outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying, outstanding">131,804,100</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying, outstanding">47,172,096</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying, outstanding">181,374,062</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying, outstanding">82,377,050</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zCCt7tgizIei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per share for the year ended December 31, 2021 is calculated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdTubQvnnq82" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BB_zSucv8jCoxbd" style="display: none">Diluted loss per share</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_492_20210101__20211231_zwrtibPeXRNk" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td> <td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td> <td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_zlht7nPE8M6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Net income attributable to common shareholders</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,698</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--IncomeAttributableToConvertibleDebenturesAndPreferredStock_pp0p0_zisvrhOp5CEb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income attributable to convertible instruments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,928</td> <td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--ExpenseAttributableToConvertibleDebentures_pp0p0_zGOLTQFWZD83" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Expense attributable to convertible instruments</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">829</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_zi9L2KKvXRc8" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted loss attributable to common shareholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(1,401</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--BasicSharesOutstanding_pid_z49TPM86s9Gj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic shares outstanding</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,645,186</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ConvertibleInstuments_pid_zSMBFIRpxLX5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Dilutive convertible instruments</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">13,487,262</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DilutedSharesOutstanding_pid_zBr2ManntNil" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">21,132,448</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DilutedLossPerShare_pid_zKR2LSlZzQub" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted loss per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A9_zRtz7x0Uak1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_zhpMbidgRF57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zOYb2VWpDdI4">Derivative Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZf24VKJ5Nbj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zzS6Vh3PAfzk">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of one year or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The derivative liabilities consist of our convertible notes and Series F preferred stock with variable conversion features. The Company uses the Black-Scholes option-pricing model to value its derivative liabilities which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zqqc9LmKpt8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zcBTGP4bwb4g">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded a derivative liability for its convertible notes and preferred stock with variable conversion features as of December 31, 2022 and 2021. The tables below summarize the fair values of our financial liabilities as of December 31, 2022 and 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zY2w6uOTr6eh" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B6_zbkj1BZoGCpc" style="display: none">Schedule of fair values of financial liabilities</span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value at<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Convertible notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20221231_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">285</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">285</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98A_ecustom--PreferredStock_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">595</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0589">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_983_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">595</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Derivative liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0597">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value at<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Convertible notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--ConvertibleDebt_c20211231_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">518</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0605">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">518</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_989_ecustom--PreferredStock_c20211231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">606</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_986_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0613">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">606</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Derivative liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zKnktsOF6jAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock_z9dTn2JrabMc" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BA_z6qXdxioStTd" style="display: none">Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Balance at beginning of year</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20220101__20221231_zSY9Uqs6FDmd" style="width: 9%; text-align: right" title="Balance at beginning of year">1,124</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231_zqZIGUdHrOk8" style="width: 9%; text-align: right" title="Balance at beginning of year">6,828</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Additions to derivative instruments</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20220101__20221231_pn3n3" style="text-align: right" title="Additions to derivative instruments"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20210101__20211231_pn3n3" style="text-align: right" title="Additions to derivative instruments">1,354</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Reclassification on conversion</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_981_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_c20220101__20221231_pn3n3" style="text-align: right" title="Reclassification on conversion">(507</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_c20210101__20211231_pn3n3" style="text-align: right" title="Reclassification on conversion">(3,371</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Loss (gain) on change in fair value of derivative liability</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Loss (gain) on change in fair value of derivative liability">263</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20210101__20211231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Loss (gain) on change in fair value of derivative liability">(3,687</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance at end of year</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20220101__20221231_z6zmT5m7lAVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231_zdfRe4yTurM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zVIQmZx75mkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zev9nK8o2cq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zx5qn7FkQqQ9">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zxq6k92hdtr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_znvJXLSaVTjf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zfFYolNhzbZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_zksCyrPbAA89">Other Comprehensive Income</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not have any activity that results in Other Comprehensive Income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zA6ZpoYDoBIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zwMXU7xpQiF5">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2022 that are of significance or potential significance to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zPsfduA5jnhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zwyOVUQoAp2d">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the parent company, Rebus Holdings, Inc., (fka Inspyr Therapeutics, Inc.) and its wholly-owned subsidiaries, Inspyr Therapeutics, Inc., Lewis &amp; Clark Pharmaceuticals, Inc. and Ridgeway Therapeutics, Inc. (a California corporation). All significant intercompany accounts and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_ecustom--ReverseStockSplitAndIncreaseInAuthorizedSharesPolicyTextBlock_zytSXyjFkIfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zbguKSHV5S7l">Reverse Stock Split and Increase in Authorized Shares</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The one for seventy-five (<span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_zmwGfElKh1Rc" title="Reverse stock split, description">1-for-75</span>) Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split and the 2020 Reverse Stock Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1-for-75 <p id="xdx_846_eus-gaap--UseOfEstimates_z9bNFTXjbCvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_ztv32CJj6OYi">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zHX0ZK9BMBCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z9T0e7GtPNQi">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for pre-clinical research, toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs associated therewith.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We incurred research and development expenses of $<span id="xdx_901_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_dm_c20220101__20221231_zEYnLD8MXXx5" title="Research and development">0.2</span> million and $<span id="xdx_90B_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_dm_c20210101__20211231_zaHv0vwUmh56" title="Research and development">0.5</span> million for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 200000 500000 <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zm1sKZ3Ec8ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zrb8BP77MXeh">Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did <span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_dmo_c20221231_zVs5AdntSw88" title="Cash equivalents"><span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_dmo_c20211231_zvykpSBBZdi8" title="Cash equivalents">no</span></span>t have any cash equivalents at December 31, 2022 or 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zqDjDdiQUqZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zRFvDwDX89b8">Concentrations of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash was $<span id="xdx_903_eus-gaap--Cash_iI_pp0p0_c20221231_z0x79YCADhc4" title="Cash">5,000</span> and $<span id="xdx_90E_eus-gaap--Cash_iI_pn3n3_dm_c20211231_zwzQr9yA57ub" title="Cash">0.7</span> million at December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, there was <span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_pp0p0_dmo_c20221231_z49BB0DKbfhi" title="Uninsured amount"><span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_pp0p0_do_c20211231_z651CtX7weTl" title="Uninsured amount">no</span></span> cash over the federally insured limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 5000 700000 0 0 <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zDS461PR1y91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zOlQQZOtQ32a">Income (Loss) per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic income (loss) per share is calculated by dividing net income (loss) and net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding for the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s potentially dilutive securities are detailed in the table below. The potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as of December 31, 2022 and 2021, as they would be anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zCN0rQunOg6j" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BC_zXdoEbsYvmU8" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ended<br/> December 31,</b></td> <td style="padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td> <td style="padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Shares underlying warrants outstanding</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="width: 9%; text-align: right" title="Shares underlying, outstanding">1</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="width: 9%; text-align: right" title="Shares underlying, outstanding">23</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shares underlying convertible notes outstanding</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" style="text-align: right" title="Shares underlying, outstanding">49,569,961</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" style="text-align: right" title="Shares underlying, outstanding">35,204,931</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Shares underlying convertible preferred stock outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying, outstanding">131,804,100</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying, outstanding">47,172,096</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying, outstanding">181,374,062</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying, outstanding">82,377,050</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zCCt7tgizIei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per share for the year ended December 31, 2021 is calculated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdTubQvnnq82" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BB_zSucv8jCoxbd" style="display: none">Diluted loss per share</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_492_20210101__20211231_zwrtibPeXRNk" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td> <td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td> <td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_zlht7nPE8M6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Net income attributable to common shareholders</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,698</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--IncomeAttributableToConvertibleDebenturesAndPreferredStock_pp0p0_zisvrhOp5CEb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income attributable to convertible instruments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,928</td> <td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--ExpenseAttributableToConvertibleDebentures_pp0p0_zGOLTQFWZD83" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Expense attributable to convertible instruments</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">829</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_zi9L2KKvXRc8" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted loss attributable to common shareholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(1,401</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--BasicSharesOutstanding_pid_z49TPM86s9Gj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic shares outstanding</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,645,186</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ConvertibleInstuments_pid_zSMBFIRpxLX5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Dilutive convertible instruments</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">13,487,262</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DilutedSharesOutstanding_pid_zBr2ManntNil" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">21,132,448</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DilutedLossPerShare_pid_zKR2LSlZzQub" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted loss per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A9_zRtz7x0Uak1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zCN0rQunOg6j" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BC_zXdoEbsYvmU8" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ended<br/> December 31,</b></td> <td style="padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2022</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2021</b></td> <td style="padding-bottom: 1pt"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Shares underlying warrants outstanding</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="width: 9%; text-align: right" title="Shares underlying, outstanding">1</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="width: 9%; text-align: right" title="Shares underlying, outstanding">23</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shares underlying convertible notes outstanding</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" style="text-align: right" title="Shares underlying, outstanding">49,569,961</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" style="text-align: right" title="Shares underlying, outstanding">35,204,931</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Shares underlying convertible preferred stock outstanding</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying, outstanding">131,804,100</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying, outstanding">47,172,096</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying, outstanding">181,374,062</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying, outstanding">82,377,050</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1 23 49569961 35204931 131804100 47172096 181374062 82377050 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdTubQvnnq82" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BB_zSucv8jCoxbd" style="display: none">Diluted loss per share</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_492_20210101__20211231_zwrtibPeXRNk" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td> <td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td> <td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0p0_zlht7nPE8M6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Net income attributable to common shareholders</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,698</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--IncomeAttributableToConvertibleDebenturesAndPreferredStock_pp0p0_zisvrhOp5CEb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income attributable to convertible instruments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,928</td> <td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--ExpenseAttributableToConvertibleDebentures_pp0p0_zGOLTQFWZD83" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Expense attributable to convertible instruments</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">829</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_zi9L2KKvXRc8" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted loss attributable to common shareholders</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(1,401</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--BasicSharesOutstanding_pid_z49TPM86s9Gj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Basic shares outstanding</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,645,186</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ConvertibleInstuments_pid_zSMBFIRpxLX5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Dilutive convertible instruments</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">13,487,262</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DilutedSharesOutstanding_pid_zBr2ManntNil" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted shares outstanding</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">21,132,448</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DilutedLossPerShare_pid_zKR2LSlZzQub" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Diluted loss per share</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 2698 -4928 829 -1401 7645186 13487262 21132448 -0.07 <p id="xdx_84B_eus-gaap--DerivativesPolicyTextBlock_zhpMbidgRF57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zOYb2VWpDdI4">Derivative Liability</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company’s balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZf24VKJ5Nbj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zzS6Vh3PAfzk">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of one year or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The derivative liabilities consist of our convertible notes and Series F preferred stock with variable conversion features. The Company uses the Black-Scholes option-pricing model to value its derivative liabilities which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zqqc9LmKpt8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zcBTGP4bwb4g">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded a derivative liability for its convertible notes and preferred stock with variable conversion features as of December 31, 2022 and 2021. The tables below summarize the fair values of our financial liabilities as of December 31, 2022 and 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zY2w6uOTr6eh" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B6_zbkj1BZoGCpc" style="display: none">Schedule of fair values of financial liabilities</span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value at<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Convertible notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20221231_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">285</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">285</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98A_ecustom--PreferredStock_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">595</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0589">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_983_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">595</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Derivative liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0597">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value at<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Convertible notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--ConvertibleDebt_c20211231_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">518</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0605">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">518</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_989_ecustom--PreferredStock_c20211231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">606</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_986_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0613">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">606</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Derivative liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zKnktsOF6jAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock_z9dTn2JrabMc" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BA_z6qXdxioStTd" style="display: none">Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Balance at beginning of year</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20220101__20221231_zSY9Uqs6FDmd" style="width: 9%; text-align: right" title="Balance at beginning of year">1,124</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231_zqZIGUdHrOk8" style="width: 9%; text-align: right" title="Balance at beginning of year">6,828</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Additions to derivative instruments</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20220101__20221231_pn3n3" style="text-align: right" title="Additions to derivative instruments"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20210101__20211231_pn3n3" style="text-align: right" title="Additions to derivative instruments">1,354</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Reclassification on conversion</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_981_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_c20220101__20221231_pn3n3" style="text-align: right" title="Reclassification on conversion">(507</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_c20210101__20211231_pn3n3" style="text-align: right" title="Reclassification on conversion">(3,371</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Loss (gain) on change in fair value of derivative liability</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Loss (gain) on change in fair value of derivative liability">263</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20210101__20211231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Loss (gain) on change in fair value of derivative liability">(3,687</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance at end of year</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20220101__20221231_z6zmT5m7lAVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231_zdfRe4yTurM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zVIQmZx75mkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zY2w6uOTr6eh" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span id="xdx_8B6_zbkj1BZoGCpc" style="display: none">Schedule of fair values of financial liabilities</span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value at<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Convertible notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20221231_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">285</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_986_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--ConvertibleDebt_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">285</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98A_ecustom--PreferredStock_c20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">595</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0589">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_983_ecustom--PreferredStock_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">595</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Derivative liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0597">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value at<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurement Using</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Convertible notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--ConvertibleDebt_c20211231_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">518</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0605">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_987_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--ConvertibleDebt_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="width: 9%; text-align: right" title="Convertible notes">518</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_989_ecustom--PreferredStock_c20211231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">606</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_986_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0613">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_ecustom--PreferredStock_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Preferred stock">606</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Derivative liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_c20211231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_984_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 285000 285000 595000 595000 880000 880000 518000 518000 606000 606000 1124000 1124000 <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock_z9dTn2JrabMc" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BA_z6qXdxioStTd" style="display: none">Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Balance at beginning of year</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20220101__20221231_zSY9Uqs6FDmd" style="width: 9%; text-align: right" title="Balance at beginning of year">1,124</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20211231_zqZIGUdHrOk8" style="width: 9%; text-align: right" title="Balance at beginning of year">6,828</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Additions to derivative instruments</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20220101__20221231_pn3n3" style="text-align: right" title="Additions to derivative instruments"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c20210101__20211231_pn3n3" style="text-align: right" title="Additions to derivative instruments">1,354</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Reclassification on conversion</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_981_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_c20220101__20221231_pn3n3" style="text-align: right" title="Reclassification on conversion">(507</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98F_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification_c20210101__20211231_pn3n3" style="text-align: right" title="Reclassification on conversion">(3,371</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Loss (gain) on change in fair value of derivative liability</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20220101__20221231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Loss (gain) on change in fair value of derivative liability">263</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c20210101__20211231_pn3n3" style="border-bottom: Black 1pt solid; text-align: right" title="Loss (gain) on change in fair value of derivative liability">(3,687</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Balance at end of year</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20220101__20221231_z6zmT5m7lAVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">880</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210101__20211231_zdfRe4yTurM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">1,124</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1124000 6828000 1354000 -507000 -3371000 263000 -3687000 880000 1124000 <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zev9nK8o2cq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zx5qn7FkQqQ9">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zxq6k92hdtr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_znvJXLSaVTjf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zfFYolNhzbZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_zksCyrPbAA89">Other Comprehensive Income</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not have any activity that results in Other Comprehensive Income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zA6ZpoYDoBIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zwMXU7xpQiF5">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2022 that are of significance or potential significance to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80C_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zD0Wj3Mkc0fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_824_zwCAXV91Yvok">SUPPLEMENTAL CASH FLOW INFORMATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table contains additional information for the periods reported (in thousands).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_pn3n3_zdchyVi5oT46" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BC_zYnBZ9sFXhSc" style="display: none">Schedule of additional information of cash flow</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20220101__20221231_zqwemN6MumRk" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20210101__20211231_zeeNLvJSKCX9" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-cash financial activities:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--StockIssued1_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Common stock issued on conversion of notes payable and derivative liability</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">790</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,447</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtConversionConvertedInstrumentAmount1_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Debentures converted to common stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">462</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,694</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DerivativeLiabilityExtinguished_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Derivative liability extinguished upon conversion of notes payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">507</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,371</td> <td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DerivativeLiabilityIssued_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Derivative liability issued</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,354</td> <td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccountsPayablePaidThroughIssuanceOfDebentures_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts payable paid through issuance of debentures</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100</td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--AccruedDirectorsFeesForgivenAndCreditedToPaidInCapital_pn3n3_zKlRAyN0Pn6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued director fees forgiven and credited to paid in capital</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">336</td> <td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There was no cash paid for interest and income taxes for the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_pn3n3_zdchyVi5oT46" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BC_zYnBZ9sFXhSc" style="display: none">Schedule of additional information of cash flow</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20220101__20221231_zqwemN6MumRk" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20210101__20211231_zeeNLvJSKCX9" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-cash financial activities:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--StockIssued1_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Common stock issued on conversion of notes payable and derivative liability</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">790</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,447</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtConversionConvertedInstrumentAmount1_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Debentures converted to common stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">462</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,694</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DerivativeLiabilityExtinguished_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Derivative liability extinguished upon conversion of notes payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">507</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,371</td> <td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DerivativeLiabilityIssued_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Derivative liability issued</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,354</td> <td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccountsPayablePaidThroughIssuanceOfDebentures_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accounts payable paid through issuance of debentures</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100</td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--AccruedDirectorsFeesForgivenAndCreditedToPaidInCapital_pn3n3_zKlRAyN0Pn6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued director fees forgiven and credited to paid in capital</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">336</td> <td style="text-align: left"> </td></tr> </table> 790000 4447000 462000 2694000 507000 3371000 1354000 100000 336000 <p id="xdx_80E_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z9xYXDctTM3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82D_zbjoP6IvQeij">INTELLECTUAL PROPERTY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We solely own or have exclusive licenses to all of our patents and patent applications. Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $<span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20220101__20221231_zyFWcu9fl69f" title="Payments in cash and common stock">212,000</span> in cash and common stock. As a result of these payments and pursuant to the agreements, we acquired worldwide, exclusive, fully paid up rights in know-how, pre-clinical data, development data and certain patent portfolios that relate to, and form the basis of, our technology. Under these agreements, we are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to JHU, UC, or the Assignee Co-Founders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangibles have been fully amortized at December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 212000 <p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zCqE0D3rw1q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_822_zP1Wfc7bHcql">ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consist of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zY5bCuwr1Jj3" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BA_zTEHQveVAEo1" style="display: none">Schedule of accrued expenses</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_496_20221231_zHGs2u6YCqZf" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20211231_zwH9qfjsY62" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzGY9_zB0O2LTNCsZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accrued compensation and benefits</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">1,326</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">1,326</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pn3n3_maALCzGY9_zfZOoX7DSY9c" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">233</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">233</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzGY9_zkHwpkl7V4r9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accrued other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">519</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">445</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzGY9_zDC1DuRu1nFk" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,078</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,004</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zY5bCuwr1Jj3" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BA_zTEHQveVAEo1" style="display: none">Schedule of accrued expenses</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_496_20221231_zHGs2u6YCqZf" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20211231_zwH9qfjsY62" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzGY9_zB0O2LTNCsZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accrued compensation and benefits</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">1,326</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">1,326</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pn3n3_maALCzGY9_zfZOoX7DSY9c" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued research and development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">233</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">233</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzGY9_zkHwpkl7V4r9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Accrued other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">519</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">445</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzGY9_zDC1DuRu1nFk" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,078</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,004</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1326000 1326000 233000 233000 519000 445000 2078000 2004000 <p id="xdx_806_eus-gaap--DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_zlt98X4S9Jci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_827_zlQXgcFNEKJa">DERIVATIVE LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for equity-linked financial instruments, such as our convertible preferred stock, convertible debentures and our common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the respective agreement. Equity-linked financial instruments are accounted for as derivative liabilities, in accordance with ASC Topic 815 – Derivatives and Hedging, if the instrument allows for cash settlement or issuance of a variable number of shares. We classify derivative liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have issued convertible debentures and preferred stock which contain variable conversion features, anti-dilution protection and other conversion price adjustment provisions. As a result, the Company assessed its outstanding equity-linked financial instruments and concluded that the convertible notes and preferred stock are subject to derivative accounting. The fair value of the conversion feature is classified as a liability in the consolidated financial statements, with the change in fair value during the periods presented recorded in the consolidated statement of losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, we recorded loss of approximately $<span id="xdx_908_eus-gaap--DerivativeGainLossOnDerivativeNet_pn3n3_dm_c20220101__20221231_zvFeuhvGCNe8" title="Gain and loss on change in fair value of the derivative liability">0.3</span> million and gain of approximately $<span id="xdx_90C_eus-gaap--DerivativeGainLossOnDerivativeNet_pn3n3_dm_c20210101__20211231_zFD6XHd3gRA6" title="Gain and loss on change in fair value of the derivative liability">3.7</span> million, respectively, related to the change in fair value of the derivative liabilities during the periods. For purpose of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuations of the derivatives for the years ended December 31, 2022 and 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuSEX7OeiBjh" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B1_z40UAXB6xFKe" style="display: none">Schedule of black scholes valuations of derivatives</span></td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31</b></span></p></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 68%; text-align: left">Expected dividends</td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_906_ecustom--DerivativeLiabilityMeasurementInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zTyICEoyExRb" title="Derivative liability measurement input">0</span>%</td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_905_ecustom--DerivativeLiabilityMeasurementInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zW7YYTQTxYT" title="Derivative liability measurement input">0</span>%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected volatility</td> <td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--DerivativeLiabilitiesMeasurementInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zTn06oLUiTA1" title="Derivative liability measurement input">198</span>% - <span id="xdx_900_ecustom--DerivativeLiabilitiesMeasurementInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zVy4PSbFh8k6" title="Derivative liability measurement input">260</span>%</td> <td> </td> <td style="text-align: center"><span id="xdx_90B_ecustom--DerivativeLiabilitiesMeasurementInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zf2fc6F1hza" title="Derivative liability measurement input">205</span>% - <span id="xdx_90B_ecustom--DerivativeLiabilitiesMeasurementInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z1abjhVSdwzl" title="Derivative liability measurement input">262</span>%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Risk free interest rate</td> <td> </td> <td style="text-align: center"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementsInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zN0weXp2pFxk" title="Derivative liability measurement input">0.22</span>% - <span id="xdx_903_ecustom--DerivativeLiabilityMeasurementsInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zYmSmHFpK8el" title="Derivative liability measurement input">4.76</span>%</td> <td> </td> <td style="text-align: center"><span id="xdx_903_ecustom--DerivativeLiabilityMeasurementsInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zxpvIjQHt83c" title="Derivative liability measurement input">0.06</span>% - <span id="xdx_907_ecustom--DerivativeLiabilityMeasurementsInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zc4bsKm7wrJ6" title="Derivative liability measurement input">0.19</span>%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected term</td> <td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtSecuritiesAvailableForSaleTerm_iI_dtM_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zuYowkksgMej" title="Derivative liability term">3</span> – <span id="xdx_90C_eus-gaap--DebtSecuritiesAvailableForSaleTerm_iI_dtM_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zOV3UWciPQ6a" title="Derivative liability term">12</span> Months</td> <td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--DebtSecuritiesAvailableForSaleTerm_iI_dtM_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zOqoc7064O08" title="Derivative liability term">3</span> –<span id="xdx_901_eus-gaap--DebtSecuritiesAvailableForSaleTerm_iI_dtM_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zlieAgduEK0c" title="Derivative liability term"> 6</span> Months</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the derivative liability recognized in the financial statements was approximately $<span id="xdx_90C_eus-gaap--DerivativeLiabilities_iI_pn3n3_dm_c20221231_z9bHx93B8Sid" title="Derivative Liability">0.9</span> million and $<span id="xdx_90C_eus-gaap--DerivativeLiabilities_iI_pn3n3_dm_c20211231_zJHREUMoPg3i" title="Derivative Liability">1.1</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 300000 3700000 <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuSEX7OeiBjh" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B1_z40UAXB6xFKe" style="display: none">Schedule of black scholes valuations of derivatives</span></td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31</b></span></p></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 68%; text-align: left">Expected dividends</td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_906_ecustom--DerivativeLiabilityMeasurementInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zTyICEoyExRb" title="Derivative liability measurement input">0</span>%</td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_905_ecustom--DerivativeLiabilityMeasurementInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zW7YYTQTxYT" title="Derivative liability measurement input">0</span>%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected volatility</td> <td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--DerivativeLiabilitiesMeasurementInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zTn06oLUiTA1" title="Derivative liability measurement input">198</span>% - <span id="xdx_900_ecustom--DerivativeLiabilitiesMeasurementInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zVy4PSbFh8k6" title="Derivative liability measurement input">260</span>%</td> <td> </td> <td style="text-align: center"><span id="xdx_90B_ecustom--DerivativeLiabilitiesMeasurementInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zf2fc6F1hza" title="Derivative liability measurement input">205</span>% - <span id="xdx_90B_ecustom--DerivativeLiabilitiesMeasurementInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z1abjhVSdwzl" title="Derivative liability measurement input">262</span>%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Risk free interest rate</td> <td> </td> <td style="text-align: center"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementsInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zN0weXp2pFxk" title="Derivative liability measurement input">0.22</span>% - <span id="xdx_903_ecustom--DerivativeLiabilityMeasurementsInputPercentages_iI_dp_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zYmSmHFpK8el" title="Derivative liability measurement input">4.76</span>%</td> <td> </td> <td style="text-align: center"><span id="xdx_903_ecustom--DerivativeLiabilityMeasurementsInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zxpvIjQHt83c" title="Derivative liability measurement input">0.06</span>% - <span id="xdx_907_ecustom--DerivativeLiabilityMeasurementsInputPercentages_iI_dp_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zc4bsKm7wrJ6" title="Derivative liability measurement input">0.19</span>%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expected term</td> <td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--DebtSecuritiesAvailableForSaleTerm_iI_dtM_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zuYowkksgMej" title="Derivative liability term">3</span> – <span id="xdx_90C_eus-gaap--DebtSecuritiesAvailableForSaleTerm_iI_dtM_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zOV3UWciPQ6a" title="Derivative liability term">12</span> Months</td> <td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--DebtSecuritiesAvailableForSaleTerm_iI_dtM_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zOqoc7064O08" title="Derivative liability term">3</span> –<span id="xdx_901_eus-gaap--DebtSecuritiesAvailableForSaleTerm_iI_dtM_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zlieAgduEK0c" title="Derivative liability term"> 6</span> Months</td></tr> </table> 0 0 1.98 2.60 2.05 2.62 0.0022 0.0476 0.0006 0.0019 P3M P12M P3M P6M 900000 1100000 <p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zQU6NsaUnwZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_826_zyUnPwN63Ey7">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Leases</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently does not have any ongoing leases for office space. It has availability to office space on an as needed basis. Its employees work on a remote basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There was <span id="xdx_902_eus-gaap--OperatingLeasesRentExpenseNet_pp0p0_do_c20220101__20221231_zcFZt2ctZ891" title="Rental expenses"><span id="xdx_909_eus-gaap--OperatingLeasesRentExpenseNet_pp0p0_do_c20210101__20211231_zTL2jo0M6457" title="Rental expenses">no</span></span> rent expense for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal Matters</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject at times to legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Uncertainty Due to Geopolitical Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to Russia’s invasion of Ukraine, which began in February 2022, and the resulting sanctions and other actions against Russia and Belarus, there has been uncertainty and disruption in the global economy. Although the Russian war against Ukraine did not have a material adverse impact on the Company’s financial results for the year ended December 31, 2022, at this time the Company is unable to fully assess the aggregate impact the Russian war against Ukraine will have on its business due to various uncertainties, which include, but are not limited to, the duration of the war, the war’s effect on the economy, its impact to the business of the Company, and actions that may be taken by governmental authorities related to the war.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19 Uncertainty</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The extent of the public-health impact of the outbreak is currently unknown and rapidly evolving, and the related health crisis could adversely affect the global economy, resulting in an economic downturn. Any disruption of the Company’s facilities or those of our suppliers could likely adversely impact the Company’s operations. At this time, there is significant uncertainty relating to the potential effect of the novel coronavirus on our business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxniXwN0vye8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_829_z5ItrSctOk4k">CAPITAL STOCK AND STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue 30,000,000 shares of preferred stock. As of December 31, 2022 and 2021, there were outstanding 133.8 <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zZ7VZOhYMvda" style="display: none">134 </span>shares of Series A Preferred Stock, <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmGIQtefL9Y" title="Preferred stock, shares outstanding">71</span> shares of Series B Preferred Stock, <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zP0A1PAMoGv6" title="Preferred stock, shares outstanding">290</span>.4 shares of Series C Preferred Stock, <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z25UwFwrWRzj" title="Preferred stock, shares outstanding">5,000</span> shares of Series D Preferred Stock, <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z9eYUBXWkh8f" title="Preferred stock, shares outstanding">5,000</span> shares of Series E Preferred Stock and <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zjDekZ9oepD7" title="Preferred stock, shares outstanding">8,000</span> shares of Series F Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series F Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 6, 2020, the Company filed a certificate of designation of Series F Preferred Stock (“Series F COD”) with the Secretary of State of the State of Delaware that contains the rights, preferences, and privileges of the Series F Preferred Stock. Pursuant to the Series F COD, each share of Series F Preferred Stock has a stated value of $<span id="xdx_90F_ecustom--PreferredStockStatedValuePerShare_c20201006__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_pdd" title="Preferred stock, stated value">10.00</span> per share and is convertible into Common Stock at any time at the election of the holder. We issued all <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20201006__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RidgewayTherapeuticsIncMember_pdd" title="Stock issued during period, shares">8,000</span> shares of the Series F stock to Ridgeway Therapeutics, Inc. in connection with the Termination Agreement described in Note 1. In the aggregate, all of the Series F Preferred Stock issued to Ridgeway is convertible into such number of shares of Common Stock equal to eighty percent (80%) of the issued and outstanding shares of Common Stock, post-conversion, on the conversion date (taking into effect any forward or reverse stock splits or consolidations). As the number of shares of common stock issuable upon conversion is variable, the related contingent liability is accounted as a derivative liability. The Series F Preferred Stock votes on an as if converted to common stock basis. Additionally, upon the Company’s outstanding Convertible Debentures (as such term is defined in the Series F COD) being terminated, converted, or otherwise extinguished, the Series F Preferred Stock will automatically convert into Common Stock.</span> The Series F preferred stock is accounted for as equity classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series E Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 2, 2020, we sold <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200501__20200502__us-gaap--StatementClassOfStockAxis__custom--SeriesE0ConvertiblePreferredStockMember_pdd" title="Sale of stock, shares">5,000</span> shares of Series E 0% Convertible Preferred Stock to an accredited investor at a price per share of $<span id="xdx_909_ecustom--PreferredStockStatedValuePerShare_c20200502__us-gaap--StatementClassOfStockAxis__custom--SeriesE0ConvertiblePreferredStockMember_pdd" title="Preferred stock, stated value">1.00</span> for aggregate gross proceeds of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200501__20200502__us-gaap--StatementClassOfStockAxis__custom--SeriesE0ConvertiblePreferredStockMember_pdp0" title="Sale of stock value">5,000</span>. Pursuant to the certificate of designation of Series E Preferred Stock (“Series E COD”), each share of Series E Preferred Stock has stated value of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_c20200502__us-gaap--StatementClassOfStockAxis__custom--SeriesE0ConvertiblePreferredStockMember_pdd" title="Sale of stock, price per share">1.00</span> and is convertible, at any time after the Original Issue Date (as such term is defined in the Series E COD) at the option of the Holder into that number of shares of Common Stock (Subject to the limitations set forth in Section 6(d) of Series E COD), determined by dividing the stated value by the then in effect conversion price. As of December 31, 2022, the conversion price is $<span id="xdx_901_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20200502__us-gaap--StatementClassOfStockAxis__custom--SeriesE0ConvertiblePreferredStockMember_zTLpKLByD3C7" title="Conversion price per share">22.50</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As provided for in the Series E COD, with respect to a vote of stockholders to approve a reverse split of the Common Stock to occur no later than December 31, 2022 only, <span id="xdx_907_eus-gaap--PreferredStockVotingRights_c20200501__20200502__us-gaap--StatementClassOfStockAxis__custom--SeriesE0ConvertiblePreferredStockMember_zHJnaoRkdHw6">each share of Series E Preferred Stock held by a holder, as such, is entitled to 1,333 votes.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series E Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series E Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series E Preferred Stock shall vote together with the holders of Common Stock as a single class. </span>The Series E preferred stock is accounted for as equity classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series D Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During December 2018, we designated <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20181231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, shares authorized">5,000</span> shares of preferred stock as Series D 0% Convertible Preferred Stock (the “Series D Preferred Stock”). Each share of Preferred Stock has a par value of $<span id="xdx_90F_ecustom--PreferredStockParValuePerShare_c20181231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, par value">0.0001</span> per share and a stated value equal to $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20181231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, stated value">1.00</span>. During January 2019, we issued the <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_c20181231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock shares issued">5,000</span> shares of Series D Convertible Preferred Stock for proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20181201__20181231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdp0" title="Proceeds of preferred stock">5,000</span>. Pursuant to the certificate of designation of Series D Preferred stock (“Series D COD”), each share of Series D Preferred Stock shall be convertible, at any time and from time to time from and after its original issue date at the option of the holder thereof, into that number of shares of Common Stock (subject to beneficial ownership limitations contained in Section 6(d) of the Series D COD) determined by dividing the stated value of such share of Series D Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $<span id="xdx_907_eus-gaap--PreferredStockConvertibleConversionPrice_c20181231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Conversion price per share">281.25</span> per share of Series D Preferred Stock. The Series D preferred stock is accounted for as equity classification.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series D Preferred Stock shall vote together with the holders of Common Stock as a single class.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series C Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March and April 2017, we issued <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_c20170430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd">290.43148 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C 0% Convertible Preferred Stock (the “Series C Preferred Stock”). Pursuant to the certificate of designation of Series C Preferred Stock (“Series C COD”), the Series C Preferred Stock has a stated value of $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20170430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd">1,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Pursuant to the Series C COD, the Series C Preferred Stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series C COD) determined by dividing the stated value of such Series C Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_c20170430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd">1,125.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share for 200 shares of Series C Preferred Stock and $<span id="xdx_90B_ecustom--PreferredStockSharesValued_c20170430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd">562.50 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per shares for <span id="xdx_903_ecustom--BeneficialOwnershipLimitation_c20170401__20170430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd">90.43418 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Series C preferred, subject to certain beneficial ownership limitations and subject to adjustment pursuant to stock splits and dividends. </span>The Series C preferred stock is accounted for as equity classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series B Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2016, we issued <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_c20161231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd">1,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our Series B 0% Convertible Preferred Stock (the “Series B Preferred Stock”). Pursuant to the certificate of designation of the Series B Preferred Stock (“Series B COD”), the Series B Preferred Stock has a stated value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20161231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd">1,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. Pursuant to the Series B COD, the Series B Preferred stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series B COD), determined by dividing the stated value of such Series B Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $<span id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_c20161231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd">0.0217 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, subject to adjustment pursuant to stock splits and dividends, and subject to adjustment pursuant to anti-dilution protection for subsequent equity sales and other conversion price adjustments. </span>The Series B preferred stock is accounted for as equity classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series A Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2015, we issued <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_c20151231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd">1,853 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our Series A 0% Convertible Preferred Stock (the “Series A Preferred Stock”). Pursuant to the certificate of designation of Series A Preferred Stock (“Series A COD”), the Series A Preferred Stock has a stated value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20151231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd">1,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. Pursuant to the Series A COD, the Series A Preferred Stock is convertible into that number of shares of Common Stock (subject to beneficial ownership limitations as set forth in Section 6(d) of the Series A COD), determined by dividing the stated value of such Series A Preferred Stock by the conversion price in effect. As of December 31, 2022, the conversion price is $<span id="xdx_90D_eus-gaap--PreferredStockConvertibleConversionPrice_c20151231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd">29,812.50 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, subject to adjustment pursuant to stock splits and dividends. </span>The Series A preferred stock is accounted for as equity classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20220101__20221231" title="Conversion price, description">As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2022, (ii) our Series B Preferred Stock has been reduced to $0.0217 per share at December 31, 2022, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2022, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zv8hpZtj2NX" title="Common stock, shares authorized">1,000,000,000</span> shares of common stock. There were <span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zUVFLiQW8mZi" title="Common stock, shares outstanding">32,132,907</span> and <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zt8nzQaMLcw4" title="Common stock, shares outstanding">11,769,221</span> shares of common stock outstanding at December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse Stock Split</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2021, <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20210829__20210902_zZF5DrYvM3e4" title="Reverse stock split, description">the Board of Directors approved a one-for-seventy-five (<span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20220101__20221231_z2wbrfuPZwLb" title="Reverse stock split, description">1-for-75</span>) Reverse Stock Split.</span> The Reverse Stock Split became effective with the Secretary of State of Delaware as of 4:59 p.m. Eastern Time on October 5, 2021, and the Company began trading on a post Reverse Stock Split basis at the market open on October 12, 2021. As a result of the Reverse Stock Split, each of the holders of the Company’s Common Stock received one (1) new share of Common Stock for every seventy-five (75) shares such shareholder held immediately prior. No fractional shares were issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares. The Reverse Stock Split also affected the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and resulted in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share and per share data has been retroactively adjusted in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the Reverse Stock Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Activity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, we issued a total of <span id="xdx_904_ecustom--CommonStockSharesIssuedActivity_c20220101__20221231_pdd" title="Common stock shares issued activity">20,363,686</span> shares of common stock, valued at $<span id="xdx_905_ecustom--CommonStockValuedActivity_c20220101__20221231_pp0p0" title="Common stock valued activity">789,699</span>, upon the conversion of $<span id="xdx_901_ecustom--PrincipalAmountActivityConvertible_c20220101__20221231_pp0p0" title="Principal amount activity convertible">461,972</span> principal amount of our convertible debentures. We recorded loss on conversion of debt of $<span id="xdx_906_ecustom--GainOfConversionOfDebtActivity_c20220101__20221231_pp0p0" title="Gain of conversion of debt activity">23,746</span> during the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, we issued a total of <span id="xdx_902_ecustom--CommonStockSharesIssuedActivity_c20210101__20211231_pdd" title="Common stock shares issued activity">9,290,364</span> shares of common stock, valued at $<span id="xdx_907_ecustom--CommonStockValuedActivity_c20210101__20211231_pp0p0" title="Common stock valued activity">4,447,246</span>, upon the conversion of $<span id="xdx_903_ecustom--PrincipalAmountActivityConvertible_c20210101__20211231_pp0p0" title="Principal amount activity convertible">2,693,596</span> principal amount of our convertible debentures. We recorded gain on conversion of debt of $<span id="xdx_904_ecustom--GainOfConversionOfDebtActivity_c20210101__20211231_pp0p0" title="Gain of conversion of debt activity">1,116,424</span> during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, we issued a total of 9 shares of common stock in settlement of outstanding options, pursuant to the merger discussed in Note 1.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2021, we entered into settlement and release agreements with two of our independent directors for the settlement of past due director fees and the mutual release of all claims. Pursuant to the agreements, the directors agreed to waive an aggregate of $<span id="xdx_90A_ecustom--DirectorsFeesWaived_c20210101__20210331_pp0p0" title="Directors fees waived">435,667</span> in outstanding director fees in exchange for the following: (i) <span id="xdx_904_ecustom--DirectorsFeesWaivedDescription_c20210101__20210331" title="Directors fees waived description">the aggregate payment of $100,000 (of which $50,000 was paid in November 2020 and $50,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021 (which has yet to occur), common stock purchase options with an aggregate Black Scholes’ value of $80,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. The difference between the amount waived of $435,667 and the cash paid of $100,000 has been credited to paid in capital during 2021.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 134 71 290 5000 5000 8000 10.00 8000 5000 1.00 5000 1.00 22.50 each share of Series E Preferred Stock held by a holder, as such, is entitled to 1,333 votes. 5000 0.0001 1.00 5000 5000 281.25 290.43148 1000 1125.00 562.50 90.43418 1000 1000 0.0217 1853 1000 29812.50 As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at December 31, 2022, (ii) our Series B Preferred Stock has been reduced to $0.0217 per share at December 31, 2022, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at December 31, 2022, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at December 31, 2022. 1000000000 32132907 11769221 the Board of Directors approved a one-for-seventy-five (1-for-75) Reverse Stock Split. 1-for-75 20363686 789699 461972 23746 9290364 4447246 2693596 1116424 435667 the aggregate payment of $100,000 (of which $50,000 was paid in November 2020 and $50,000 in February 2021) and (ii) immediately prior to the announcement that the Company has received approval from the FDA to commence its first Phase 1 clinical trial after March 1, 2021 (which has yet to occur), common stock purchase options with an aggregate Black Scholes’ value of $80,000, having an exercise price equal to the closing price on the day preceding the announcement, and a term of 10 years. The difference between the amount waived of $435,667 and the cash paid of $100,000 has been credited to paid in capital during 2021. <p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zTZwDE2WvcCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_828_zVBjyRjJa6Fj">STOCK OPTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred Compensation Plan</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded “top hat” plan which is maintained primarily to provide deferred compensation benefits for a select group of our “management or highly compensated employees” within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company Compensation Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s 2007 Equity Compensation Plan (2007 Plan), 2009 Executive Compensation Plan (2009 Plan), 2017 Equity Compensation Plan (2017 Plan), and the Inducement Award Stock Option Plan (Inducement Plan) (together, the Plans) provided for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of the Company and its stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans were administered by a committee of non-employee directors (the Committee). The Committee determined: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination of Compensation Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our 2007 Equity Compensation Plan, 2009 Executive Compensation Plan, Inducement Award Stock Option Plan and 2017 Equity Compensation Plan have all expired or been terminated by the Board as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock option activity for the year ended December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsg3rj1swnrc" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zvSxqHNTfvx5" style="display: none">Schedule of stock option activity</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> exercise price</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> remaining contractual term<br/> (in years)</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Outstanding at December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zegO5lWqnfUe" style="width: 9%; text-align: right" title="Number of shares outstanding at beginning">16</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztiyV5p618N3" style="width: 9%; text-align: right" title="Weighted average exercise price outstanding at beginning">355,342</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price granted"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Settled with shares pursuant to merger</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_985_ecustom--SettledWithSharesPursuantToMerger_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Settled with shares pursuant to merger">(9</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_985_ecustom--SettledWithSharesPursuantToMergers_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, Settled with shares pursuant to merger">477,238</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBsE4OqdT3Lf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares Forfeited">(7</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price forfeited">198,619</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Outstanding at December 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgjiy1pJoID2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwZDY4PYRDD9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No options were issued or exercised during the years ended December 31, 2022 and 2021. </span>As of December 31, 2022, there were <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_do_c20221231_zkMZ95Ty4ro3" title="Number of share option outstanding">no</span> options outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsg3rj1swnrc" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B4_zvSxqHNTfvx5" style="display: none">Schedule of stock option activity</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> exercise price</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> remaining contractual term<br/> (in years)</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Outstanding at December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zegO5lWqnfUe" style="width: 9%; text-align: right" title="Number of shares outstanding at beginning">16</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztiyV5p618N3" style="width: 9%; text-align: right" title="Weighted average exercise price outstanding at beginning">355,342</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price granted"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Settled with shares pursuant to merger</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_985_ecustom--SettledWithSharesPursuantToMerger_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Settled with shares pursuant to merger">(9</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_985_ecustom--SettledWithSharesPursuantToMergers_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, Settled with shares pursuant to merger">477,238</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBsE4OqdT3Lf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares Forfeited">(7</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price forfeited">198,619</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Outstanding at December 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgjiy1pJoID2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwZDY4PYRDD9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 16 355342 -9 477238 7 198619 0 <p id="xdx_804_ecustom--WarrantsDisclosureTextBlock_zyPEA1gyPYGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span id="xdx_825_z2xGiijaPbj9">WARRANTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions involving our warrants are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zSzKIPGSeaX9" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_zMmCxoMYY6z4" style="display: none">Schedule of transactions involving of warrants</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> exercise price</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> remaining contractual term<br/> (in years)</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Outstanding at December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuOOy6YwW78c" style="width: 9%; text-align: right" title="Number of shares outstanding at beginning">53</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt0fWDoHCdw2" style="width: 9%; text-align: right" title="Weighted average exercise price outstanding at beginning">5,033</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7hkfbx8h2ee" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVmqNjZUhUsb" style="text-align: right" title="Weighted average exercise price granted"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8tVtXaYUcH7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited">(30</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQHUu53DOWZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price forfeited">22</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Outstanding at December 31, 2021</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpCSzdHOAlW5" style="text-align: right" title="Number of shares outstanding at beginning">23</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLQzsCfLiXub" style="text-align: right" title="Weighted average exercise price outstanding at beginning">11,568</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3Arvn0H1sh" title="Weighted- average remaining contractual term at beginning">0.3</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm4xvUPNJUb5" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuKIVJaOIAB" style="text-align: right" title="Weighted average exercise price granted"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUVsLU95a3z3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited">(22</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyNEZhIjITMb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price forfeited">972</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Outstanding at December 31, 2022</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8IvI55w8EL4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding at ending">1</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOJXo3Ncwhu4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding at ending">244,688</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z02G69OtWDfe" title="Weighted- average remaining contractual term at ending">0.6</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Exercisable at December 31, 2022</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_983_ecustom--WarrantsExercisable_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6Pq6BqqweYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant exercisable">1</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrices_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3c446EGtqia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price warrant exercisable">244,688</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdQO5Q0aXRTk" title="Weighted- average remaining contractual term, exercisable">0.6</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zPaPj4s8y3cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No warrants were issued or exercised during the years ended December 31, 2022 and 2021. The warrants had no intrinsic value at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes outstanding common stock purchase warrants as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zelAlwetWHq2" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"><span id="xdx_8B3_zahFm01N0Txj" style="display: none">Schedule of outstanding common stock purchase warrants</span></td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> exercise price</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Issued to consultants</td> <td style="width: 1%"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_pdd" style="width: 10%; text-align: center" title="Number of shares">1</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_pdd" style="width: 9%; text-align: right" title="Weighted Average Exercise price">244,688</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td id="xdx_985_ecustom--ExpirationDateEndings_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember" style="width: 11%; text-align: center" title="Expiration date ending">August 2023</td></tr> </table> <p id="xdx_8AF_zJgoXtT9eB41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zSzKIPGSeaX9" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B8_zMmCxoMYY6z4" style="display: none">Schedule of transactions involving of warrants</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> exercise price</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> remaining contractual term<br/> (in years)</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Outstanding at December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuOOy6YwW78c" style="width: 9%; text-align: right" title="Number of shares outstanding at beginning">53</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt0fWDoHCdw2" style="width: 9%; text-align: right" title="Weighted average exercise price outstanding at beginning">5,033</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7hkfbx8h2ee" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVmqNjZUhUsb" style="text-align: right" title="Weighted average exercise price granted"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8tVtXaYUcH7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited">(30</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQHUu53DOWZ1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price forfeited">22</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Outstanding at December 31, 2021</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpCSzdHOAlW5" style="text-align: right" title="Number of shares outstanding at beginning">23</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLQzsCfLiXub" style="text-align: right" title="Weighted average exercise price outstanding at beginning">11,568</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo3Arvn0H1sh" title="Weighted- average remaining contractual term at beginning">0.3</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zm4xvUPNJUb5" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl0886">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuKIVJaOIAB" style="text-align: right" title="Weighted average exercise price granted"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUVsLU95a3z3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares forfeited">(22</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyNEZhIjITMb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price forfeited">972</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Outstanding at December 31, 2022</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8IvI55w8EL4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding at ending">1</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOJXo3Ncwhu4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding at ending">244,688</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z02G69OtWDfe" title="Weighted- average remaining contractual term at ending">0.6</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Exercisable at December 31, 2022</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td id="xdx_983_ecustom--WarrantsExercisable_pp0p0_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6Pq6BqqweYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant exercisable">1</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrices_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3c446EGtqia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price warrant exercisable">244,688</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdQO5Q0aXRTk" title="Weighted- average remaining contractual term, exercisable">0.6</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 53 5033 30 22 23 11568 P0Y3M18D 22 972 1 244688 P0Y7M6D 1 244688 P0Y7M6D <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zelAlwetWHq2" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"><span id="xdx_8B3_zahFm01N0Txj" style="display: none">Schedule of outstanding common stock purchase warrants</span></td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- average<br/> exercise price</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Issued to consultants</td> <td style="width: 1%"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_pdd" style="width: 10%; text-align: center" title="Number of shares">1</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_pdd" style="width: 9%; text-align: right" title="Weighted Average Exercise price">244,688</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td id="xdx_985_ecustom--ExpirationDateEndings_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember" style="width: 11%; text-align: center" title="Expiration date ending">August 2023</td></tr> </table> 1 244688 August 2023 <p id="xdx_808_ecustom--ConvertibleDebenturesAndNotesTextBlock_zdQWkvzjcKhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12 – <span id="xdx_821_zY6ChOlS7KE9">CONVERTIBLE DEBENTURES AND NOTES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">June 2021 Debentures</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 18, 2021, the Company sold an aggregate of $<span id="xdx_906_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20210601__20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zqcY7CP2WQQb" title="Principal amount">600,000</span> of senior convertible debentures (“June Debentures”) for (i) $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20210601__20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zQVqsLDg3AB5" title="Cash received">500,000</span> in cash and (ii) $<span id="xdx_90F_ecustom--CancellationAmount_iI_pp0p0_c20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_z4ZizecRxxGh" title="Cancellation amount">100,000</span> in cancellation of outstanding indebtedness to existing accredited and institutional investors of the Company. The June Debentures (i) are non-interest bearing, (ii) have a maturity date of June 18, 2022, (iii) are convertible into shares of Common Stock at the election of the holders at any time, subject to a beneficial ownership limitation of <span id="xdx_905_ecustom--BeneficialOwnershipLimitation1_dp_c20210601__20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_z8Om7Orsk3Yj" title="Beneficial ownership limitation percentage">9.99</span>%, and (iv) <span id="xdx_90E_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20210601__20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember" title="Conversion price, description">have a conversion price equal to the lesser of $24.75 and 85% of the lowest Volume Weighted Average Price (VWAP) during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein.</span> The maturity date of the debentures has been extended to <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20210601__20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember" title="Maturity date">December 31, 2023</span>. There were no other modifications to the June 2021 Debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The June Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investors also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the June Debentures contains anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the June Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the June Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the June Debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, $<span id="xdx_90F_ecustom--ConvertedDebentures_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zqSeGuipyI4e" title="Converted debentures">461,972</span> of June Debentures have been converted to Common Stock and $<span id="xdx_90C_ecustom--DebenturesRemainingAmount_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zCi8keeJv3p8" title="Debentures remaining amount">100,000</span> remains outstanding at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, $<span id="xdx_90F_ecustom--ConvertedDebentures_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_ziFdmGRt6w36" title="Converted debentures">38,028</span> of June Debentures have been converted to Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recorded an initial derivative liability of $<span id="xdx_907_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zcYQpSlGmuce" title="Derivative liability">644,457</span> related to the fair value of the derivative liability associated with the June Debentures. We recorded debt discount of $<span id="xdx_90A_ecustom--DebtDiscount_pp0p0_c20210601__20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zQN9WjOQlli3" title="Debt discount">600,000</span>, which will be amortized to interest expense over the term of the June Debentures, and we charged $<span id="xdx_905_eus-gaap--InterestExpenseDebt_pp0p0_c20210601__20210618__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_z1aLOCXxZpa1" title="Interest Expense, Debt">44,457</span> to interest expense upon issue. We have amortized $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_ztuye7CwJ2bk" title="Debt discount">54,292</span> of discount to interest expense during the year ended December 31, 2022 and $<span id="xdx_908_ecustom--AmortizationOfDebtChargedOff_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zXNJr2ZVL3d" title="Amortization of debt charged off">203,458</span> of discount has been charged off against loss upon the conversion of the June Debentures during 2022. We have amortized $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zWRz657PSA4f" title="Debt discount">324,561</span> of discount to interest expense during the year December 31, 2021 and $<span id="xdx_90A_ecustom--AmortizationOfDebtChargedOff_pp0p0_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_zB1WqwRcUEzl" title="Amortization of debt charged off">17,689</span> has been charged off against gain upon the conversion of the June Debentures during the year ended December 31, 2021. There was <span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_do_c20221231__us-gaap--DebtInstrumentAxis__custom--June2021DebentureMember_z2K9FOmNmJf2" title="Unamortized of debt discount">no</span> unamortized discount at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">January 2021 Debenture</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2021, we sold a $<span id="xdx_903_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20210101__20210112__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember_zWNiH04kf506" title="Principal amount">500,000</span> senior convertible debenture (“January Debenture”) for $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20210101__20210112__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember_zUBK72MxG3vl" title="Cash received">500,000</span> in cash to an existing institutional investor of the Company. The January Debenture (i) is non-interest bearing, (ii) has a maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20210101__20210112__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember" title="Maturity date">January 12, 2022</span>, (iii) is convertible into shares of Common Stock at the election of the holder at any time, subject to a beneficial ownership limitation of <span id="xdx_904_ecustom--BeneficialOwnershipLimitation1_dp_c20210101__20210112__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember_zG0RlIr3oEd8" title="Beneficial ownership limitation percentage">9.99</span>%, and (iv) <span id="xdx_905_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20210101__20210112__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember" title="Conversion price, description">has a conversion price equal to the lesser of $24.75 and 85% of the lowest VWAP during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The January Debenture also contains provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investor also has the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the January Debentures contains anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the January Debenture is no longer outstanding. Additionally, the Company has the option to redeem some or all of the January Debenture for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the January Debenture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The January Debentures were fully converted to Common Stock during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recorded an initial derivative liability of $<span id="xdx_908_eus-gaap--DerivativeLiabilities_iI_pp0p0_c20210112__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember_zBbwlVUu2vg" title="Derivative liability">709,835</span> related to the fair value of the derivative liability associated with the January debenture. We recorded debt discount of $<span id="xdx_900_ecustom--DebtDiscount_pp0p0_c20210101__20210112__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember_z10F3PD1bZD6" title="Debt discount">500,000</span>, which will be amortized to interest expense over the term of the January debenture, and we charged $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pp0p0_c20210101__20210112__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember_zTQX24nTv7kj" title="Interest Expense, Debt">209,835</span> to interest expense upon issue. We have amortized $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember_zSHlYZ3BeGs5" title="Debt discount">327,450</span> of discount to interest expense during the year ended December 31, 2021 and $<span id="xdx_904_ecustom--GainOnChargedOffConversionOfDebentures_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--January2021DebentureMember_zcFz9cuZdYU4" title="Gain on charged off conversion of debentures">172,550</span> has been charged off against gain upon the conversion of the October Debentures during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">October 2020 Debentures</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 23, 2020, the Company sold an aggregate of $<span id="xdx_903_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20201001__20201023__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zLyGhv4d2AO2" title="Principal amount">600,000</span> of senior convertible debentures (“October Debentures”) for (i) $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20201001__20201023__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zxsQiS63yp32" title="Cash received">500,000</span> in cash and (ii) $<span id="xdx_90A_ecustom--CancellationAmount_iI_pp0p0_c20201023__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zMNFhGM6zcM2" title="Cancellation amount">100,000</span> in cancellation of outstanding indebtedness to existing accredited and institutional investors of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The October Debentures (i) are non-interest bearing, (ii) have a maturity date of <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20201001__20201023__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember" title="Maturity date">October 23, 2021</span>, (iii) are convertible into shares of common stock at the election of the holders at any time, subject to a beneficial ownership limitation of <span id="xdx_90E_ecustom--BeneficialOwnershipLimitation1_dp_c20201001__20201023__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zar47bZkbJI4" title="Beneficial ownership limitation percentage">9.99</span>%, and (iv) <span id="xdx_901_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20201001__20201023__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember" title="Conversion price, description">have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion.</span> The maturity date of the debentures has been extended to December 31, 2023. There were no other modifications to the October Debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The October Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The holders also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the October Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the October Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the October Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the October Debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without the approval of the October Debenture holders holding at least 67% of the then outstanding principal amount of the October Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any holder, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zezjOrFlIeDc" title="Debt conversion amount">500,000</span> of October Debentures have been converted to common stock and $<span id="xdx_900_ecustom--DebtConversionAmountRemainsOutstanding_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zqXYTZGvXdA3" title="Debt conversion amount remains outstanding">100,000</span> remains outstanding at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We had recorded debt discount of $<span id="xdx_902_ecustom--DebtDiscount_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zkhw6l2nileh" title="Debt discount">600,000</span> related to the October Debentures, which will be amortized to interest expense over the term of the October Debentures. We have amortized $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zN9K1PtdbHM4" title="Debt discount">176,389</span> of discount to interest expense during the year ended December 31, 2021 and $<span id="xdx_90F_ecustom--GainOnChargedOffConversionOfDebentures_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_z7hwV2NNCli1" title="Gain on charged off conversion of debentures">311,111</span> has been charged off against gain upon the conversion of the October Debentures during the year ended December 31, 2021. We recorded an initial derivative liability of $<span id="xdx_90B_ecustom--FairValueIntialDerivativeLiability_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zZCMcMTZKzff" title="Fair value intial derivative liability">619,627</span> related to the fair value of the derivative liability associated with the debentures, of which $<span id="xdx_908_ecustom--DebtDiscount_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zaUsijcbz1X3" title="Debt discount">600,000</span> was recorded as discount and $<span id="xdx_905_eus-gaap--InterestExpenseLongTermDebt_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2020DebenturesMember_zlgRTd7qrt7a" title="Interest expense">19,627</span> was charged to interest expense upon issue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">March 2020 Debentures</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2020, the Company sold an aggregate of $<span id="xdx_909_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20200301__20200306__us-gaap--DebtInstrumentAxis__custom--March2020DebenturesMember_zPoU6Kj4kKLd" title="Principal amount">250,000</span> of senior convertible debentures (the “March Debentures”) for cash to existing accredited institutional investors of the Company (the “March 2020 Offering”). The March Debentures issued (i) are non-interest bearing, (ii) have a maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20200301__20200306__us-gaap--DebtInstrumentAxis__custom--March2020DebenturesMember" title="Maturity date">July 16, 2020</span> and (iii) are convertible into shares of common stock of the Company at the election of the holder at any time, subject to a beneficial ownership limitation of <span id="xdx_901_ecustom--BeneficialOwnershipLimitation1_dp_c20200301__20200306__us-gaap--DebtInstrumentAxis__custom--March2020DebenturesMember_zJVXMYbJXZV2" title="Beneficial ownership limitation percentage">9.99</span>%. The March <span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20200301__20200306__us-gaap--DebtInstrumentAxis__custom--March2020DebenturesMember" title="Conversion price, description">Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to June 30, 2021.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The March Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The holders will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the March Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the March Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the March Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the March Debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore, without the approval of the debenture holders holding at least 67% of the then outstanding principal amount of the March Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any investor, (ii) repay or repurchase or acquire shares of its common stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The March Debentures were fully converted to Common Stock during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">November 2019 Debentures</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sabby Volatility Warrant Master Fund, Ltd. has paid certain of our accounts payable in the amount of $<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--November2019DebenturesMember_zEvmWRnVAOdi" title="Debt conversion amount">26,235</span>. We issued $<span id="xdx_908_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--November2019DebenturesMember_zZesWwWDF3o4" title="Accounts payable">26,235</span> in new debentures with substantially the same terms as those issued in our Debenture Offerings. The debentures were issued in November 2019. The debentures originally matured November 20, 2020. The maturity date of the debentures has been extended to June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The debentures were fully converted to Common Stock during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">October 2019 Debentures</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective September 30 2019, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures and notes issued in our Debenture Offerings and extended the maturity date of such debentures until March 31, 2020 in exchange for the issuance of $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--October2019DebenturesMember_zwOyu4RZ0XFf" title="Debt conversion amount">96,000</span> in new debentures with substantially the same terms as those issued in our Debenture Offerings. The debentures were issued in October 2019. The debentures originally matured on October 1, 2020. The maturity date of the debentures has been extended to June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The debentures were fully converted to Common Stock during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">July 2019 Debentures</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 16, 2019, we entered into securities purchase agreements with certain institutional investors. Pursuant to the securities purchase agreement, we issued an aggregate of $<span id="xdx_906_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20190701__20190716__us-gaap--DebtInstrumentAxis__custom--July2019DebentureMember_zuCibvIsEU4b" title="Principal amount">154,000</span> of senior convertible debentures (the “July 2019 Debentures”) in exchange for the extension of the maturity date of our December 2018 convertible notes and certain of our July 2018 and September 2017 convertible debentures, and the waiver of certain default provisions of our July 2018 and September 2017 convertible debentures. We charged $<span id="xdx_90F_ecustom--FinanceCost_pp0p0_c20190701__20190716__us-gaap--DebtInstrumentAxis__custom--July2019DebentureMember_zdyyytIBNInd" title="Finance cost">154,000</span> to finance cost at the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The July 2019 Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the investor at any time, subject to a beneficial ownership limitation of <span id="xdx_904_ecustom--BeneficialOwnershipLimitation1_dp_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--July2019DebentureMember__srt--RangeAxis__srt--MinimumMember_zAhqQ4EIMUwj" title="Beneficial ownership limitation percentage">4.99</span>% which may be increased to <span id="xdx_903_ecustom--BeneficialOwnershipLimitation1_dp_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--July2019DebentureMember__srt--RangeAxis__srt--MaximumMember_zE613bOgStOd" title="Beneficial ownership limitation percentage">9.99</span>% <span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--July2019DebentureMember_zzydGnlhIEBb" title="Conversion price, description">by the investor upon 61 days’ notice. The July 2019 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion.</span> The July 2019 Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the July 2019 Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the July 2019 Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the July 2019 Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the July 2019 Debentures. The maturity date of the July 2019 has been extended to June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore, without the approval of the investors holding at least 67% of the then outstanding principal amount of the July 2019 Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also obligated under the Securities Purchase Agreement to pay investors, as partial liquidated damages, a fee of 2.0% of each investor’s initial principal amount of such investor’s July 2019 Debenture in cash upon our failure to have current public information available beginning six (6) months after the issuance date of the Debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The July 2019 Debentures were fully converted to Common Stock during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">December 2018 Notes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 13, 2018 we issued an aggregate of $<span id="xdx_901_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20181201__20181213__us-gaap--DebtInstrumentAxis__custom--December2018DebenturesMember_zWZ4zxgTbEgj" title="Principal amount">25,000</span> in convertible promissory notes (“Notes”) for cash proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20181201__20181213__us-gaap--DebtInstrumentAxis__custom--December2018DebenturesMember_zGcQsBLqeUM" title="Cash received">25,000</span>. The Notes will mature on the earlier of (i) <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_c20181201__20181213__us-gaap--DebtInstrumentAxis__custom--December2018DebenturesMember" title="Maturity date">June 30, 2019</span> or (ii) such time as we raise capital in exchange for the sale of securities (“Note Maturity Date”) and bear interest at <span id="xdx_909_esrt--InterestBearingLiabilitiesAverageRatePaid_dp_c20181201__20181213__us-gaap--DebtInstrumentAxis__custom--December2018DebenturesMember_zEYrw1NGIX3d" title="Interest rate">10</span>% per year, payable on the Note Maturity Date. Pursuant to the terms of the Notes, the Notes may be converted into shares of common stock upon an Event of Default (as such term is defined in the Notes) or upon the Maturity Date at the election of the holder at a price per share equal to <span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_c20181201__20181213__us-gaap--DebtInstrumentAxis__custom--December2018DebenturesMember_zX2vSRoUHfKg" title="Trading price">75</span>% of the lowest trade price of our common stock on the trading day immediately prior to the date such exchange is exercised by the holder. The Note Maturity Date has been extended to June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Notes were fully converted to Common Stock during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">July 2018 Debentures</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2018, we entered into securities purchase agreements with certain institutional investors. Pursuant to the securities purchase agreement, we sold an aggregate of $<span id="xdx_90F_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20180701__20180703__us-gaap--DebtInstrumentAxis__custom--July2018DebenturesMember_zXm3H3LHgVBl" title="Principal amount">515,000</span> of senior convertible debentures (“July 2018 Debentures”) consisting of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20180701__20180703__us-gaap--DebtInstrumentAxis__custom--July2018DebenturesMember_zbZgdd6aO4D5" title="Cash received">500,000</span> in cash and the cancellation of $<span id="xdx_90C_ecustom--CancellationAmount_iI_pp0p0_c20180703__us-gaap--DebtInstrumentAxis__custom--July2018DebenturesMember_zuQozcwpUKG6" title="Cancellation amount">15,000</span> of obligations of the Company. Pursuant to the terms of the securities purchase agreement, we issued $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20180701__20180703__us-gaap--DebtInstrumentAxis__custom--July2018DebenturesMember_zrxd1xcL48I5" title="Debt conversion amount">515,000</span> in principal amount of July 2018 Debentures. The July 2018 Debentures have substantially the same terms as the July 2019 Debentures. The maturity date of the July 2018 Debentures has been extended to June 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The July 2018 Debentures were fully converted to common stock during the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">September 2017 Debentures</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 12, 2017, we entered into an exchange agreement (“Exchange Agreement”) with certain holders of our Series A Preferred Stock and Series B Preferred Stock. Pursuant to the terms of the Exchange Agreement, we issued to the investors approximately $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_pn3n3_dm_c20170912__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember_z0oWzGzPc4q6" title="Remaining debt outstanding">2.5</span> million in principal amount of senior convertible debentures (the “September 2017 Debentures”) in exchange for <span id="xdx_901_ecustom--PreferredStockValueShares_c20170901__20170912__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember_zksJm0uPmhj" title="Stated value of the preferred shares">1,614</span>.8125 shares of Series A Preferred Stock with a stated value of approximately $<span id="xdx_90B_eus-gaap--PreferredStockValue_iI_pn3n3_dm_c20170912__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zQ2CcTqnKD3a" title="Stated value of the preferred shares">1.6</span> million and <span id="xdx_90A_ecustom--PreferredSharesExchanged_iI_c20170912__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember_zSuHAcQBNgF8" title="Preferred shares exchanged">890</span> shares of Series B Preferred Stock with a stated value of approximately $<span id="xdx_903_eus-gaap--PreferredStockValue_iI_pn3n3_dm_c20170912__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zKD9sNpQ2G43" title="Stated value of the preferred shares">0.9</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 12, 2017, we sold an aggregate of $<span id="xdx_90E_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20170905__20170912__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember_zC0iuTVQhRte" title="Principal amount">320,000</span> of our September 2017 Debentures. The sale consisted of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20170905__20170912__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember_zz0NOT3vJuo5" title="Cash received">250,000</span> in cash and the cancellation of $<span id="xdx_901_ecustom--CancellationAmount_iI_pp0p0_c20170912__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember_z1VRtVsZjTFl" title="Cancellation amount">70,000</span> of obligations of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The September 2017 Debentures have substantially the same terms as the July 2019 Debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021 $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember_zGZHnaMShM8l" title="Debt conversion amount">589,334</span> of debenture were converted to common stock and $<span id="xdx_906_eus-gaap--ConvertibleDebt_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--September2017DebenturesMember_zIm9aN7eNGRk" title="Remaining debt outstanding">110,072</span> remains outstanding at December 31, 2022. The remaining outstanding debentures have been extended to December 31, 2023. There were no other modifications to the September 2017 Debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2022, we recorded imputed interest on the outstanding September 2017, October 2020 and June 2021 debentures in the amount of $<span id="xdx_907_ecustom--ImputedInterestOnDebenture_c20220101__20221231_zNX56dy1vUtl" title="Imputed interest on debenture">15,500</span>. This amount has been credited to additional paid-in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 600000 500000 100000 0.0999 have a conversion price equal to the lesser of $24.75 and 85% of the lowest Volume Weighted Average Price (VWAP) during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein. 2023-12-31 461972 100000 38028 644457 600000 44457 54292 203458 324561 17689 0 500000 500000 2022-01-12 0.0999 has a conversion price equal to the lesser of $24.75 and 85% of the lowest VWAP during the five (5) trading days immediately prior to the conversion date, subject to adjustment, as described therein. 709835 500000 209835 327450 172550 600000 500000 100000 2021-10-23 0.0999 have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. 500000 100000 600000 176389 311111 619627 600000 19627 250000 2020-07-16 0.0999 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. The maturity date of the debentures has been extended to June 30, 2021. 26235 26235 96000 154000 154000 0.0499 0.0999 by the investor upon 61 days’ notice. The July 2019 Debentures have a conversion price equal to the lesser of (i) $24.75 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion. 25000 25000 2019-06-30 0.10 0.75 515000 500000 15000 515000 2500000 1614 1600000 890 900000 320000 250000 70000 589334 110072 15500 <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zLpceMkMqqSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13 — <span id="xdx_82B_zSpfsJvILF3a">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September of 2021, we began paying $<span id="xdx_904_ecustom--PaymentToRelatedParties_iI_pp0p0_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_zVcZnAUDCOOa" title="Payment to related parties">10,000</span> per month to Silvestre Law Group, P.C., our outside corporate counsel, for our SEC compliance legal work (“Monthly Fee”). Mr. Silvestre, our CEO since August 16, 2021, is a principal of Silvestre Law Group, P.C. Additionally, Silvestre Law Group bills us at their standard rates for additional services outside of the scope of the Monthly Fee. For the year ended December 31, 2022, we accrued $<span id="xdx_909_eus-gaap--LegalFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_pp0p0" title="Legal fees">125,844</span> in legal fees to Silvestre Law Group. We paid Silvestre Law Group $<span id="xdx_906_eus-gaap--OtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_pp0p0" title="Payment for monthly fee">110,000</span> for the Monthly Fee and recorded an additional $<span id="xdx_904_eus-gaap--LegalFees_c20220101__20221231_pp0p0" title="Legal fees">15,844</span> in legal fees for other services not covered by the Monthly Fee during 2022. Between January 1, 2021 and August 15, 2021, we accrued $<span id="xdx_908_eus-gaap--LegalFees_c20150801__20150815__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_pp0p0" title="Legal fees">84,224</span> in legal fees to Silvestre Law Group. From August 16, 2021 through December 31, 2021, we paid Silvestre Law Group $<span id="xdx_90E_eus-gaap--OtherExpenses_c20210816__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_pp0p0" title="Payment for monthly fee">40,000</span> for the Monthly Fee and recorded an additional $<span id="xdx_904_eus-gaap--LegalFees_c20210816__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_pp0p0" title="Legal fees">54,141</span> in legal fees for other services not covered by the Monthly Fee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company had a balance due to Silvestre Law Group of $<span id="xdx_90B_ecustom--AmountDueToRelatedParty_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_zJgIOySQD6C1" title="Amount due to related party">309,848</span> and $<span id="xdx_905_ecustom--AmountDueToRelatedParty_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_zf93j4l5unol" title="Amount due to related party">294,005</span> at December 31, 2022 and 2021, respectively. Silvestre Law Group also holds $<span id="xdx_909_eus-gaap--ConvertibleDebtNoncurrent_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SilvestreLawGroupPCMember_pp0p0" title="Convertible debentures">290,000</span> of our convertible debentures at December 31, 2022 and 2021. During 2022, we recorded imputed interest of $<span id="xdx_903_ecustom--ImputedInterestOnDebentures_c20220101__20221231_zmQEWz2tYVzl" title="Imputed interest on debentures">14,500</span> on the debentures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000 125844 110000 15844 84224 40000 54141 309848 294005 290000 14500 <p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zDwLvHDouhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14 — <span id="xdx_82E_zFOorgiD3LW5">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had, subject to limitation, $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20221231_zfs027OosqK6" title="Net operating loss carryforwards">44</span> million of net operating loss carryforwards (“NOL”) at December 31, 2022, of which $<span id="xdx_90C_ecustom--NetOperatingLossCarryforwardsExpireAmount_iI_pn3n3_dm_c20221231_zlBtJqN3P9nb" title="Net operating loss carryforwards expire amount">39.9</span> million will <span id="xdx_90E_ecustom--OperatingLossCarryforwardsExpirationPeriod_c20220101__20221231" title="Expiration period">expire at various dates through 2037.</span> In addition, the Company has research and development tax credits of approximately $<span id="xdx_907_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_c20221231_zyn3ITFpldp7" title="Research and development tax credits">496,000</span> at December 31, 2022 available to offset future taxable income, which will <span id="xdx_90B_ecustom--ExpirationPeriodForTaxCredit_c20220101__20221231" title="Expiration period for tax credit">expire from 2028 through 2042.</span> We have provided a 100% valuation allowance for the deferred tax benefits resulting from the net operating loss carryover and our tax credits due to our lack of earnings history. In addressing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The valuation allowance decreased by approximately $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n3_dm_c20220101__20221231_zdD52FUL9pyj" title="Change in valuation allowance">1.7 </span> million and increased by approximately $<span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210101__20211231_z7SECAyzPUEf" title="Change in valuation allowance">306,000</span> for the years ended December 31, 2022 and 2021, respectively. Significant components of deferred tax assets and liabilities are as follows (in thousands): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zmR7NZkVIVm8" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B6_zDxQwy0AMM0g" style="display: none">Schedule of deferred tax assets and liabilities</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20221231_zSvjHrMBRCii" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49A_20211231_zmZdda7gHyxb" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred tax assets:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net operating loss carryover</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">9,525</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">9,343</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,920</td> <td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">334</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">334</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">30</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">30</td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Tax credits</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">496</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">485</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total deferred tax assets</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,385</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,112</td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zBXzrQ8oha03" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(10,385</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(12,112</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zH2LveD0KC6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The above NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL carryforward that can be utilized to offset future taxable income. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. The Company has not completed an IRC Section 382/383 analysis. If a change in ownership were to have occurred, NOL carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company’s effective tax rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2022 and 2021 (computed by applying the U.S. Federal Corporate tax rate of 21% to income before taxes) are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zBuCeqaI6U25" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BF_zudYyZQ8iV3j" style="display: none">Schedule of actual tax benefit differs from the expected tax benefit</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20220101__20221231_zT5mpPA3x5x2" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_496_20210101__20211231_zldiekUoBA6g" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_zvGtapu8too5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Statutory federal income tax rate</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">(21.0</td> <td style="width: 1%; text-align: left">)%</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">(21.0</td> <td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_z69f9oURKHs5" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">State income taxes, net of federal benefits</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(7.0</td> <td style="text-align: left">)%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(7.0</td> <td style="text-align: left">)%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zU96HWXXwpHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-deductible items</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(240.8</td> <td style="text-align: left">)%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">38.3</td> <td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zfB6q6P7ivg6" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Valuation allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">268.8</td> <td style="padding-bottom: 1pt; text-align: left">%</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(10.3</td> <td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zdLqz02zKkE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left">%</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1151">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8AC_z5NLRUjGGpbf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s tax returns for the previous six years remain open for audit by the respective tax jurisdictions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> 44000000 39900000 expire at various dates through 2037. 496000 expire from 2028 through 2042. 1700000 306000 <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zmR7NZkVIVm8" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B6_zDxQwy0AMM0g" style="display: none">Schedule of deferred tax assets and liabilities</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20221231_zSvjHrMBRCii" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49A_20211231_zmZdda7gHyxb" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred tax assets:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net operating loss carryover</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">9,525</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">9,343</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,920</td> <td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">334</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">334</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">30</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">30</td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Tax credits</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">496</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">485</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total deferred tax assets</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,385</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,112</td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zBXzrQ8oha03" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(10,385</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(12,112</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 9525000 9343000 1920000 334000 334000 30000 30000 496000 485000 10385000 12112000 10385000 12112000 <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zBuCeqaI6U25" style="font: 10pt Times New Roman, Times, Serif; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8BF_zudYyZQ8iV3j" style="display: none">Schedule of actual tax benefit differs from the expected tax benefit</span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_493_20220101__20221231_zT5mpPA3x5x2" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_496_20210101__20211231_zldiekUoBA6g" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_zvGtapu8too5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Statutory federal income tax rate</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">(21.0</td> <td style="width: 1%; text-align: left">)%</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">(21.0</td> <td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_z69f9oURKHs5" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">State income taxes, net of federal benefits</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(7.0</td> <td style="text-align: left">)%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(7.0</td> <td style="text-align: left">)%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_zU96HWXXwpHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-deductible items</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(240.8</td> <td style="text-align: left">)%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">38.3</td> <td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zfB6q6P7ivg6" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Valuation allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">268.8</td> <td style="padding-bottom: 1pt; text-align: left">%</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(10.3</td> <td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_zdLqz02zKkE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left">%</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1151">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 -0.070 -0.070 -2.408 0.383 2.688 -0.103 EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 128 274 1 false 42 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://inspyrtherapeutics.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT Sheet http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - BACKGROUND Sheet http://inspyrtherapeutics.com/role/Background BACKGROUND Notes 7 false false R8.htm 00000008 - Disclosure - MANAGEMENT???S PLANS TO CONTINUE AS A GOING CONCERN Sheet http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcern MANAGEMENT???S PLANS TO CONTINUE AS A GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES Sheet http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimates SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES Notes 9 false false R10.htm 00000010 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION Sheet http://inspyrtherapeutics.com/role/SupplementalCashFlowInformation SUPPLEMENTAL CASH FLOW INFORMATION Notes 10 false false R11.htm 00000011 - Disclosure - INTELLECTUAL PROPERTY Sheet http://inspyrtherapeutics.com/role/IntellectualProperty INTELLECTUAL PROPERTY Notes 11 false false R12.htm 00000012 - Disclosure - ACCRUED EXPENSES Sheet http://inspyrtherapeutics.com/role/AccruedExpenses ACCRUED EXPENSES Notes 12 false false R13.htm 00000013 - Disclosure - DERIVATIVE LIABILITY Sheet http://inspyrtherapeutics.com/role/DerivativeLiability DERIVATIVE LIABILITY Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://inspyrtherapeutics.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - CAPITAL STOCK AND STOCKHOLDERS??? EQUITY Sheet http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquity CAPITAL STOCK AND STOCKHOLDERS??? EQUITY Notes 15 false false R16.htm 00000016 - Disclosure - STOCK OPTIONS Sheet http://inspyrtherapeutics.com/role/StockOptions STOCK OPTIONS Notes 16 false false R17.htm 00000017 - Disclosure - WARRANTS Sheet http://inspyrtherapeutics.com/role/Warrants WARRANTS Notes 17 false false R18.htm 00000018 - Disclosure - CONVERTIBLE DEBENTURES AND NOTES Notes http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotes CONVERTIBLE DEBENTURES AND NOTES Notes 18 false false R19.htm 00000019 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://inspyrtherapeutics.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 19 false false R20.htm 00000020 - Disclosure - INCOME TAXES Sheet http://inspyrtherapeutics.com/role/IncomeTaxes INCOME TAXES Notes 20 false false R21.htm 00000021 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies) Sheet http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies) Policies 21 false false R22.htm 00000022 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables) Sheet http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables) Tables http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimates 22 false false R23.htm 00000023 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) Sheet http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationTables SUPPLEMENTAL CASH FLOW INFORMATION (Tables) Tables http://inspyrtherapeutics.com/role/SupplementalCashFlowInformation 23 false false R24.htm 00000024 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://inspyrtherapeutics.com/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://inspyrtherapeutics.com/role/AccruedExpenses 24 false false R25.htm 00000025 - Disclosure - DERIVATIVE LIABILITY (Tables) Sheet http://inspyrtherapeutics.com/role/DerivativeLiabilityTables DERIVATIVE LIABILITY (Tables) Tables http://inspyrtherapeutics.com/role/DerivativeLiability 25 false false R26.htm 00000026 - Disclosure - STOCK OPTIONS (Tables) Sheet http://inspyrtherapeutics.com/role/StockOptionsTables STOCK OPTIONS (Tables) Tables http://inspyrtherapeutics.com/role/StockOptions 26 false false R27.htm 00000027 - Disclosure - WARRANTS (Tables) Sheet http://inspyrtherapeutics.com/role/WarrantsTables WARRANTS (Tables) Tables http://inspyrtherapeutics.com/role/Warrants 27 false false R28.htm 00000028 - Disclosure - INCOME TAXES (Tables) Sheet http://inspyrtherapeutics.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://inspyrtherapeutics.com/role/IncomeTaxes 28 false false R29.htm 00000029 - Disclosure - BACKGROUND (Details Narrative) Sheet http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative BACKGROUND (Details Narrative) Details http://inspyrtherapeutics.com/role/Background 29 false false R30.htm 00000030 - Disclosure - MANAGEMENT???S PLANS TO CONTINUE AS A GOING CONCERN (Details Narrative) Sheet http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcernDetailsNarrative MANAGEMENT???S PLANS TO CONTINUE AS A GOING CONCERN (Details Narrative) Details http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcern 30 false false R31.htm 00000031 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) Sheet http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) Details http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables 31 false false R32.htm 00000032 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1) Sheet http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1 SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1) Details http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables 32 false false R33.htm 00000033 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2) Sheet http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2 SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2) Details http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables 33 false false R34.htm 00000034 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3) Sheet http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails3 SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3) Details http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables 34 false false R35.htm 00000035 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Narrative) Sheet http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetailsNarrative SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Narrative) Details http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables 35 false false R36.htm 00000036 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details) Sheet http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails SUPPLEMENTAL CASH FLOW INFORMATION (Details) Details http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationTables 36 false false R37.htm 00000037 - Disclosure - INTELLECTUAL PROPERTY (Details Narrative) Sheet http://inspyrtherapeutics.com/role/IntellectualPropertyDetailsNarrative INTELLECTUAL PROPERTY (Details Narrative) Details http://inspyrtherapeutics.com/role/IntellectualProperty 37 false false R38.htm 00000038 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://inspyrtherapeutics.com/role/AccruedExpensesDetails ACCRUED EXPENSES (Details) Details http://inspyrtherapeutics.com/role/AccruedExpensesTables 38 false false R39.htm 00000039 - Disclosure - DERIVATIVE LIABILITY (Details) Sheet http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails DERIVATIVE LIABILITY (Details) Details http://inspyrtherapeutics.com/role/DerivativeLiabilityTables 39 false false R40.htm 00000040 - Disclosure - DERIVATIVE LIABILITY (Details Narrative) Sheet http://inspyrtherapeutics.com/role/DerivativeLiabilityDetailsNarrative DERIVATIVE LIABILITY (Details Narrative) Details http://inspyrtherapeutics.com/role/DerivativeLiabilityTables 40 false false R41.htm 00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://inspyrtherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://inspyrtherapeutics.com/role/CommitmentsAndContingencies 41 false false R42.htm 00000042 - Disclosure - CAPITAL STOCK AND STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative CAPITAL STOCK AND STOCKHOLDERS??? EQUITY (Details Narrative) Details http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquity 42 false false R43.htm 00000043 - Disclosure - STOCK OPTIONS (Details) Sheet http://inspyrtherapeutics.com/role/StockOptionsDetails STOCK OPTIONS (Details) Details http://inspyrtherapeutics.com/role/StockOptionsTables 43 false false R44.htm 00000044 - Disclosure - STOCK OPTIONS (Details Narrative) Sheet http://inspyrtherapeutics.com/role/StockOptionsDetailsNarrative STOCK OPTIONS (Details Narrative) Details http://inspyrtherapeutics.com/role/StockOptionsTables 44 false false R45.htm 00000045 - Disclosure - WARRANTS (Details) Sheet http://inspyrtherapeutics.com/role/WarrantsDetails WARRANTS (Details) Details http://inspyrtherapeutics.com/role/WarrantsTables 45 false false R46.htm 00000046 - Disclosure - WARRANTS (Details 1) Sheet http://inspyrtherapeutics.com/role/WarrantsDetails1 WARRANTS (Details 1) Details http://inspyrtherapeutics.com/role/WarrantsTables 46 false false R47.htm 00000047 - Disclosure - CONVERTIBLE DEBENTURES AND NOTES (Details Narrative) Notes http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative CONVERTIBLE DEBENTURES AND NOTES (Details Narrative) Details http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotes 47 false false R48.htm 00000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://inspyrtherapeutics.com/role/RelatedPartyTransactions 48 false false R49.htm 00000049 - Disclosure - INCOME TAXES (Details) Sheet http://inspyrtherapeutics.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://inspyrtherapeutics.com/role/IncomeTaxesTables 49 false false R50.htm 00000050 - Disclosure - INCOME TAXES (Details 1) Sheet http://inspyrtherapeutics.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://inspyrtherapeutics.com/role/IncomeTaxesTables 50 false false R51.htm 00000051 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://inspyrtherapeutics.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://inspyrtherapeutics.com/role/IncomeTaxesTables 51 false false All Reports Book All Reports rebusholdings_10k.htm rbsh-20221231.xsd rbsh-20221231_cal.xml rbsh-20221231_def.xml rbsh-20221231_lab.xml rbsh-20221231_pre.xml rebusholdings_ex31-1.htm rebusholdings_ex31-2.htm rebusholdings_ex32-1.htm rebusholdings_ex32-2.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rebusholdings_10k.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 462, "http://xbrl.sec.gov/dei/2022": 34 }, "contextCount": 128, "dts": { "calculationLink": { "local": [ "rbsh-20221231_cal.xml" ] }, "definitionLink": { "local": [ "rbsh-20221231_def.xml" ] }, "inline": { "local": [ "rebusholdings_10k.htm" ] }, "labelLink": { "local": [ "rbsh-20221231_lab.xml" ] }, "presentationLink": { "local": [ "rbsh-20221231_pre.xml" ] }, "schema": { "local": [ "rbsh-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 414, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 62, "http://inspyrtherapeutics.com/20221231": 20, "http://xbrl.sec.gov/dei/2022": 4, "total": 86 }, "keyCustom": 70, "keyStandard": 204, "memberCustom": 17, "memberStandard": 25, "nsprefix": "RBSH", "nsuri": "http://inspyrtherapeutics.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://inspyrtherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION", "menuCat": "Notes", "order": "10", "role": "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformation", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - INTELLECTUAL PROPERTY", "menuCat": "Notes", "order": "11", "role": "http://inspyrtherapeutics.com/role/IntellectualProperty", "shortName": "INTELLECTUAL PROPERTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - ACCRUED EXPENSES", "menuCat": "Notes", "order": "12", "role": "http://inspyrtherapeutics.com/role/AccruedExpenses", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - DERIVATIVE LIABILITY", "menuCat": "Notes", "order": "13", "role": "http://inspyrtherapeutics.com/role/DerivativeLiability", "shortName": "DERIVATIVE LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "14", "role": "http://inspyrtherapeutics.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - CAPITAL STOCK AND STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "15", "role": "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquity", "shortName": "CAPITAL STOCK AND STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - STOCK OPTIONS", "menuCat": "Notes", "order": "16", "role": "http://inspyrtherapeutics.com/role/StockOptions", "shortName": "STOCK OPTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RBSH:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - WARRANTS", "menuCat": "Notes", "order": "17", "role": "http://inspyrtherapeutics.com/role/Warrants", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RBSH:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RBSH:ConvertibleDebenturesAndNotesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - CONVERTIBLE DEBENTURES AND NOTES", "menuCat": "Notes", "order": "18", "role": "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotes", "shortName": "CONVERTIBLE DEBENTURES AND NOTES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RBSH:ConvertibleDebenturesAndNotesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "19", "role": "http://inspyrtherapeutics.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "20", "role": "http://inspyrtherapeutics.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)", "menuCat": "Policies", "order": "21", "role": "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies", "shortName": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)", "menuCat": "Tables", "order": "22", "role": "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables", "shortName": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "menuCat": "Tables", "order": "23", "role": "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationTables", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - ACCRUED EXPENSES (Tables)", "menuCat": "Tables", "order": "24", "role": "http://inspyrtherapeutics.com/role/AccruedExpensesTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - DERIVATIVE LIABILITY (Tables)", "menuCat": "Tables", "order": "25", "role": "http://inspyrtherapeutics.com/role/DerivativeLiabilityTables", "shortName": "DERIVATIVE LIABILITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - STOCK OPTIONS (Tables)", "menuCat": "Tables", "order": "26", "role": "http://inspyrtherapeutics.com/role/StockOptionsTables", "shortName": "STOCK OPTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "RBSH:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - WARRANTS (Tables)", "menuCat": "Tables", "order": "27", "role": "http://inspyrtherapeutics.com/role/WarrantsTables", "shortName": "WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "RBSH:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "28", "role": "http://inspyrtherapeutics.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2020-03-31", "decimals": "0", "first": true, "lang": null, "name": "RBSH:DebtSecuritiesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - BACKGROUND (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative", "shortName": "BACKGROUND (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2020-03-31", "decimals": "0", "first": true, "lang": null, "name": "RBSH:DebtSecuritiesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "RBSH:ManagementPlansToContinueAsGoingConcernDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "RBSH:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - MANAGEMENT\u2019S PLANS TO CONTINUE AS A GOING CONCERN (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcernDetailsNarrative", "shortName": "MANAGEMENT\u2019S PLANS TO CONTINUE AS A GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "RBSH:ManagementPlansToContinueAsGoingConcernDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "RBSH:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details)", "menuCat": "Details", "order": "31", "role": "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails", "shortName": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1)", "menuCat": "Details", "order": "32", "role": "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1", "shortName": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2)", "menuCat": "Details", "order": "33", "role": "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2", "shortName": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "lang": null, "name": "RBSH:PreferredStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3)", "menuCat": "Details", "order": "34", "role": "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails3", "shortName": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2021-08-292021-09-02", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetailsNarrative", "shortName": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ResearchAndDevelopmentExpensePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:OtherResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssued1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Details)", "menuCat": "Details", "order": "36", "role": "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssued1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - INTELLECTUAL PROPERTY (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://inspyrtherapeutics.com/role/IntellectualPropertyDetailsNarrative", "shortName": "INTELLECTUAL PROPERTY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - ACCRUED EXPENSES (Details)", "menuCat": "Details", "order": "38", "role": "http://inspyrtherapeutics.com/role/AccruedExpensesDetails", "shortName": "ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember", "decimals": "INF", "first": true, "lang": null, "name": "RBSH:DerivativeLiabilityMeasurementInputPercentages", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - DERIVATIVE LIABILITY (Details)", "menuCat": "Details", "order": "39", "role": "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails", "shortName": "DERIVATIVE LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember", "decimals": "INF", "first": true, "lang": null, "name": "RBSH:DerivativeLiabilityMeasurementInputPercentages", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - DERIVATIVE LIABILITY (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetailsNarrative", "shortName": "DERIVATIVE LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://inspyrtherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - CAPITAL STOCK AND STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "shortName": "CAPITAL STOCK AND STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "lang": null, "name": "RBSH:CommonStockSharesIssuedActivity", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2020-12-31_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - STOCK OPTIONS (Details)", "menuCat": "Details", "order": "43", "role": "http://inspyrtherapeutics.com/role/StockOptionsDetails", "shortName": "STOCK OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2020-12-31_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - STOCK OPTIONS (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://inspyrtherapeutics.com/role/StockOptionsDetailsNarrative", "shortName": "STOCK OPTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "RBSH:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - WARRANTS (Details)", "menuCat": "Details", "order": "45", "role": "http://inspyrtherapeutics.com/role/WarrantsDetails", "shortName": "WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "RBSH:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "RBSH:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember_custom_ConsultantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - WARRANTS (Details 1)", "menuCat": "Details", "order": "46", "role": "http://inspyrtherapeutics.com/role/WarrantsDetails1", "shortName": "WARRANTS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "RBSH:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember_custom_ConsultantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertiblePreferredStockTermsOfConversion", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - CONVERTIBLE DEBENTURES AND NOTES (Details Narrative)", "menuCat": "Details", "order": "47", "role": "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "shortName": "CONVERTIBLE DEBENTURES AND NOTES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "RBSH:ConvertibleDebenturesAndNotesTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "RBSH:ImputedInterestOnDebenture", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LegalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LegalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "49", "role": "http://inspyrtherapeutics.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT", "menuCat": "Statements", "order": "5", "role": "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit", "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - INCOME TAXES (Details 1)", "menuCat": "Details", "order": "50", "role": "http://inspyrtherapeutics.com/role/IncomeTaxesDetails1", "shortName": "INCOME TAXES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "51", "role": "http://inspyrtherapeutics.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "RBSH:LossGainOnChangeInFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - BACKGROUND", "menuCat": "Notes", "order": "7", "role": "http://inspyrtherapeutics.com/role/Background", "shortName": "BACKGROUND", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RBSH:ManagementPlansToContinueAsGoingConcernDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - MANAGEMENT\u2019S PLANS TO CONTINUE AS A GOING CONCERN", "menuCat": "Notes", "order": "8", "role": "http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcern", "shortName": "MANAGEMENT\u2019S PLANS TO CONTINUE AS A GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "RBSH:ManagementPlansToContinueAsGoingConcernDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES", "menuCat": "Notes", "order": "9", "role": "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimates", "shortName": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rebusholdings_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "RBSH_AccountsPayablePaidThroughIssuanceOfDebentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts payable paid through issuance of debentures.", "label": "Accounts payable paid through issuance of debentures" } } }, "localname": "AccountsPayablePaidThroughIssuanceOfDebentures", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "RBSH_AccountsPayableRelatedParty": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable - related party" } } }, "localname": "AccountsPayableRelatedParty", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RBSH_AccruedDirectorsFeesForgivenAndCreditedToPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued directors fees forgiven and credited to paid in capital.", "label": "Accrued director fees forgiven and credited to paid in capital" } } }, "localname": "AccruedDirectorsFeesForgivenAndCreditedToPaidInCapital", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "RBSH_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/AccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development.", "label": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "RBSH_AmortizationOfDebtChargedOff": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization of debt charged off" } } }, "localname": "AmortizationOfDebtChargedOff", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_AmountDueToRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Amount due to related party" } } }, "localname": "AmountDueToRelatedParty", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_AmountRaised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount raised.", "label": "Amount raised" } } }, "localname": "AmountRaised", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_BasicSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic shares outstanding" } } }, "localname": "BasicSharesOutstanding", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1" ], "xbrltype": "sharesItemType" }, "RBSH_BeneficialOwnershipLimitation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:BeneficialOwnershipLimitation]" } } }, "localname": "BeneficialOwnershipLimitation", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RBSH_BeneficialOwnershipLimitation1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of beneficial ownership limitation.", "label": "Beneficial ownership limitation percentage" } } }, "localname": "BeneficialOwnershipLimitation1", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "RBSH_CancellationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cancellation.", "label": "Cancellation amount" } } }, "localname": "CancellationAmount", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_CommonStockSharesIssuedActivity": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares issued activity" } } }, "localname": "CommonStockSharesIssuedActivity", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RBSH_CommonStockValuedActivity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common stock valued activity" } } }, "localname": "CommonStockValuedActivity", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of related party.", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "RBSH_ConvertedDebentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Converted debentures" } } }, "localname": "ConvertedDebentures", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_ConvertibleDebenturesAndNotesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE DEBENTURES AND NOTES" } } }, "localname": "ConvertibleDebenturesAndNotesTextBlock", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotes" ], "xbrltype": "textBlockItemType" }, "RBSH_ConvertibleDebenturesRelatedPartyNetOfCurrent": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible debentures - related party, net of current" } } }, "localname": "ConvertibleDebenturesRelatedPartyNetOfCurrent", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RBSH_ConvertibleInstuments": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive convertible instruments" } } }, "localname": "ConvertibleInstuments", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1" ], "xbrltype": "sharesItemType" }, "RBSH_DebenturesRemainingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debentures remaining amount" } } }, "localname": "DebenturesRemainingAmount", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_DebtConversionAmountRemainsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt conversion amount remains outstanding" } } }, "localname": "DebtConversionAmountRemainsOutstanding", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_DebtDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Discount recorded at issuance.", "label": "Debt discount" } } }, "localname": "DebtDiscount", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_DebtSecuritiesSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt securities sold.", "label": "Debt securities sold" } } }, "localname": "DebtSecuritiesSold", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_December2018DebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 2018 Debentures [Member]" } } }, "localname": "December2018DebenturesMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_DerivativeLiabilitiesMeasurementInputPercentages": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DerivativeLiabilitiesMeasurementInputPercentages", "verboseLabel": "Derivative liability measurement input" } } }, "localname": "DerivativeLiabilitiesMeasurementInputPercentages", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "percentItemType" }, "RBSH_DerivativeLiabilityAbstract": { "auth_ref": [], "localname": "DerivativeLiabilityAbstract", "nsuri": "http://inspyrtherapeutics.com/20221231", "xbrltype": "stringItemType" }, "RBSH_DerivativeLiabilityDisclosure": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DerivativeLiabilityDisclosure [Line Items]" } } }, "localname": "DerivativeLiabilityDisclosure", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "stringItemType" }, "RBSH_DerivativeLiabilityExtinguished": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative liability extinguished upon conversion of notes payable.", "label": "Derivative liability extinguished upon conversion of notes payable" } } }, "localname": "DerivativeLiabilityExtinguished", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "RBSH_DerivativeLiabilityIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative liability issued.", "label": "Derivative liability issued" } } }, "localname": "DerivativeLiabilityIssued", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "RBSH_DerivativeLiabilityMeasurementInputPercentages": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative liability measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInputPercentages", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "percentItemType" }, "RBSH_DerivativeLiabilityMeasurementsInputPercentages": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DerivativeLiabilityMeasurementsInputPercentages", "verboseLabel": "Derivative liability measurement input" } } }, "localname": "DerivativeLiabilityMeasurementsInputPercentages", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "percentItemType" }, "RBSH_DerivativeLiabilityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DerivativeLiabilityTable [Table]" } } }, "localname": "DerivativeLiabilityTable", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "stringItemType" }, "RBSH_DilutedLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DilutedLossPerShare", "verboseLabel": "Diluted loss per share" } } }, "localname": "DilutedLossPerShare", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1" ], "xbrltype": "perShareItemType" }, "RBSH_DilutedSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diluted shares outstanding" } } }, "localname": "DilutedSharesOutstanding", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1" ], "xbrltype": "sharesItemType" }, "RBSH_DirectorCompensationWaived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Director compensation waived.", "label": "Director compensation waived" } } }, "localname": "DirectorCompensationWaived", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RBSH_DirectorsFeesWaived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Directors fees waived.", "label": "Directors fees waived" } } }, "localname": "DirectorsFeesWaived", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_DirectorsFeesWaivedDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Directors fees waived description.", "label": "Directors fees waived description" } } }, "localname": "DirectorsFeesWaivedDescription", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "RBSH_DisclosureConvertibleDebenturesAndNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Debentures And Notes" } } }, "localname": "DisclosureConvertibleDebenturesAndNotesAbstract", "nsuri": "http://inspyrtherapeutics.com/20221231", "xbrltype": "stringItemType" }, "RBSH_DisclosureManagementsPlansToContinueAsGoingConcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Managements Plans To Continue As Going Concern" } } }, "localname": "DisclosureManagementsPlansToContinueAsGoingConcernAbstract", "nsuri": "http://inspyrtherapeutics.com/20221231", "xbrltype": "stringItemType" }, "RBSH_DisclosureWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "DisclosureWarrantsAbstract", "nsuri": "http://inspyrtherapeutics.com/20221231", "xbrltype": "stringItemType" }, "RBSH_ExpenseAttributableToConvertibleDebentures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Expense attributable to convertible instruments" } } }, "localname": "ExpenseAttributableToConvertibleDebentures", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1" ], "xbrltype": "monetaryItemType" }, "RBSH_ExpirationDateEndings": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration date ending" } } }, "localname": "ExpirationDateEndings", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "RBSH_ExpirationPeriodForTaxCredit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the expiration period for tax credits.", "label": "Expiration period for tax credit" } } }, "localname": "ExpirationPeriodForTaxCredit", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "RBSH_FairValueIntialDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value intial derivative liability" } } }, "localname": "FairValueIntialDerivativeLiability", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "It refers to the amount of liability reclassified as fair value.", "label": "Reclassification on conversion" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails3" ], "xbrltype": "monetaryItemType" }, "RBSH_FinanceCost": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Finance cost" } } }, "localname": "FinanceCost", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows", "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_GainLossOnConversionOfDebt": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainLossOnConversionOfDebt", "negatedLabel": "(Gain) loss on conversion of debt" } } }, "localname": "GainLossOnConversionOfDebt", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RBSH_GainOfConversionOfDebtActivity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gain of conversion of debt activity" } } }, "localname": "GainOfConversionOfDebtActivity", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_GainOnChargedOffConversionOfDebentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of discount charged off against the gain on conversion.", "label": "Gain on charged off conversion of debentures" } } }, "localname": "GainOnChargedOffConversionOfDebentures", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_ImputedInterestOnDebenture": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Imputed interest on debenture" } } }, "localname": "ImputedInterestOnDebenture", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_ImputedInterestOnDebentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Imputed interest on debentures" } } }, "localname": "ImputedInterestOnDebentures", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_ImputedInterestOnNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Imputed interest on notes" } } }, "localname": "ImputedInterestOnNotes", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RBSH_ImputedInterestOnNotesPayable": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Imputed interest on notes payable" } } }, "localname": "ImputedInterestOnNotesPayable", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RBSH_IncomeAttributableToConvertibleDebenturesAndPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income attributable to convertible debentures and preferred stock.", "label": "Income attributable to convertible instruments" } } }, "localname": "IncomeAttributableToConvertibleDebenturesAndPreferredStock", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1" ], "xbrltype": "monetaryItemType" }, "RBSH_IssuanceOfCommonStockInSettlementOfOptionsPursuantToMerger": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock in settlement of options, pursuant to merger" } } }, "localname": "IssuanceOfCommonStockInSettlementOfOptionsPursuantToMerger", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "RBSH_IssuanceOfCommonStockInSettlementOfOptionsPursuantToMergerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock in settlement of options, pursuant to merger, shares" } } }, "localname": "IssuanceOfCommonStockInSettlementOfOptionsPursuantToMergerShares", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "RBSH_January2021DebentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 2021 Debenture [Member]" } } }, "localname": "January2021DebentureMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_July2018DebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July 2018 Debentures [Member]" } } }, "localname": "July2018DebenturesMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_July2019DebentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July 2019 Debenture [Member]" } } }, "localname": "July2019DebentureMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_June2021DebentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "June 2021 Debenture [Member]" } } }, "localname": "June2021DebentureMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_LossGainOnChangeInFairValueOfDerivativeLiability": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "LossGainOnChangeInFairValueOfDerivativeLiability", "negatedLabel": "(Gain) loss on change in fair value of derivative liability" } } }, "localname": "LossGainOnChangeInFairValueOfDerivativeLiability", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "RBSH_ManagementPlansToContinueAsGoingConcernDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MANAGEMENT\u2019S PLANS TO CONTINUE AS A GOING CONCERN" } } }, "localname": "ManagementPlansToContinueAsGoingConcernDisclosureTextBlock", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcern" ], "xbrltype": "textBlockItemType" }, "RBSH_March2020DebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2020 Debentures [Member]" } } }, "localname": "March2020DebenturesMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_NetOperatingLossCarryforwardsExpireAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards expire amount" } } }, "localname": "NetOperatingLossCarryforwardsExpireAmount", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_November2019DebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 2019 Debentures [Member]" } } }, "localname": "November2019DebenturesMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_October2019DebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 2019 Debentures [Member]" } } }, "localname": "October2019DebenturesMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_October2020DebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 2020 Debentures [Member]" } } }, "localname": "October2020DebenturesMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_OperatingLossCarryforwardsExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents as a operating loss carryforwards expiration period.", "label": "Expiration period" } } }, "localname": "OperatingLossCarryforwardsExpirationPeriod", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "RBSH_PaymentToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payment to related parties" } } }, "localname": "PaymentToRelatedParties", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_PercentageOfIssuedAndOutstandingSharesOfCommonstock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of issued and outstanding shares of common stock.", "label": "Percentage of issued and outstanding shares of common stock" } } }, "localname": "PercentageOfIssuedAndOutstandingSharesOfCommonstock", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "percentItemType" }, "RBSH_PercentageOfTotalAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of total assets.", "label": "Percentage of total assets" } } }, "localname": "PercentageOfTotalAssets", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "RBSH_PreferredSharesExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares exchanged.", "label": "Preferred shares exchanged" } } }, "localname": "PreferredSharesExchanged", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RBSH_PreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred stock.", "label": "Preferred stock" } } }, "localname": "PreferredStock", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "monetaryItemType" }, "RBSH_PreferredStockParValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock, par value.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParValuePerShare", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "RBSH_PreferredStockSharesValued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:PreferredStockSharesValued-0]" } } }, "localname": "PreferredStockSharesValued", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "RBSH_PreferredStockStatedValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock, stated value.", "label": "Preferred stock, stated value" } } }, "localname": "PreferredStockStatedValuePerShare", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "RBSH_PreferredStockValueShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stated value of the preferred shares" } } }, "localname": "PreferredStockValueShares", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "RBSH_PrincipalAmountActivityConvertible": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Principal amount activity convertible" } } }, "localname": "PrincipalAmountActivityConvertible", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "RBSH_RelatedPartyTransactionDueFromToRelatedPartys": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible debenture - related party, net of unamortized discount of $0 and $46" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedPartys", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "RBSH_ReverseStockSplitAndIncreaseInAuthorizedSharesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reverse Stock Split and Increase in Authorized Shares" } } }, "localname": "ReverseStockSplitAndIncreaseInAuthorizedSharesPolicyTextBlock", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "RBSH_RidgewayTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ridgeway Therapeutics, Inc [Member]" } } }, "localname": "RidgewayTherapeuticsIncMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_September2017DebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 2017 Debentures [Member]" } } }, "localname": "September2017DebenturesMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_SeriesE0ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series E 0% Convertible Preferred Stock [Member]" } } }, "localname": "SeriesE0ConvertiblePreferredStockMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_SeriesFPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series F Preferred Stocks [Member]" } } }, "localname": "SeriesFPreferredStocksMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_SettledWithSharesPursuantToMerger": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Settled with shares pursuant to merger" } } }, "localname": "SettledWithSharesPursuantToMerger", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "RBSH_SettledWithSharesPursuantToMergers": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Settled with shares pursuant to merger" } } }, "localname": "SettledWithSharesPursuantToMergers", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "RBSH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price warrant exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrices", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "RBSH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted- average remaining contractual term at ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "durationItemType" }, "RBSH_SilvestreLawGroupPCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Silvestre Law Group P C [Member]" } } }, "localname": "SilvestreLawGroupPCMember", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "RBSH_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "RBSH_WarrantsExercisable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant exercisable" } } }, "localname": "WarrantsExercisable", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "monetaryItemType" }, "RBSH_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://inspyrtherapeutics.com/20221231", "presentation": [ "http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r439", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r439", "r441", "r442" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r439", "r441", "r442" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r439", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r439", "r441", "r442" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_InterestBearingLiabilitiesAverageRatePaid": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Average rate paid on interest-bearing liabilities.", "label": "Interest rate" } } }, "localname": "InterestBearingLiabilitiesAverageRatePaid", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "srt_MaximumMember": { "auth_ref": [ "r231", "r232", "r233", "r234", "r288", "r373", "r393", "r402", "r403", "r418", "r422", "r427", "r468", "r485", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r231", "r232", "r233", "r234", "r288", "r373", "r393", "r402", "r403", "r418", "r422", "r427", "r468", "r485", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r231", "r232", "r233", "r234", "r280", "r288", "r302", "r303", "r304", "r372", "r373", "r393", "r402", "r403", "r418", "r422", "r427", "r464", "r468", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r231", "r232", "r233", "r234", "r280", "r288", "r302", "r303", "r304", "r372", "r373", "r393", "r402", "r403", "r418", "r422", "r427", "r464", "r468", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r426" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r126", "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://inspyrtherapeutics.com/role/AccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/AccruedExpensesDetails", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r10", "r426" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r309", "r310", "r311", "r458", "r459", "r460", "r478" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r33", "r40", "r116", "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r259", "r360", "r416", "r417", "r454" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Shares underlying, outstanding" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r122", "r134", "r150", "r170", "r215", "r217", "r219", "r221", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r338", "r342", "r353", "r426", "r466", "r467", "r483" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r147", "r155", "r170", "r221", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r338", "r342", "r353", "r426", "r466", "r467", "r483" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BroadcastersLicenseAgreementCommitmentsDescription": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability.", "label": "Description of cancellation of a license agreement" } } }, "localname": "BroadcastersLicenseAgreementCommitmentsDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r399", "r400", "r426", "r449" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash balances", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcernDetailsNarrative", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r42", "r149", "r406" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r37", "r42", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of year", "periodStartLabel": "Cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r37", "r115" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r449" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "SUPPLEMENTAL CASH FLOW INFORMATION" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Uninsured amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r151", "r152", "r153", "r170", "r191", "r192", "r199", "r201", "r205", "r206", "r221", "r235", "r237", "r238", "r239", "r242", "r243", "r261", "r262", "r266", "r270", "r277", "r353", "r404", "r448", "r455", "r461" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative", "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Weighted Average Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Number of shares" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r127", "r138" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r59", "r229", "r230", "r401", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common stock shares issued" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r458", "r459", "r478" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r9", "r426" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $.0001 per share; 1,000,000,000 shares authorized, 32,132,907 and 11,769,221 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r132", "r210" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r90", "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r44", "r45", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Principal amount" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r5", "r124", "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible notes", "verboseLabel": "Remaining debt outstanding" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r3" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible debentures, net of unamortized discount of $0 and $212" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r60", "r244", "r245", "r250", "r251", "r252", "r255", "r256", "r257", "r258", "r259", "r413", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r21" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible debentures, net of current", "verboseLabel": "Convertible debentures" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r261", "r262", "r266" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "auth_ref": [ "r7", "r8", "r67", "r70", "r71", "r72" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for preferred stock.", "label": "Conversion price, description" } } }, "localname": "ConvertiblePreferredStockTermsOfConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Payment for expenses and costs" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r44", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debentures converted to common stock", "verboseLabel": "Debt conversion amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r3", "r4", "r5", "r123", "r124", "r133", "r174", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r361", "r413", "r414", "r415", "r416", "r417", "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Trading price" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r156", "r413", "r480" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r174", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r361", "r413", "r414", "r415", "r416", "r417", "r456" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r116", "r117", "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Net of unamortized discount, convertible debentures", "verboseLabel": "Unamortized of debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r116", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Derivative liability term" } } }, "localname": "DebtSecuritiesAvailableForSaleTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r88", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryover" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r87", "r88", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r87", "r88", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Research and development tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r88", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Accrued compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": { "auth_ref": [ "r88", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.", "label": "Other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r88", "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r477" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Gain and loss on change in fair value of the derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r96", "r97", "r99", "r100", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r105", "r344" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "DERIVATIVE LIABILITY" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiability" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r157", "r158", "r352", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability [Default Label]", "terseLabel": "Derivative liability", "verboseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r157" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r91", "r92", "r93", "r94", "r95", "r98", "r99", "r101", "r103", "r104", "r344" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r91", "r92", "r94", "r95", "r102", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Liability" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r289", "r306", "r307", "r308", "r313", "r423" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "STOCK OPTIONS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptions" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r165", "r180", "r181", "r182", "r183", "r184", "r188", "r191", "r199", "r200", "r201", "r203", "r347", "r348", "r389", "r391", "r410" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net income (loss) per common share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r165", "r180", "r181", "r182", "r183", "r184", "r191", "r199", "r200", "r201", "r203", "r347", "r348", "r389", "r391", "r410" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net income (loss) per common share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r171", "r317", "r331" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r473", "r476" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r473", "r476" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Non-deductible items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r473", "r476" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State income taxes, net of federal benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://inspyrtherapeutics.com/role/AccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r66", "r145", "r162", "r163", "r164", "r175", "r176", "r177", "r179", "r185", "r187", "r204", "r222", "r279", "r309", "r310", "r311", "r327", "r328", "r346", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of black scholes valuations of derivatives" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock": { "auth_ref": [ "r110", "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of gains or losses for the period included in earnings or resulted in a change to net assets, have arisen from the use of significant unobservable inputs (level 3) to measure the fair value of assets, liabilities, and financial instruments classified in shareholders' equity.", "label": "Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarningsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r252", "r281", "r282", "r283", "r284", "r285", "r286", "r349", "r369", "r370", "r371", "r414", "r415", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r252", "r281", "r286", "r349", "r369", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r252", "r281", "r286", "r349", "r370", "r414", "r415", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r252", "r281", "r282", "r283", "r284", "r285", "r286", "r349", "r371", "r414", "r415", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r106", "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Schedule of fair values of financial liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r351" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Loss (gain) on change in fair value of derivative liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Additions to derivative instruments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r252", "r281", "r282", "r283", "r284", "r285", "r286", "r369", "r370", "r371", "r414", "r415", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r113", "r114" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r225", "r226", "r227", "r228", "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r40", "r61", "r62" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (loss) on conversion of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "INTELLECTUAL PROPERTY" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IntellectualProperty" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r27", "r121", "r128", "r141", "r215", "r216", "r218", "r220", "r390", "r412" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r171", "r318", "r319", "r325", "r329", "r332", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r172", "r186", "r187", "r214", "r316", "r330", "r333", "r392" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r161", "r314", "r315", "r319", "r320", "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r39" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r39" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Accounts payable- related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r39" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r33", "r257", "r260", "r416", "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseLongTermDebt": { "auth_ref": [ "r131", "r404", "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of interest paid or due on all long-term debt.", "label": "Interest expense" } } }, "localname": "InterestExpenseLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r130" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest (expense), net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r170", "r221", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r339", "r342", "r343", "r353", "r411", "r466", "r483", "r484" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r14", "r125", "r137", "r426", "r457", "r463", "r481" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r148", "r170", "r221", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r339", "r342", "r343", "r353", "r426", "r466", "r483", "r484" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r0", "r1", "r2", "r5", "r6", "r170", "r221", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r339", "r342", "r343", "r353", "r466", "r483", "r484" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/DerivativeLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r207", "r213" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "BACKGROUND" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/Background" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r167" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r167" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r37", "r38", "r41" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r41", "r129", "r140", "r146", "r159", "r160", "r164", "r170", "r178", "r180", "r181", "r182", "r183", "r186", "r187", "r197", "r215", "r216", "r218", "r220", "r221", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r348", "r353", "r412", "r466" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows", "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r180", "r181", "r182", "r183", "r188", "r189", "r198", "r201", "r215", "r216", "r218", "r220", "r412" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net income attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r190", "r193", "r194", "r195", "r196", "r198", "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Diluted loss attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash financial activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r25", "r26" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r215", "r216", "r218", "r220", "r412" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Rental expenses" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://inspyrtherapeutics.com/role/AccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r32", "r142" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Payment for monthly fee" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "Other Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments in cash and common stock" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IntellectualPropertyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Conversion price per share" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred Stock, Convertible, Shares Issuable", "verboseLabel": "Convertible preferred stock" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r8", "r261" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Convertible preferred stock, par value (in dollars per share)", "verboseLabel": "Preferred stock, stated value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Convertible preferred stock, shares authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r8", "r261" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Convertible preferred stock, shares issued", "verboseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Convertible preferred stock, shares outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r8", "r426" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Convertible preferred stock", "verboseLabel": "Stated value of the preferred shares" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r8", "r67" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r154", "r223", "r224", "r407" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Cash received" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r35" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from convertible notes" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherEquity": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the issuance of equity classified as other.", "label": "Proceeds from equity financing" } } }, "localname": "ProceedsFromOtherEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r146", "r159", "r160", "r166", "r170", "r178", "r186", "r187", "r215", "r216", "r218", "r220", "r221", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r337", "r340", "r341", "r348", "r353", "r390", "r412", "r424", "r425", "r452", "r466" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r287", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r287", "r365", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r363", "r364", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r84", "r143", "r491" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r11", "r73", "r136", "r397", "r398", "r426" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ManagementsPlansToContinueAsGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r145", "r175", "r176", "r177", "r179", "r185", "r187", "r222", "r309", "r310", "r311", "r327", "r328", "r346", "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of stock value" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of stock, shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of stock, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of additional information of cash flow" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Diluted loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of actual tax benefit differs from the expected tax benefit" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r56", "r57", "r375" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r118", "r119" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r79", "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of transactions involving of warrants" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r78", "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r63", "r64", "r65", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r151", "r152", "r153", "r205", "r261", "r262", "r264", "r266", "r270", "r275", "r277", "r418", "r448", "r455" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r75", "r77" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of outstanding common stock purchase warrants" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r450", "r451", "r470" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r450", "r451", "r470" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r450", "r451", "r470" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r450", "r451", "r470" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [ "r450", "r451", "r470" ], "lang": { "en-us": { "role": { "documentation": "Series E preferred stock.", "label": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesFPreferredStockMember": { "auth_ref": [ "r450", "r451", "r470" ], "lang": { "en-us": { "role": { "documentation": "Series F preferred stock.", "label": "Series F Preferred Stock [Member]" } } }, "localname": "SeriesFPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of shares forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share", "verboseLabel": "Weighted average exercise price forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share", "verboseLabel": "Weighted average exercise price granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "auth_ref": [ "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value", "periodEndLabel": "Weighted average exercise price outstanding at ending", "periodStartLabel": "Weighted average exercise price outstanding at beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of shares outstanding at ending", "periodStartLabel": "Number of shares outstanding at beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)", "verboseLabel": "Number of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Number of share option outstanding", "periodEndLabel": "Number of shares outstanding at ending", "periodStartLabel": "Number of shares outstanding at beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails", "http://inspyrtherapeutics.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price outstanding at ending", "periodStartLabel": "Weighted average exercise price outstanding at beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average exercise price forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r290", "r299", "r300", "r301", "r302", "r305", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted- average remaining contractual term, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted- average remaining contractual term at beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/WarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r49", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimates" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r151", "r152", "r153", "r170", "r191", "r192", "r199", "r201", "r205", "r206", "r221", "r235", "r237", "r238", "r239", "r242", "r243", "r261", "r262", "r266", "r270", "r277", "r353", "r404", "r448", "r455", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative", "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r66", "r145", "r162", "r163", "r164", "r175", "r176", "r177", "r179", "r185", "r187", "r204", "r222", "r279", "r309", "r310", "r311", "r327", "r328", "r346", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r175", "r176", "r177", "r204", "r374" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://inspyrtherapeutics.com/role/ConvertibleDebenturesAndNotesDetailsNarrative", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r44", "r45", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Common stock issued on conversion of notes payable and derivative liability" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r23", "r66", "r67", "r73", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of notes, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r9", "r66", "r73" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock issued during period, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r24", "r66", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/StockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r9", "r12", "r13", "r55", "r426", "r457", "r463", "r481" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets", "http://inspyrtherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r76", "r169", "r262", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r279", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "CAPITAL STOCK AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split", "verboseLabel": "Reverse stock split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/BackgroundDetailsNarrative", "http://inspyrtherapeutics.com/role/CapitalStockAndStockholdersEquityDetailsNarrative", "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r40" ], "calculation": { "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Gain (loss) on change in fair value of derivative liability" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r52", "r53", "r54", "r208", "r209", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/SummaryOfCriticalAccountingPoliciesAndUseOfEstimatesDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails", "http://inspyrtherapeutics.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r190", "r201" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r188", "r201" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://inspyrtherapeutics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=6472701&loc=d3e49107-107924", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.8)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r428": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r432": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r433": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r434": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r435": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r436": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r437": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r438": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r439": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r441": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r442": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r443": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r444": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r445": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r446": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r447": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "https://asc.fasb.org/topic&trid=2134446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 69 0001829126-23-002497-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001829126-23-002497-xbrl.zip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